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ABSTRACT
The use of metal complexes as anticancer agents is at the present time a very active 
area of research. This thesis describes the synthesis, characterization and DNA binding 
properties of two different classes o f metal complexes that have potential in cancer 
treatment regimes. Dinuclear platinum complexes bridged by the dpzm ligand are one type 
discussed, while the other class involves the use of the borocaptate anion as a ligand to 
produce metal complexes with a high boron content for use in boron neutron capture 
therapy.
Chapter One presents an overview of cancer chemotherapy with particular attention 
paid to transition metal anticancer drugs. Topics discussed include the discovery, clinical 
aspects and mode of action of cisplatin as an anticancer agent. Second generation 
platinum drugs, which appear likely to replace cisplatin in the clinic, are included. Also 
discussed are novel approaches to new classes of metal chemotherapeutic agents, which 
may display improved properties over cisplatin and its analogues, such as dinuclear 
platinum complexes, and complexes with non-platinum metals. The discussion is 
extended to boron neutron capture therapy and the potential use transition metal 
complexes may have in this form of cancer treatment.
Chapter Two discusses the synthesis and characterization o f the dinuclear 
monobridged platinum complexes, cis-[{PtCl2(NH 3))2(/i-dpzm )], frans-[{PtCl2- 
(Me2SO)}2(/f-dpzm)] and cis-[{PtCl2(Me2SO))2(/f-dpzm)]. An attempt to produce 
[{Pt(mal)(Me2SO)}2(/f-dpzm)] is also discussed but due to its lack of solubility only a 
very limited characterization of this complex could be made. An improved method for the 
synthesis of the dpzm ligand is also described.
A discussion of the known chemistry of the borocaptate anion, in relation to its 
potential as a ligand in transition metal complexes, is presented in Chapter Three. This 
chapter describes the synthesis and characterization of the first complexes to feature 
coordinated borocaptate; [R u(SB i2H ii)(N H 3)5], [Ru(SBi2H n)(terpy)(O H 2)2] and 
fra^5-[Ru(SB i2H ii)(en )2(OH2)]. The chemical properties of the borocaptate ligand, 
particularly the strong electron donating effects that are manifested in these complexes, is
vi
also discussed.
The details of the X-ray crystal structure determination of 
[Ru(SBi2Hh )(NH3)5]-2H20 is presented in Chapter Four. The crystals of the complex 
are monoclinic, space group P2i/c, with unit cell parameters a = 8.056(1), b = 
14.240(2), c = 15.172(2), ß = 98.48° and Z = 4. The structure was solved by the 
Patterson heavy atom method and was refined to R = 0.041, based upon 2196 
reflections.The structure features discrete molecules of the complex separated from the 
waters of crystallization by normal Van der Waals contacts. The geometry of the complex 
can be described as a distorted octahedron. The distortions probably arise from the strong 
electron donating properties and large steric bulk of the borocaptate ligand.
Chapter Five presents the results of time-dependent DNA binding experiments 
conducted with the complexes described. The complex czs-[{PtCl2(NH3))2(/t-dpzm)] 
shows a significantly faster rate of unwinding of supercoiled circular pUC9 DNA, 
compared to cisplatin at equivalent concentrations, with the unwinding of Form I to Form 
Io DNA occurring about 2.5 times more rapidly. The complex trans-  
[ {PtCl2(Me2SO)} 2(M_dPzm)l shows a rate of unwinding of DNA that is comparable to 
that of cisplatin, but after the convergence of the Form I and Form II bands little 
separation due to rewinding is observed, indicating that this complex has a time limited 
effect on DNA. Only very small effects on DNA are observed with cis- 
[{PtCl2(Me2SO))2(/*-dpzm)] over the course of the experiment. This suggests that either 
competitive reactions are involved, or that possible steric constraints prevent its binding to 
DNA. The interaction of the borocaptate anion and of the complexes 
[Ru(SBi2H i i )(NH3)5] and [Ru(SBi2Hii)(en)2(OH2)] with DNA is also discussed. 
Although no binding occurred, these compounds did act as DNA cutting agents. The rate 
of this cutting, as monitored by the appearance of linear Form in DNA, was significantly 
slower in the complexes than for the free ligand. The relevance of these results when 
compared to the data obtained from in vitro anticancer screens presented in Appendix One 
is also discussed.
Chapter Six gives full experimental details for the work described in this thesis.
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ABBREVIATIONS
Anal. Calc. analysis calculated
ATPase adenosine 5'-triphosphatase
BNCT boron neutron capture therapy
Bu butyl group
ca. circa (about)
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dach 1,2-diaminocyclohexane
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1.1. INTRODUCTION
This chapter presents an overview of the treatment of cancer, with particular 
attention paid to platinum based chemotherapeutic agents and to the use of boron 
compounds in boron neutron capture therapy. It includes the discovery, clinical aspects 
and mode of action of platinum anticancer drugs, as well as the potential dinuclear 
platinum complexes have as anticancer treatments. As an extension, other metal 
complexes that have shown promise as anticancer drugs are included. The use of boron 
neutron capture therapy in the treatment of cancer is also discussed. This includes the 
rationale behind the technique, the success it has had in the treatment of brain tumours 
and an overview of the boron compounds that have been investigated for use in the 
therapy.
This thesis describes the synthesis and characterization of transition metal 
complexes that have a potential use in the treatment of cancer. Two distinct approaches 
have been investigated. The first involved mono-bridged dinuclear platinum complexes, 
where the bridging ligand is 4,4'-dipyrazolylmethane. The other approach was to 
investigate the possible use of mercaptoundecahydro—c/oso-dodecaborate as a ligand to 
produce complexes with a high boron content that could be of use in boron neutron 
capture therapy. The DNA binding properties of these complexes, along with results from 
some preliminary in vitro anticancer screens are also presented.
1.2. THE TREATMENT OF CANCER
Cancer is defined as “a cellular tumour the natural course of which is fatal”1. 
Cancer cells exhibit the properties of invasion and metastasis, and are characterized by 
reversed development. More than 270 types of human cancer have been recognised and 
defined histologically, but the degrees of variation within a single tumour type can be 
infinite. The clinical spectrum of these various diseases can be likewise infinite2.
Cancer can be described as cured only when all cancerous cells have been 
eradicated. There are four principal forms of treatment which may accomplish this -
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surgery, radiotherapy, chemotherapy and immunotherapy3. Surgery and radiotherapy are 
particularly useful when the tumour is solid and localised. Often, at the time of diagnosis 
the cancer is disseminated throughout the body as microscopic foci, which are very 
difficult to detect and treat by these methods. Chemotherapy has the advantage, in theory 
at least, that it can selectively attack these foci. The problem is in obtaining the selectivity, 
as both healthy cells and disease cells are fundamentally the same. Fortunately there are 
some differences which can be exploited to gain the necessary selectivity. Cancer cells are 
characterized by their more rapid rates of replication, and thus they utilize biosynthetic 
precursors, such as amino acids, purines and pyrimidines, at an enhanced rate. This 
intensified uptake means that certain anticancer drugs can be accumulated preferentially in 
tumour cells.
Another difference, which can be used to gain selectivity, is that a tumour grows as 
a cellular mass without any real form of vasculature, thus it is generally undersupplied 
with oxygen, making it hypoxic. This lack of oxidizing potential makes the tumour 
resistant to the effects of radiation, but this may be exploited by certain chemotherapeutic 
agents which are activated under reducing conditions to give toxic effects.
Immunotherapy is still an experimental form of treatment, relying upon the 
stimulation of natural mechanisms to fight the disease. It is not uncommon for cancer 
patients to experience what is known as a spontaneous cure, whereby their own immune 
system fights and destroys the cancer without any external intervention. What triggers the 
immune system to recognise and attack cancer cells is still unknown, and much work is 
still necessary in order to produce an effective treatment4.
All these forms of treatment are commonly used in combination to combat and cure 
cancer3. One particular combination treatment is boron neutron capture therapy (BNCT), 
which will be discussed in detail later.
1.3. THE CHEMOTHERAPY OF CANCER
Chemotherapy involves the use of chemicals that will destroy disease without 
seriously harming the patient. One of the first examples of chemotherapy successfully
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treating a disease dates to the Incas of Peru, who treated malaria with a tea made from 
cinchona bark which is a rich source of the drug quinine3. Many centuries later Paul 
Ehrlich5 laid the foundations of modem chemotherapy when he discovered that the dye 
trypan red could inhibit the growth of the trypanosoma parasite, which causes sleeping 
sickness. He later introduced Salvarsan, which was successful in the treatment of 
syphilis6»7. In 1935 Gerhard Domagk8 reported that Prontosil, the first of the 
sulfonamide drugs, could cure streptococcal infections. Shortly after, the development of 
penicillin was achieved by Chain, Florey and Gardner9, thereby establishing 
chemotherapy as an effective means of disease management.
The use of chemicals to treat cancer was originally based on mustard gas, 1,1 — 
thiobis[2-chloroethane]. It was observed that individuals heavily gassed with this during 
World War I suffered damage to bone marrow and lymphoid tissue. Animal studies 
performed with the nitrogen mustards (N-methyl-2,2'-<üchlorodiethylamine and similar 
molecules) showed that these compounds selectively destroyed lymphoid cells and trials 
were undertaken for the treatment of cancers of this tissue, such as lymphosarcoma and 
Hodgkin’s disease10. Initially these drugs were highly effective in treating tumours of 
this type, but because of their severe toxicity to bone marrow it was impossible to 
continue the treatment and completely cure the patient. Many derivatives have been 
subsequently synthesized, the most successful being cyclophosphamide11’12, which is 
still used frequently in the treatment of lymphosarcoma and Hodgkin’s disease, as well as 
breast, ovarian and lung cancers3.
Drugs of this type are known as alkylating agents as they covalently bind organic 
groups to DNA, RNA and certain important enzymes that are necessary for cellular 
function. Another class of anticancer drugs are the antimetabolites. An antimetabolite is a 
drug that is structurally quite similar to a compound essential to the organism. These 
agents act by inhibiting key enzymes in metabolic pathways vital to the cell. As cancer 
cells have generally a higher uptake of metabolites, these drugs are selectively 
accumulated, to the detriment of the cell. The antimetabolites of folic acid, such as 
aminopterin and methotrexate, were the first compounds of this type to be used for cancer
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treatment13. Other antimetabolites are employed in many drug regimes and are selective 
for a variety of cancer cells.
Certain antibiotics have been found to also have antineoplastic activity. Some of the 
more successful antibiotic-anticancer drugs are actinomycin D 14, daunorubicin15, 
doxorubicin (adriamycin)1^  and mitomycin C 17. Other natural sources have provided 
many active agents. For example, vinblastine and vincristine, alkaloids derived from the 
periw inkle plant (Vinca rosea), are particularly useful against leukemias and 
lymphomas18, while semisynthetic derivatives of podophyllotoxin derived from the May 
apple (Podophyllum peltatin) have been used against solid tumors19.
The discovery of the antineoplastic properties of certain platinum compounds by 
Rosenberg et al-20 in 1969 introduced yet another class of anticancer drugs -  those based 
on coordination chemistry.
1.4. PLATINUM ANTICANCER DRUGS
Rosenberg, while conducting experiments on the effects electric fields have on cell 
division, noted that when such a field was applied to a culture of the bacterium 
Escherichia coli (E. coli), unusual growth characteristics were observed. The cells grew 
up to 300 times their normal length, but failed to divide21. Further experiments showed 
that the growth was not in fact due to the electric field, but could be attributed to the 
presence of platinum-ammine complexes, formed in an electrochemical reaction between 
the platinum electrodes and the growth medium used in the experiment21-23.
The major species identified was the hexachloroplatinate(IV) anion, [PtClö]2-. 
Sequential replacement of the chloro ligands by ammonia, over the period of the 
experiment, gave complexes of the form c/.s-[PtCl6-x(N H 3)x](2-x)-, where x < 2. 
Subsequent studies into the effects these complexes had on the growth of E. coli 
demonstrated that [PtCl^]2- was bacteriostatic, the amminepentachloroplatinum(TV) anion 
[PtCl5(N H 3)]_ had little effect on cell growth or division, but the uncharged cis- 
diamminetetrachloroplatinum(IV) cis-[PtC4(NH3)2] was found to be a potent inhibitor of 
the processes of cell division (Figure 1.1). Notably, the corresponding Irans isomer,
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rrfl/i5-[PtCl4(NH3)2], was shown to be ineffective in inhibiting cell division, and thus it 
was concluded that ds-[PtCl4(NH3)2] was the species responsible for the unusual growth 
observed in the original experiments2^ .
The cytotoxic activity of the platinum(II) analogues ds-[PtCl2(NH3)2] and trans- 
[PtCl2(NH3)2] was examined in vitro. Again, the cis isomer was found to be active, 
whereas the trans isomer was essentially inactive. Rosenberg next took the intuitive step 
of examining the anticancer properties of platinum complexes on the premise that the 
inhibition of cell division would be an advantage in halting the progress of cancer cells20. 
It was found that the complexes c/5-[PtCl4(NH3)2], c/.s-[PtCl2(NH3)2], [PtCL^en)] and 
[PtCl2(en)] (en = 1,2-ethanediamine, Figure 1.1) were highly active against Sarcoma 180 
and L1210 leukemia in mice with ds-[PtCl2(NH3)2] displaying the best activity. The 
corresponding fra/is-diammine isomers were once again found to be inactive.
Figure 1.1. The molecular structures of neutral chloroammineplatinum 
complexes, which were the first transition metal complexes to display 
anticancer activity, (a) cis-[PtCl2(NH3)2] or cisplatin. (b) The 
platinum(TV) analogue cis-[PtCl4(NH3)2]. (c) The 1,2-ethanediamine- 
Pt(II) analogue [PtCl2(en)J. (d) The 12 -ethanediamine-Pt(TV) complex 
[PtCl4(en)J.
Further animal studies conducted with cw-[PtCl2(NH3)2], or cisplatin as it is now 
commonly known, demonstrated that it has a broad spectrum of activity against slowly or 
rapidly growing solid, disseminated or ascitic tumours24. When compared with 
established and clinically available organic drugs in the National Cancer Institute (NCI) 
murine tumour panel, cisplatin was found to have comparable or better activity (Table
1.1)25.
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Table 1.1. Comparison of cisplatin25 with other drugs in the NCI murine tumour panelf
Drug Substantial
Activity
Minimal
Activity
No Activity Erratic
Activity
Cisplatin L1210
B16
CD8 F 1
LL
Colon 38
5-Fluorouracil L1210 
CD8 F 1 
Colon 38
B16 LL
Doxorubicin L1210
B16
CD8 F 1
Colon 38 LL
Bis(chloroethylnitrosourea) L1210
CD8 F 1
B16
LL
Colon 38
Methotrexate L1210 B16
CD8 F 1
LL
Colon 38
t L1210 = L1210 lymphoid leukemia, B16 = B16 melanotic melanoma, CD8F 1 = CD8F 1 mammary 
carcinoma, LL = Lewis lung carcinoma and Colon 38 = Colon 38 carcinoma.
1.4.1. Clinical aspects of cisplatin
With the completion of successful animal trials, the next step was to investigate the 
applicability of cisplatin to human patients. Clinical trials were started in 1971 under 
sponsorship from the National Cancer Institute26. During these early stages the complex 
showed little or no activity against common tumours and its use was associated with 
severe toxicity to the patient. Cisplatin was virtually abandoned as a drug but incidental 
testing in patients afflicted with testicular cancer produced favourable results. 
Subsequently, the drug was advanced as a treatment for this cancer in combination with 
other drugs, with the results obtained demonstrating its excellent activity27. Clinical trials 
of cisplatin were completed in 1978. It was soon approved for use in a number of 
countries, including Australia, where it is now a mainstay for the curative treatment of
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advanced testicular cancer when used in combination with other drugs, such as 
vinblastine and doxorubicin. Its effectiveness against this form of cancer can be seen in 
the 70% of patients who are apparently cured and the 90% who are in long term 
remission after this form of treatment. The drug is also used to treat other cancers of the 
genitourinary region, notably bladder and ovarian, as well as those of the head and 
neck28.
1.4.2. Disadvantages of cisplatin
Despite its success, cisplatin has a number of drawbacks. Testicular cancer 
accounts for less than 1% of all malignancies encountered, thus its actual spectrum of 
activity is limited. Dose limiting toxic side effects are also a problem associated with the 
use of cisplatin. It is nephrotoxic27»29 and neurotoxic20, although its nephrotoxicity can 
be largely overcome by the administration of large amounts of intravenous fluids and by 
the introduction of diuretics such as D-mannitol31 and furosemide29»32»33. The neurotoxic 
effects are manifested as demyelenation and axonal degeneration of peripheral nerves 
when high or prolonged doses of the complex are administered. High frequency hearing 
loss (ototoxicity) can also occur, due to damage to the hair-cells of the organ of Corti. 
This occurs especially in young children and in some cases has resulted in total hearing 
loss. Other side-effects that have been reported include Raynauds phenomenon (a 
disorder causing chilblain like symptoms), impairment of sex hormone production, 
psycho-sexual difficulties, elevated blood pressure and elevated levels of blood 
cholesterol34. Cisplatin also displays the toxic effects, which are common to other 
anticancer drugs, such as severe nausea and vomiting. Mild haematological toxicity is 
observed as well, but this is not as severe as is observed with other anticancer drugs or 
with radiation therapy35.
Yet another major obstacle to the clinical utility of cisplatin is that cancer cells may 
develop resistance to its cytotoxic effects3^. Because of these limitations many thousands 
of platinum derivatives have been synthesized in the hope that better pharmacological 
properties could be obtained.
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1.4 .3 . Second generation platinum anticancer drugs
Of all the platinum complexes screened over the past two decades or so, only very 
few have actually progressed to the stage of clinical trials. In order to justify the time and 
expense required for such a trial, the compound must show at least comparable activity to 
cisplatin and should display some improvement in either the spectrum of activity or the 
minimization of toxic side effects. One particular drug, carboplatin37 (d iam m ine(l,l- 
cyclobutanedicarboxylato-OjOOplatinumCII)), appears to be the successor to cisplatin for 
clinical use38»39 (Figure 1.2(a)). Although its activity is much the same as that of 
cisplatin, it can be given safely at a much higher dose40. Its nephrotoxicity is 
considerably lower and as a result the hydration regime used with cisplatin can be 
eliminated. Furthermore, it is now possible to give platinum chemotherapy in the course 
of a short visit to the outpatient's department. Unfortunately, cancer cells which are 
resistant to cisplatin appear to be similarly resistant to carboplatin, so this problem still 
remains unsolved. It would appear that both cisplatin and carboplatin act upon the same 
intracellular target30.
O
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(a) (b)
O
o ch3 
\\ I
c c6h13
' c- c- c6h13 
o ch3
Figure 1.2. Second generation platinum  anticancer drugs, (a) 
Carboplatin. (b) , (c) and (d) Platinum compounds with the dach 
ligand, which are currently undergoing clinical trials30.
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Another group of analogues which has received a great deal of attention involves 
the replacement of the ammine groups of cisplatin with 1,2-diaminocyclohexane (dach), 
on the basis that platinum complexes containing this ligand are known to be effective 
agents against the L1210 leukemia cell line resistant to cisplatin41. However, considerable 
doubt now exists as to the utility of the murine leukemias as a model of cisplatin- 
refractory disease, since dach compounds are frequently cross-resistant with cisplatin in 
other platinum resistance models; for example human ovarian carcinoma xenografts42. A 
total of eleven different dach complexes have entered clinical trials in the past two 
decades, but most have failed early in development because of either formulation 
difficulties or unacceptable clinical toxicity. Clinical evidence for the activity of platinum- 
dach complexes against resistant cells has yet to be found. However, three dach 
compounds remain in clinical trials30 (Figure 1.2).
Both cisplatin and carboplatin are administered intravenously. The compliance and 
quality of life of patients receiving platinum chemotherapy could be enhanced if the 
treatment could be administered orally. The Institute of Cancer Research, along with 
Johnson Matthey and Bristol-Myers Squibb Oncology are currently developing a cisplatin 
analogue which can be absorbed by the gastrointestinal tract. One of the more promising 
of these agents is the platinum(IV) complex d 5,rra«5,cw-[PtCl2(0 2 CPr)2(NH2C6H n)- 
(NH3)], or as it is generically known JM 216 (Figure 1.3), which has recently entered 
clinical trials30. Animal studies, involving a panel of four human ovarian carcinoma 
xenografts in rodents, have shown that after oral administration JM 216 has an activity 
comparable to cisplatin and carboplatin. The toxic side effects that have been observed are 
similar to those observed for carboplatin30.
Figure 13 . JM 216, an orally administered platinum anticancer drug 
currently undergoing clinical trial.
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1.4.4. Deoxyribonucleic acid as the target of platinum 
drugs
Deoxyribonucleic acid (DNA) is the primary genetic material of all forms of life, 
with the possible exception of a few viruses42. Clearly DNA is vitally important for the 
survival of the cell. Aberrations in the function of DNA are thought to be responsible for 
the changes that occur when a healthy cell becomes cancerous44»45.
It was realized by Rosenberg that the filamentous growth of bacterial cells under 
the influence of cisplatin was due to the inhibition of DNA synthesis21. Other 
fundamental functions of the cell, such as RNA and protein syntheses were unaffected. 
Further experiments with cultured human cells46 and Ehrlich ascites cells47 showed that 
at therapeutically relevant doses cisplatin caused the inhibition of DNA synthesis. It was 
found that this inhibition was due to a reaction with the DNA template and not to the 
inhibition of the important replication enzyme DNA polymerase48. Measurement of the 
amount of platinum bound to various macromolecular fractions of cultured HeLa cells 
demonstrated that a far greater amount of platinum would bind to DNA than to either 
RNA or protein, when the molecular weights of macromolecules were considered49. The 
amount of cisplatin that was bound to either the RNA or protein fractions could not be 
lethal to the cell. Additional experiments showed that mutant cell lines50-54, deficient in 
DNA-excision repair mechanisms, are far more susceptible to the action of cisplatin. The 
complex is mutagenic toward both eukaryotic55»56 and prokaryotic cells50»52 and 
produces chromosomal abnormalities in eukaryotic cells57-59. All this evidence strongly 
implicates DNA as the intracellular target of cisplatin.
A two hour lag time exists between intravenous injection of cisplatin into animals 
and the onset of its cytotoxic action46»47. A similar lag time is observed on incubation of 
cisplatin with bacterial cells52. This suggests that cisplatin requires metabolic activation 
for it to be effective, thus making it a pro-drug. Under the high chloride concentration 
found in blood (ca. 103 mM) the complex remains undissociated and electrically 
neutral60. On diffusion into the cytoplasm of the cell, the complex encounters a greatly
Chapter One 12
decreased chloride concentration (c a . 4 mM). Under these conditions a number of 
hydrolysis products are formed by the replacement of the labile chloro ligands61*62. The 
rate limiting step for the binding of cisplatin to DNA is believed to be this hydrolysis65.
DNA offers a number of potential sites where a metal could coordinate66. Covalent 
binding can occur to the phosphodiester backbone, to the sugar residues or to the purine 
or pyrimidine bases. A non-covalent mode that can occur is the intercalation of planar 
molecules between the base pairs of DNA, which is promoted by Van der Waals forces 
and in many cases by electrostatic interactions. It is expected that the sp2-hybridised 
nitrogen atoms of the purine and pyrimidine bases would be the most favourable sites for 
the binding of the metal. It has been found that the N-7 atom of guanine is the most 
preferred site for platinum(II) coordination, but the N-7 atom of adenine is also 
favoured67. These results have been confirmed by numerous studies60*68-73.
The binding of cisplatin to DNA (Figure 1.3) can occur in either a mono- or 
bifunctional manner66. The monofunctional manner involves the coordination of one 
donor atom from DNA to the platinum centre. Evidence suggests that this mode is not 
responsible for the anticancer activity observed. The complexes rra«s-[PtCl2 (NH3)2] and 
[PtCl(dien)]+ (dien = V-(2-aminoethyl)-l,2-ethanediamine), for example, bind to DNA in 
this manner, yet are both inactive74. Bifunctional binding involves the coordination of 
two donor atoms to adjacent sites in the square-plane of platinum(II) and it is this mode 
which is most likely responsible for the anticancer properties of cisplatin. Bifunctional 
binding can occur in a number of possible ways66. These include chelation to a single 
base, DNA-protein crosslinking, interstrand crosslinking and intrastrand crosslinking.
The chelation of cisplatin to a single base, for example via the N-7 and 0 -6  atoms 
of guanine has been predicted by molecular modelling studies75 and was one of the first 
proposed modes76. However, no experimental evidence is available to support the actual
existence of this mode.
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Figure 1.3. Schematic representation of the binding modes of cisplatin 
to DNA. 1. Monofuctional binding. 2. DNA-protein crosslinking. 3. 
Interstrand crosslinking. 4. Intrastrand crosslinking d(GpG)
5. Intrastrand crosslinking d(ApG) 6. Intrastrand crosslinking 
d(GpNpG) where N is adenine, cytosine or thymine66.
Both cisplatin and frarts-[PtCl2 (NH3 )2 ] are capable of forming DNA-protein 
crosslinks in vivo. It has been estimated, however, that this mode accounts for only 
0.15% of the total cisplatin-DNA adducts formed in mammalian cell lines55. As trans- 
[PtCl2 (NH3)2] is more capable of forming these crosslinks, it is highly unlikely that the 
activity of cisplatin is due to this mode of binding77’78.
Interstrand crosslinks are formed when there is covalent binding of cisplatin to 
guanine N-7 donor atoms which are on opposite strands of the DNA duplex. Estimates 
suggest that this accounts for less than 1% of the total adducts formed in mammalian 
cells55. The role, if any, interstrand crosslinking plays in the anticancer activity of 
cisplatin has yet to be shown60.
The majority of adducts formed by the binding of cisplatin to DNA involve 
intrastrand crosslinks. These occur when cisplatin binds to adjacent adenine and guanine 
bases d(ApG), to two adjacent guanine bases d(GpG), or to two guanine bases separated 
by another nucleotide d(GpNpG) where N may be adenine, cytosine or thymine60.
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Interestingly, the attachment of cisplatin to d(GpA) sequences has not been observed. 
Molecular mechanics modelling suggests that this is due to a highly unfavourable 
interaction between the ammine ligand and the 0 -6  atom of the 3' guanine79.
The predominant adduct of bifunctional cisplatin binding has been identified as cis- 
[Pt(NH3)2(d(GpG))]. In vitro studies80»81 suggest that this adduct accounts for about 
65% of all platinum-DNA adducts found, whereas in vivo studies82 indicate that this 
figure is about 50%. It is believed that adducts involving intrastrand crosslinks are 
primarily responsible for the biological effects of cisplatin. Experiments have shown that 
only a very low level of cisplatin is required to inhibit the replication of a platinated S V40 
viral genome; 50% inhibition occurs when only about four platinum atoms are bound per 
genome. It is highly unlikely that the low frequency adducts would be present in such 
systems77. Another experiment has been conducted where one cw-Pt(NH3)2d(GpG) 
intrastrand crosslink is incorporated into a E. coli bacteriophage M l3 genome. The 
viability of the genome was only 10% of normal, demonstrating that just one platinum 
intrastrand crosslink can be lethal to the bacteriophage83.
Although cisplatin inhibits DNA replication, thereby blocking cell division, the 
exact mechanism by which it does this and so kills the cell remains obscure84. The 
biochemical basis by which cisplatin is selectively toxic toward only certain cancer cells is 
also uncertain. It is thought85 that the binding of cisplatin induces changes in the tertiary 
structure of the DNA duplex, such as unwinding or kinking of the molecule8^ 87. This 
can be caused by the hydrogen-bonding of the ammine ligands with either the phosphate 
backbone or with adjacent nucleotide bases. These structural changes may prevent the 
machinery of DNA synthesis from functioning. The actual stage of the cell cycle when 
inhibition occurs may also be important in placing the cancer cell in a non-viable state88.
Cells which are deficient in DNA repair mechanisms are far more susceptible to the 
actions of cisplatin than are normal cells54»89. Conversely, in cells which are resistant to 
cisplatin, the platinum-DNA adducts that are formed have been found to be repaired at an 
enhanced rate. These observations may partly explain the selectivity cisplatin has for 
cancer cells. If it is assumed that cancer cells are in some manner deficient in the repair
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mechanisms present within normal cells, then they would indeed be more susceptible to 
the effects of cisplatin.
Recently, proteins that bind to DNA structurally modified by cisplatin have been 
isolated from yeast and human cells90. It has been found that a strain of yeast, which is 
deficient in the gene that encodes for this protein, is two to three times more resistant to 
cisplatin than a normal yeast cell91.
While these results have provided clues, the actual biochemical mechanisms for the 
effects cisplatin has on DNA replication are still largely unknown. It should, however, be 
noted that the mechanisms of replication in eukaryotic cells are not fully understood 
either. Until such time as the full process of replication has been elucidated, it is likely 
that the mechanism of cisplatins action on cancer cells will remain obscure.
1.4.5. Dinuclear platinum complexes for use as anticancer 
drugs
A class of platinum complexes has been recently described which appear to be 
quite effective against cisplatin resistant cell lines. These complexes involve the linking of 
two cisplatin-like centres with a bridging ligand that replaces one or both of the ammine 
groups. The types of bridging ligands that have given complexes, which have shown 
promising anticancer results, involve diaminoalkanes, bis(dimethylaminomethyl)- 
ferrocene and 4,4'-dipyrazolylmethane.
A series of diaminoalkane bridged diplatinum complexes (Figure 1.3) have been 
described92«93 and their solution chemistry94, nucleotide binding95, DNA binding96, 
antitumour activity and cytotoxicity97*98 has been explored (Figure 1.4). The cis/cis 
isomers have shown in vitro activity against L1210 leukemia cell lines that is comparable 
to cisplatin, with the 1,4-diaminobutane (n = 4) bridged complex showing the greatest 
activity98. In vivo results with L1210 and P388 murine leukemia screens suggest that this 
complex is also the most toxic. The 1,5-diaminopentane (n = 5) bridged complex gives 
activity in these screens that is much the same as cisplatin, but with a toxicity much lower
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than that of the 1,4-diaminobutane bridged analogue98. As expected for this type of 
complex, the trans/trans analogue does not give any improved activity over trans- 
[PtCl2 (NH3)2], which has been noted previously as being inactive. However, the cationic 
trans isomer that has just one chloro group per platinum centre does show an in vitro 
toxicity that is much improved in the cisplatin resistant cell line97. This is the first 
example of a platinum species which is at least equally as active in cell lines sensitive and 
resistant to cisplatin. The mixed cisjtrans analogue does show reasonable activity in vitro, 
which suggests that the presence of one cis moiety is sufficient to impart anticancer 
properties to dinuclear platinum complexes.
H3N H2N-(CH2)n-NH2 NH3
\  ✓  \  /
H3N HoN-CCH^n-Nu NH31 2+
(C)
Cl nh3 h3n Cl
Figure 1.4. Diaminoalkane bridged dinuclear platinum complexes 
studied as potential anticancer drugs. The alkane linkers used have been 
fo r  n -  4, 5 or 6 and the analogues indicated are (a) cis/cis, (b) 
trans/trans, (c) bis(chloroplatinum) trans/trans and (d) mixed cis!trans.
Mt^SO I ^ N M ej
Cl
Figure 1.5. [rp-PtCl(M e2SO)Me2HCH2 CsH^]2Fe. A cyclometallated 
diplatinum species which has shown anticancer properties
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A novel diplatinum complex with a ferrocene derivative as the bridging ligand has 
been reported recently. This compound combines features of anticancer platinum 
complexes with those of metallocene derivatives that have also shown anticancer 
properties. The water-soluble complex that has been prepared (Figure 1.5.) exhibits low 
toxicity and has significant activity against P388 tumours in m ice".
Recent work has produced a series of doubly-bridged diplatinum complexes, 
where the bridging ligand was 4,4'-dipyrazolylmethane (dpzm)100 (Figure 1.6). It has 
been found that the Pt(II>—Pt(II) analogue possesses significant in vivo activity against the 
P388 leukemia cell line, when the complex was administered in M e2S0101. Mass-spectral 
evidence suggests that the major species was a Me2SO adduct. The other complexes 
prepared were not found to be active. The major limitation of these complexes was their 
poor solubility in water102.
Figure 1.6. Doubly-bridged diplatinum complexes, where the bridging 
ligand is 4,4,-dipyrazolylmethane, which have been investigated as 
potential anticancer drugs, (a) Pt(II)-Pt(II) cis-[{PtCI2] 2([i-dpzm)2l . 
(b) Pt(IV)-Pt(IV) cis-[{PtCl4} 2([i-dpzm)2l. (c) The mixed Pt(II)- 
Pt(IV) cis-[Cl2Pt(\i-dpzm)2PtCl4]. (d) The N-substituted Pt(II)-Pt(II) 
cis-[ {PtCl2}2(\L~l ,1 - Me2dpzm)2].
Chapter One 18
The potential of these dinuclear-platinum anticancer drugs is quite encouraging. 
Dinuclear platinum complexes which are bridged by just one dpzm ligand have not been 
examined to date. One of the aims of this research has been to investigate such complexes 
as possible anticancer drugs. It was hoped that complexes of this type would have better 
solubilities, greater degrees of freedom with respect to their possible binding modes with 
DNA, and thus improved anticancer activity.
1.4.6. Other transition metal complexes as potential 
anticancer drugs
Numerous complexes with metals other than platinum, have been investigated as 
potential anticancer agents. Octahedral dinuclear rhodium(II) carboxylates103-105 
(Figure 1.6(a)) have been found to be potent inhibitors of tumour growth, with the 
butyrate (R = CH2CH2CH3, L = H2O) and the propionate (R = CH2CH3, L = H2O) 
being the most effective106. In the series of rhodium(III) compounds which have been 
examined, antitumour activity has been found in species of the octahedral type mer- 
[RI1X3L3] (L = NH3 or another monodentate amine, X = anionic ligand)107.
Numerous ruthenium(II) and (III) complexes are characterized by antitumour 
activ ity103. The main representatives are the ruthenium (III)-am m ine complexes, 
[RuCl3(NH3)3] (which is a mixture of fac  and mer isomers), c/5-[RuCl2(NH3)4]Cl, 
[RuC1(NH3)5]C12, [Ru(0 0 C C H 2CH3)(NH3)5](C104)2 and the salt [Ru(0 4C2)(en)2] 
[R u(0 4 C 2 )2 (en )]108-1J1. The neutral ruthenium(II) complexes cis- and trans- 
[RuCl2(Me2SO)4] are also active, with the trans isomer displaying the higher activity112- 
115. Experimental evidence indicates that the mode of action of these complexes is the 
inhibition of DNA synthesis and that DNA itself is the target site, as has been found for 
the platinum anticancer drugs116. Another ruthenium complex, the so-called “ruthenium 
red”, containing a trinuclear cation (Figure 1.6(b)) also exhibits good antitumour activity
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against various experimental tumour systems117»118. Its mode of action is fundamentally 
different to that of other cytostatic ruthenium complexes. Ruthenium red inhibits 
specifically the cell membrane Ca2+-A T Pase and impairs Ca2+ transport at the 
mitochondrial and cellular membrane119»120. It is also selectively accumulated in tumour 
cells103»117.
As m entioned previously m etallocene com plexes (Figure 1.7(a)) show 
antiproliferative activity against various experimental tumours, including Ehrlich ascites 
tumour, sarcoma 180, B16 melanoma, colon 38 carcinoma, Lewis Lung carcinoma and 
xenografted human carcinomas121-124. Titanocene dichloride seems to be the most 
promising, although clinical trials have not yet commenced126.
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Figure 1.6. (a) General formula of the dinuclear rhodium carboxylates 
investigated as antitumour agents (R =  CH3, CH2CH3, CH2CH2CH3, 
CH2OCH3; L =  H2O) (b) The structure of the ruthenium red cation.
Other antitumour titanium complexes are the six coordinate bis(benzoylacetonato)- 
titanium(IV) dihalides and bis(alkoxides) (Figure 1.7(a))126-128. The bis(ethoxide) 
derivative, known commonly as “budotitane” (Figure 1.7(b)), has progressed as far as 
clinical trials in Germany129.
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Figure 1.7. (a) General formula for metallocene complexes which have 
displayed anticancer properties. (M =  Ti, V, Nb, Mo; e.g. X  =  Cl) (b) 
General formula of bis(benzoylacetonato)titanium complexes which 
have been advanced as cancer treatments.
Novel anticancer agents are described on almost a daily basis but few progress 
further than initial screening. There is however a great deal of scope left for the 
development of other transition metal based antineoplastic agents.
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1.5. THE TREATMENT OF CANCER BY BORON
NEUTRON CAPTURE THERAPY
1.5.1. Introduction
Boron neutron capture therapy (BNCT) is a type of cancer treatment that combines 
elements of both radiotherapy and chemotherapy for the destruction of tumours130-133. 
The basic strategy of this therapy is to introduce selectively a chemical species rich in 10B 
into tumour cells that are then irradiated with a stream of thermal energy neutrons. The 
nuclear reaction that takes place when the 10B nucleus captures a thermal energy neutron 
yields primary fission fragments that have a short range, high linear energy transfer 
(Scheme 1.1), and will destroy biological function of any macromolecule within then- 
flight distance of about 10 p.m. Because of the relatively inert nature of neutron radiation 
to biological material, healthy cells that have not been dosed with 10B are unaffected, 
unlike standard methods of radiation treatment that invariably cause damage to healthy 
neighbouring tissue.
7Li + y + 0.48 MeV
Scheme 1 .1 .10B neutron capture processes1^ .
The advantages of using 10B, rather than some other nuclide, are that it is non­
radioactive, it comprises about 20% of naturally occurring boron, the pathlength of the 
fission products is such that they are confined to a radius approximately the same as that 
of a single cell, and the chemistry of boron suggests that it may be incorporated into a 
multitude of different chemical structures133.
For BNCT to be effective it has been calculated that if just 17 boron-neutron
4He + 7Li + 2.79 MeV (6%)
10B + *n
4He + 7Li* + 2.31 MeV (94%)
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capture reactions occur within a single tumour cell, the cell will be destroyed. In order to 
attain this goal, a minimum of 2.5 x 1012 neutrons per gram of tumour have to be 
delivered when the average concentration of 10B is 25 jig per gram of tumour132. This 
figure would be of the order of two to five times lower if the 10B were to be localized in 
the nucleus of the cell, where the most harm could be inflicted134.
1.5.2. Early clinical trials of BNCT
The basic strategy for BNCT was probably conceived in 1936, just four years after 
the discovery of the neutron131. The first clinical trials of this treatment were conducted 
from 1951 to 1961 at the Brookhaven National Laboratory and at the Massachusetts 
Institute of Technology. However, these early studies were less than encouraging, as 
they failed to achieve any regression in the tumours treated132. This was due mainly to 
the poor uptake by tumour cells of the 10B compounds used in the study. This led to 
severe radiation induced side-effects on the central nervous and vascular systems that 
were due to high blood concentrations of boron compounds1311.
Subsequent work by Hatanaka in the late 1960's established BNCT as a viable 
means of cancer control. His work involved the treatment of brain tumours and in 
particular glioblastoma multiforme (gliomas of Grades III-IV). This disease accounts for 
45% of all brain cancers and prior to the work of Hatanaka it was invariably fatal with 
one- and five-year survival rates of 4.6 and 0 % respectively. Using BNCT, Hatanaka 
has dramatically increased these survival rates to 58 and 29 %, as has been determined 
from a group of 107 patients treated between 1968 and 1990. Recent results, where the 
techniques involved have become more refined, suggest that the survival rate after five 
years could be as high as 60%135.
1.5.3. The use of the borocaptate anion in BNCT
The boron-10 carrier used by Hatanaka was the mercaptoundecahydro-c/oj'o- 
dodecaborate anion [B^HnSH]2-, more commonly known as borocaptate (Figure 1.8).
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This compound was first described in the early 1960’s, in w ork136 detailing the 
derivative chemistry of the anions dodecahydro-c/oso-dodecaborate [Bi2Hi2]2~ and 
decahydro-c/oso-decaborate [BioHio]2-. Together with the anion [BioCl8(SH)2]2_, 
borocaptate was shown to be capable of achieving a significant concentration differential 
between gliomas and normal brain-blood in rodents. These results were the stimulus for 
the work conducted subsequently by Hatanaka. The actual biochemical and physiological 
processes by which these compounds localize in neoplasms remains unclear. It is 
apparent that the thiol group has a significant role in the observed activity, as there are 
major differences between the physiological effects of B ^ H n 2', which is essentially 
inert having a LD50 of 7 g/kg131, and its mercapto derivative.
Studies show that borocaptate will form disulfide linkages with various plasma 
p ro te in s137, but it is unclear whether this is the basis for its accumulation within 
malignant cells. It has been suggested that such boron containing proteins become 
endocytosed, possibly in an manner analogous to the incorporation of antibodies into 
malignant cells. Recent work has demonstrated a significantly greater accretion and 
diminished degradation of these proteins by cancer cells, when compared with the 
corresponding normal cells138, although further experiments confirming this hypothesis 
have yet to be conducted.
It was discovered139 that the preparations of cesium borocaptate used in the initial 
studies were sign ifican tly  con tam inated  w ith the ox idation  products 
[B12H11SSB12H11]4-  and [B i 2Hh S S (0 )B i 2H i i ]4 -. These compounds have been 
shown to achieve higher concentrations in tumour cells than does borocaptate. 
Unfortunately, these agents display an increased toxicity and so do not have any clinical 
v a lu e140. However, knowledge of the mechanisms by which sulfur-containing 
polyhedral boranes achieve selective accumulation in tumour cells would be of interest for 
the design of other boron compounds that could have even better selectivity.
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Figure 1.8. Boron compounds which have been used successfully in 
the treatment of cancer by BNCT. (a) The borocaptate anion (the B-H  
groups which occupy the vertices of the dodecahedron have been 
omitted for clarity), (b) p-Boronophenylalanine.
1.5.4. Other compounds used in BNCT
Melanoma has a high uptake of aromatic amino acids, which are converted into the 
pigment melanin. This has provided the motivation for the investigation of p- 
boronophenylalanine (Figure 1.8) as a boron carrier for BNCT. This compound has been 
used in studies involving animals14 1-143 and humans144»14^  where it has been found to 
be a useful compound for the delivery of 10B to melanotic tissue. Clinically, this 
compound has been found to be effective in treating secondary lymph-node metastasis of 
melanoma by BNCT146. It is of interest to note that only the L-form of this optically 
active compound shows any biological activity, which is in keeping with the premise that 
it is used as a biosynthetic precursor. The investigation of other boron analogues of 
amino acids146 has been conducted based on the observation that cancer cells, which 
grow more vigorously, require greater amounts of these biochemical building blocks that 
will be thus selectively incorporated into such cells.
Another approach for the delivery of boron compounds to melanomas is based on 
the fact that thiouracil is uniquely and selectively incorporated into such cancers during 
melanin formation. This has led to the investigation of a boronated thiouracil147»148 
(Figure 1.9). Similarly, chlorpromazine has exhibited a high degree of localization in 
tissue that contains preformed melanin and efforts have been directed toward the 
production of boronated promazine derivatives149; such as that shown in Figure 1.9.
Porphyrins and phthalocyanines have shown a significant ability to localize in a
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variety of tumour types. In vivo studies involving a boronated porphyrin derivative, 
Mn(III)BOPP (Figure 1.10), have shown that it can produce boron concentrations of 65 
[ig / g of tumour in murine gliomas, with no toxic effects. In addition, the compound may 
be used as a contrast agent for magnetic resonance imaging, enabling the direct 
monitoring of the tumour. Little, if any, of the agent is seen in normal brain tissue, so it 
would appear to be an ideal candidate for further study150.
Figure 1.9. Agents advanced fo r  use in BNCT. (a) 5-Dihydroxyboryl- 
2-thiouracil. (b) A boronated promazine derivative.
In an attempt to produce a boron compound that can be incorporated directly into 
the DNA of rapidly dividing cells, the boronated nucleoside 5-dihydroxyboryl-2'- 
deoxyuridine has been prepared151 (Figure 1.10). In vitro studies done on cells grown in 
the presence of this compound suggest that it replaces thymidine to the extent of 5-13%, 
with a boron concentration reaching about 6 |ig B / g cell, which is approaching the level 
required for a useful therapeutic action133. A number of other nucleosides and nucleotides 
have been also investigated134»15^ '155.
In vitro studies done on a carboranylaziridine derivative, MACB(Figure 1.11), 
have shown relatively high growth inhibition toward B16 melanoma and Hep G 2 liver 
cancer cells, when compared to results obtained from TIG-1-20 normal human foetal lung 
cells. This indicates that MACB possesses a selective toxicity toward certain cancer cells 
in its own right. Such selective toxicity has not been observed in any of the boron carriers 
reported previously. Apart from being a useful agent for BNCT there is the possibility
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that this agent may serve as a anticancer drug, independent of any other form of 
treatment156.
Figure 1.10. Agents advanced for use in BNCT. (a) Boronated 
porphyrin-manganese(III) complex MnBOPP. (b) 5-Dihydroxyboryl- 
2'-deoxy uridine.
Boronated derivatives of 2-nitroimidazole have been prepared for use as hypoxia 
selective agents157»158. One of these derivatives l-(3'-ortho[nido]c2irboTa.ny\-2'- 
hydroxy)propyl-2-nitroimidazole, CNI-1 (Figure 1.11), has been found to produce in 
vitro toxicity toward KHTn rodent tumour cells only under anaerobic conditions157. The 
magnitude of this toxicity is similar to that of misonidazole, which is used as a hypoxia- 
selective radiosensitizing drug. As a number of tumours are characterized by poor 
vasculature, and hence an oxygen deficiency, it would appear that compounds of this sort 
have plenty of potential.
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Figure 1.11. Compounds advanced as agents for BNCT. (a) 1- 
Carboranyl-3-methylaziridino-2-propanol, MACB. (b) l-(3 '~  
Ortho[nidolcarboranyl-2 '-hydroxy)propyl-2-nitroimidazole, CNI-1.
Rather than use small molecular weight compounds, another approach attempted 
has been to boronate polyclonal or monoclonal antibodies that are targeted at specific cell 
receptors159»160. The problem with this approach lies in achieving adequate boron levels 
in the antibody while still maintaining immunoreactivity. Also, the precipitation of water 
insoluble conjugates has been found to occur on boronation and certain toxic side-effects 
have been observed130’159*161. Work currently in progress suggests that these problems 
may be overcome in the near future161.
The use of liposomes and lipoproteins has been investigated as a means of 
delivering boron to cancer cells. Low density lipoprotein (LDL) is the major cholesterol 
transport protein within the human body and it is recognised by high affinity receptors on 
the surface membranes of cells162. By modifying LDL to carry small molecular weight 
lipophilic boron molecules, it seems possible to achieve an uptake of boron that is about 
100 times that of the borocaptate anion163»164. The levels of 10B, which can be 
incorporated into cancer cells, necessary for BNCT can be easily achieved with this 
approach.
1.5.5. Other nuclei for use in neutron capture therapy
Nuclei other than 10B have been also considered for neutron capture therapy. In 
order to be considered, the nuclei must have a high cross section for capture of thermal 
neutrons (Table 1.2). Originally all potential nuclei, other than 10B, were discounted, as 
they were either radioactive or did not yield particles that have a high linear energy 
transfer. However, recent work with 157Gd, which has a capture cross section more than
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50 times greater than 10B, has produced some very promising results. The process 
involved with neutron capture by 157Gd is associated with electron internal conversion 
that produces Auger electron cascade that as a consequence can cause lethal damage to 
tumour cells. Early experiments involved the use of GdCl3 in a low ionic strength buffer 
that allowed ionic association of Gd3+ with the phosphate groups of DNA. Subsequent 
neutron bombardment initiated a capture reaction that led to double strand cleavage of the 
DNA. A more effective agent for the delivery of 157Gd to DNA has been recently 
developed. This compound was produced by linking a bibenzimidazole, which is known 
to intercalate into DNA, to the chelating agent diethylenetriaminepentaacetic acid (dtpa), 
which acts as a carrier for gadolinium (Figure 1.12). Preliminary results show that this 
compound does indeed increase the rate of DNA strand breakage on irradiation with 
neutrons. The investigation of compounds of this type is still at a very early stage165.
Table 12. Thermal neutron capture cross section values of potential nuclides for neutron
capture therapy.
Nuclide Cross Section (a )  (bams) Nuclide
Cross Section (a) 
(bams)
3He 5500 155Gd 58000
6I i 953 157Gd 240000
10ß 3837 174Hf 400
113Cd 20000 199Hg 2000
135Xe* 2720000 235|j* 678
149Sm 41500 241pu * 1375
151Eu 5900 242Am* 8000
♦Nuclides are radioactive
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NH-dtpa-Gd
dtpa =
coo-
Figure 1.12. A bibenzimidazole with a linked gadolinium atom as a 
potential agent for gadolinium neutron capture therapy. The linking 
group is dtpa which is diethylenetriaminepentaacetate.
1.5.6. Boronated transition metal complexes as potential 
agents for BNCT
With the known selectivity for cancer cells displayed by a variety of transition 
metal complexes, it is somewhat surprising that no investigation into the use of such a 
compound as a tumour selective boron delivery system for use in BNCT, has been 
forthcoming. The complexes that could be envisaged would feature a non-labile ligand 
that had a high boron content and possibly a number of labile ligands that could be 
substituted for any of the possible sites on DNA. The borocaptate anion appears to be an 
ideal candidate for use as boron rich ligand. The thiol group is well known in inorganic 
chemistry as a good donor function, and coordination should be analogous to that of an 
aromatic thiol. One of the aims of the present work was to investigate the possible use of 
the borocaptate anion in a transition metal complex that may have an affinity for the DNA 
of cancer cells.
1.6. SUMMARY
The major aspects of the chemotherapy of cancer using coordination complexes 
have been discussed. These include:
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(a) The role of chemotherapy in the treatment of cancer.
(b) The discovery of the antineoplastic activity of certain platinum complexes, 
notably cisplatin (d5-[PtCl2(NH3)2])-
(c) The clinical use of cisplatin against genitourinary, head and neck cancers.
(d) The toxic side-effects associated with cisplatin use and the formation of cisplatin 
resistant cancers.
(e) Second generation platinum anticancer drugs, notably carboplatin, which have 
been found to be more effective as forms of treatment than cisplatin.
(f) Evidence that the intracellular target for platinum anticancer drugs is DNA and 
the possible mechanisms by which these drugs interfere with replication.
(g) Novel dinuclear platinum complexes that have displayed anticancer activity.
(h) Other transition metal complexes that have shown anticancer activity.
The treatment of cancer by boron neutron capture therapy, has also been discussed.
Emphasis has been placed on:
(a) The basic strategy of this therapy.
(b) Early clinical trials of the technique.
(c) The use of the borocaptate anion in BNCT.
(d) Other compounds that have been advanced as boron delivery agents.
(e) Nuclei other than boron-10 that have been investigated for use in neutron capture 
therapy.
(f) The potential of using transition metal complexes as boron delivery agents.
This discussion has provided an overview of how coordination chemistry can be
used to produce agents that can be employed in anticancer treatments.
Chapter Two
THE PREPARATION AND 
CHARACTERIZATION OF DINUCLEAR 
PLATINUM COMPLEXES BRIDGED BY THE 
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2.1. INTRODUCTIO N
As a ligand in metal complexes 4,4'-dipyrazolylmethane (dpzm) has received little 
attention, unlike the isomeric lj'-dipyrazolylmethane. The dpzm ligand has, however, 
recently attracted interest due to the anticancer properties exhibited by some of its 
platinum complexes101.
Cuadro et a/.166 have described the synthesis and characterization of polymeric 
nickel(II) and cobalt(II) complexes with dpzm and with the structurally related 3,3',5,5’- 
tetramethyl-4,4'-dipyrazolylmethane (tmdpzm) and 3,3,,5,5'-tetramethyl-4,4'-dipyrazole 
(tmdpz) ligands (Figure 2.1). The crystal structure of a dimeric complex of cobalt(II) with 
tmdpzm has been reported167 and organometallic complexes of rhodium(I) with tmdpzm 
and tmdpz have been described168. Recently, Broomhead et a/.100 have reported the 
synthesis and characterization of a number of dimeric and monomeric complexes of dpzm 
with platinum (II) and (IV). This work has been extended to dpzm complexes of 
copper(II), iron(II), manganese(II), chromium(II) and zinc(II), all of which appear to be 
polymeric in nature169.
2 1 
N — NH
3 (0 ) 5
N — NH
n3c^^y^cu3 N — NHJ O V
c h 21 c h 21 c h 21
H aC -^s" X ^ C H 3
N — NH
H3CV v ch3
N —-NH
H3CW ch3
N -—NH
(a) (b) (C) (d)
Figure 2.1. Dipyrazolyl ligands. (a) 4,4 -Dipyrazolylmethane, dpzm, 
with numbering scheme for the pyrazolyl groups, (b) 7,7'- 
Dipyrazolylmethane (c) 3,3'J5 J5'-Tetramethyl-4,4'-dipyrazolylmethane 
(d) 3,3',5,5’-Tetramethyl-4,4 - dipyrazole.
The dpzm ligand can bind potentially in a bidentate manner, but because of the 
large separation between the coordination sites and its relatively rigid nature, chelation to
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one metal centre is not possible. In its complexes dpzm has been found to be exclusively 
bridging, except when further coordination is blocked by the formation of a 
hydrochloride salt in which case the coordination is monodentate100. The bridging- 
bidentate mode of coordination associated with dpzm allows polymeric species to form 
readily, as has been observed with a number of complexes containing this ligand.
The work of Broomhead et a/.100 focused on dimeric-dibridged platinum-dpzm 
complexes. Recent work by Farrell et at.92-94,97,98 on dimeric-monobridged platinum 
complexes, where the bridging ligand was an alkyldiamine, has demonstrated that this 
class of compounds shows substantial cytotoxicity toward cancer cell lines, particularly 
those that are cisplatin resistant. As an adjunct to both of these studies, this chapter 
presents the preparation and characterization of dimeric-monobridged platinum-dpzm 
complexes.
The synthesis of dpzm was first described by Trofimenko170, who heated pyrazole 
and methylenebromide at 200°C in an autoclave for 3 hours. Despite the fact that only a 
31% yield is reported for this preparation, no other method for synthesis has been 
proposed. This chapter describes a preparation of dpzm that is more applicable as a 
laboratory scale synthesis and does not involve the use of high-pressure aparatus.
2.2. RESULTS AND DISCUSSION
The reactions used to prepare the platinum(II)—dpzm complexes described in this 
chapter are outlined in Scheme 2.1. The assignment of major infrared bands and lH 
n.m.r. resonances are shown in Tables 2.1 and 2.2 respectively.
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Table 2.1. Major infrared band assignments (cm'1) in the region 4000 -250 cm'1 for 
dinuclear-monobridged platinum(II)-dpzm complexes.
A ssignm ent c is- [ {PtCl2(NH3)} 2 -(/i-dpzm)]
tra n s-[ {PtCl2(Me2SO)} 2 
-(/i-dpzm)]
riM(PtCl2(Me2SO))2
-(^ -dpzm)]
v(N -H ) 3267, 3180, 3125 3225 3298
Aromatic v(C -H ) 3117 3127 3123
M ethylene Vas(C-H) 2974 t f
M ethylene v s(C-H) 2860 2875 t
M ethyl Vas(C-H) n.a. 3001 3004
M ethyl Vs(C-H) n.a. 2912 2915
v ring 1477, 1409, 1367 1476, 1367 1477
5s(C H 2) 1437 1440 1437
Aromatic ß(N-H ) 1140 t t
Aromatic ß(C-H) 1080, 1010, 1000 1080, 1006, 997 1083,1007
Ring breathing 975 t t
Y(C-H) 859, 827 868, 833 869, 842
Aromatic y(N-H ) 747 749 749
y Ring 586 585 594
v(Pt-Cl) 333, 322 340 337
5a(N H 3) 1570 n.a . n .a .
8 s(N H 3) 1308 n .a . n .a .
v (P t-N ) 526 n.a. n .a .
v (S = 0 ) n.a. 1120 1132
pr(CH3) n.a. 975, 933, 921 976, 932, 920
5as(CH3) n.a. 1409 1405
5 s(C H 3) n.a. 1316,1297 1317, 1298
Vas(C-S) n.a. 719 727
Vs(C-S) n.a. 698 694
6as(CSO) n.a. 438 438
8s(CSO) n.a. 374 374
t These bands are obscured by those associated with the DMSO ligand, 
n.a. Not applicable
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Table 2 2 . JH nm.r. spectral data (8, ppm) for dpzm and dpzm-platinum complexes. 
195Pt coupling constants, where observed, are shown in brackets.
Assignment dpzm cw-[ {PtCl2(NH3)} 2-</i-dpzm)]
trans-[[ PtCl2 
(Me2SO)} 2(/i-dpzm)]
pyrazolyl N-H 12.66 13.62 13.7
pyrazolyl H5 7.49 7.91 8.07
pyrazolyl H3 7.49 7.84 7.95
methylene -C H 2- 3.71 3.77 3.86
Pt-N H 3 n.a. 4.43 n.a.
O S (C H 3 )2 n.a. n.a. 3.49 (22 Hz)
n.a. Not applicable.
2.2.1. The synthesis and characterization of 
cis-[{PtCl2 (NH3)}2 (\k-dpzm)]
The original approach used in the synthesis of cw-[{PtCl2(NH3)}2(/t-dpzm)] was 
to react K[PtCl3(NH3)] with dpzm in an aqueous solution. Unfortunately this gave a 
product which was virtually insoluble in all solvents, including hot Me2SO and hot dmf. 
The infrared spectrum of this product gave peaks that were very broad and poorly 
resolved. On the basis of these observations it was concluded that this product was 
polymeric in nature, and thus, of little use in the current study. It appears likely that 
coordinated water plays an important role in the formation of these polymers.
A more effective approach was to use the salt [PPh4][PtCl3(NH3)] in the reaction 
with dpzm. This salt offered a number of synthetic advantages. It was easier to purify, 
especially as the preparations of the [PtCl3(NH3)]- anion described in the literature171’172 
were invariably contaminated with the [PtCU]2'  anion. Fractional recrystallization of the 
crude [PPh4][PtCl3(NH3)] in dmf/chloroform gave a product of high purity, free of any 
[PPh4]2[PtCl4] formed as a by-product. The presence of the tetraphenylphosphonium 
counter-ion imparts good solubility in organic solvents, particularly methylene chloride 
which was found to be useful in this preparation. Due to the lack of solubility dpzm has 
in methylene chloride it was, however, necessary to conduct the reaction in a mixture of
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methylene chloride and ethanol. The use of this solvent system prevents the formation of 
polymeric products, as ds-[{PtC l2(NH3)} 2(^-dpzm)] is insoluble and thus further 
reactions cannot occur. This solvent also prevents the formation of undesirable solvolysis 
products as its components are only weakly coordinating.
A cis geometry is expected for the product due to the increased trans directing 
influence of the chloro groups over the ammine group of the [PtCl3(NH3)]_ anion173d74 
The mechanism by which trans directed substitution occurs in square-planar platinum(II) 
complexes has been extensively discussed175. It is possible to assign the geometry of the 
complex on the basis of the frequencies observed for the v(Pt-Cl) bands176. For trans- 
[PtCl2(NH 3)2] this band is seen as a single absorption at 365 cm’1, while for cis- 
[PtC l2(N H 3)2], two absorptions are observed at 323 and 330 cm’1. For cis- 
[{PtCl2(NH3)}2(/t-dpzm)] two absorptions are present at 320 and 330 cm’1, which is as 
expected for a cis isomer. Bands associated with the dpzm, ammine and chloro ligands 
can also be seen in the infrared spectrum. The assignment of these bands is given in Table 
2 . 1.
The 1H n.m.r. spectrum of ris,-[{PtCl2(NH3)}2(//-dpzm)] in D7-dmf supports the 
proposed structure (Table 2.2). The resonance associated with the pyrazolyl N-H protons 
is seen at 13.62 ppm, which is significantly downfield from that observed for the free 
ligand (12.66 ppm). This shift can be attributed to a deshielding effect associated with the 
coordination of platinum to the neighbouring nitrogen atom. In both instances the peak is 
quite broad, which would be due to the electrical quadrupole moment of the 14N nucleus 
to which the proton is partially coupled. The addition of deuterium oxide to the n.m.r. 
solution results in the loss of this peak, indicating that this proton exchanges freely. The 
rate of exchange is fast enough to prevent coupling to the adjacent pyrazolyl H5 proton. 
The assignment of the pyrazolyl H5 and H3 protons to the resonances at 7.91 and 7.84 
ppm respectively is based upon previous assignments of these protons, where the H5 
proton was invariably seen further downfield than the H3 proton. The differences in the 
magnitudes of the 195Pt-1H coupling constants have previously been used in the 
assignment of these protons11^ . Unfortunately, in the present case it was not possible to
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observe these couplings because of the close proximity of the two resonances.
The broad resonance at 4.43 ppm can be assigned to the NH3 ligand, confirming 
the mixed ligand nature of the complex. This resonance is in the same general area as had 
been observed by Muir et al. in a series of complexes of the form [PtCl2(NH3)L], where 
L is a thiazole or imidazole ligand177. The methylene resonance is observed at much the 
same position as it is in the free dpzm ligand.
When the !H n.m.r. spectrum of the complex dissolved in Dö-Me2SO is recorded a 
number of peaks are observed, which is indicative of a rapid solvolysis reaction. A lYL 
n.m.r. study performed with cisplatin in this solvent system has demonstrated that at least 
five different species are formed as a result of ammonia exchange reactions that are 
promoted by the large kinetic trans effect of the sulfur-bound Me2SO ligand173. For a 
dinuclear complex, such as c is-[{P tC l2 (N H 3 )}2(M~dpzm)L the number of possible 
isomers that may be formed must be at least 25. Clearly, Me2SO is not a suitable solvent 
for the characterization of complexes of this type.
2.2.2. The synthesis and characterization of 
tr ans-[{PtCl2 (Me2 SO)}2 ([i-dpzm)]
This complex can be conveniently synthesized from the salt K[PtCl3(Me2SO)] and 
the dpzm ligand. The reaction was perfromed in aqueous ethanol (1:1 ethanol/water) so as 
to promote the precipitation of the product before any polymeric species could form. The 
starting material, K[PtCl3(Me2SO)], is conveniently prepared from K2[PtCl4] and a 
stoichiometric amount of Me2S0178.
As expected, the substitution reaction between dpzm and K[PtCl3(Me2SO)] 
proceeded with the formation of the trans product. This is due to the strong trans directing 
effect exhibited by the sulfur-bound Me2SO ligand, which is comparable to that of 
dimethyl sulfide and ethylene179.
The infrared spectrum of rrfl^-[{PtCl2(Me2SO)}2(/^-dpzm)] is dominated by 
bands produced by the Me2SO ligand. The S—O stretching frequency is dependent on 
whether Me2SO is sulfur or oxygen bonded. When it is oxygen bonded, this band occurs
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at a lower frequency than in the free ligand, but when it is sulfur bonded it is observed at 
a higher frequency180. In the present example the S-O stretching frequency is 1120 cm'1 
compared to 1055 cm-1 for uncomplexed M e2S0180, which indicates the sulfur bonded 
nature of the ligand that is typical of platinum-Me2SO complexes. Unfortunately, a 
number of peaks due to Me2SO obscure the v(Pt-Cl) bands, which makes assignment of 
geometry based upon these frequencies difficult. However, chemical evidence strongly 
suggests that the complex would have a trans configuration. The bright yellow colour of 
the complex is also indicative of a trans arrangement178.
The n.m.r. spectrum of rra^-[{PtCl2(Me2SO ))2(jU-dpzm)] dissolved in Dö- 
Me2SO again displays a large number of peaks and is thus indicative of a rapid solvolysis 
reaction. When a freshly prepared sample dissolved in D7-dmf is run, the spectrum is 
much simpler and is similar to that obtained for cis-[{PtCl2(NH3)}2(/*-dpzm)]. The 
broad peak at 13.55 ppm can be attributed to the pyrazolyl N-H  resonance. The H3 and 
H5 protons are only separated by a shift of 0.1 ppm and this is further complicated by the 
formyl proton of dmf at 8.02 ppm which lies between the two peaks. As a result, the 
magnitudes of the 195Pt-H couplings could not be determined. The assignment of the H3 
and H5 protons is again based upon the observation that the H5 resonance generally lies 
further downfield than the H3 resonance100. Thus, it is proposed that the H5 resonance 
occurs at 8.07 ppm with the H3 at 7.95 ppm. These shifts are downfield from that 
observed for cw-[{PtCl2(NH3)}2(^-dpzm)] and probably arise from the inductive effect 
of the trans Me2SO ligand.
The methylene bridge protons are seen as a sharp singlet at 3.86 ppm, which is 
much the same as that observed for c/5,-[{PtCl2(NH3)}2(jU—dpzm)] and free dpzm. The 
methyl groups of the Me2SO ligand are also seen as a sharp singlet at 3.44 ppm. This 
indicates that free rotation about the Pt-S bond occurs with the Me2SO ligand having no 
preferred conformation. At 300 MHz the 195P t -S - C -1H coupling is only barely 
observable, but at 80 MHz this coupling is clearly visible and has been found to be 22 
Hz.
When the spectrum was run 3 days later, it was clear that extensive solvolysis had
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occurred. The peaks in the n.m.r. spectrum that had been assigned to the H3 and H5 
protons were barely visible and peaks corresponding to free dpzm (3.71 ppm) and free 
Me2SO (2.60 ppm) could be discerned.
2.2.3. The synthesis and characterization of 
cis-[{PtCl2(Me2SO))2(\i-dpzm)]
The preparation of c/s-[{PtCl2(Me2SO)}2(^-dpzm)] has been achieved by two 
different methods. It has been observed previously that platinum-Me2SO complexes of 
the form rrfl«5-[PtCl2A(Me2SO)], where A is an amine ligand, can be converted to the 
more thermodynamically stable cis isomer by heating to about 150°C181»182 or by 
dissolving the complex in Me2SO for a number of days18^ . Attempts to isomerize trans- 
[{PtCl2(Me2SO)}2(M“dPzm)] *n the solid state by the use of elevated temperatures 
(~150°C) resulted in decomposition of the complex. In Me2SO solution the isomerization 
was successfully completed after a period of about 3 days.
A more direct method for the synthesis of ci5-[{PtCl2(Me2SO)}2(M_dpzm)] 
involved the substitution of one of the Me2SO ligands of c/s-[PtCl2(Me2SO)2] with 
dpzm. It has long been known that one of the two Me2SO ligands of cis- 
[PtCl2(Me2SO)2] can be displaced by amine-like ligands, whereas a single Me2SO can be 
replaced only with difficulty. The reaction is promoted by a mutual cfr-labilizing effect, 
presumably due to steric rather electronic repulsions of the Me2SO ligands, and proceeds 
with retention of configuration18"*. The actual reaction of dpzm with cis- 
[PtCl2(Me2SO)2] produced an off-white product that was identical to that obtained by the 
isomerization of trans- [ {PtCl2(Me2SO)} 2(/t-dpzm)].
The infrared spectrum of cfr-[{PtCl2(Me2SO)}2(/£-dpzm)] shows a spectrum that 
is quite similar to that obtained for the trans isomer. The frequency due to S—O stretching 
mode v(S=0) in this case is observed at 1132 cm-1, which is slightly higher than is 
observed for the trans isomer. A similar situation has been observed with the cis- and 
trans- isomers of [PtCl2(py)(Me2SO)] (py = pyridine), where the v(S=0) bands were
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observed at 1142 and 1134 cm-1 respectively178. The assignment of other bands is given 
in Table 2.1.
The !H n.m.r. spectrum of c/s-[{PtCl2(Me2SO)}2(M-dpzm)] could not be obtained 
in either Ö6 -Me2 SO or D7 -dmf because of rapid solvolysis reactions that produced a 
number of different species in the solutions. These solvolysis reactions would be 
promoted by the large trans labilizing effect the Me2 SO ligand has on the chloro ligand. 
These results indicate that when dissolved in either of these solvents, this complex does 
not m aintain structural integrity . Because o f the lack o f solubility cis- 
[ {PtCl2 (Me2 SO)} 2 0 i-dpzm)] has in other solvents further analyses were not possible.
2.2.4. Attempted synthesis of
It is known that the substitution of the chloro ligands by a dicarboxylate group in a 
platinum drug can give a product with desirable biological features38’39. It was hoped that 
the incorporation of malonate into a dinuclear complex would give a complex with 
enhanced solubility in aqueous media.
[{Pt(mal)(Me2 SO))2 (\L-dpzm)]
o
cnf' \\o Wo
Scheme 2.2. Preparation o f [{Ptmal(Me2SO ))2 (\i-dpzm)] from  
[Pt(mal)(Me2SO)2] and dpzm.
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The reaction of [Pt(mal)(Me2SO)2] with dpzm, conducted according to the general 
procedure described by Bitha et a/.185, did give a product that may well have been the 
desired [{Pt(mal)(Me2SO)}2(/*-dpzm)]. Its infrared spectrum suggested the presence of 
the malonato, Me2SO and dpzm ligands. The microanalytical values obtained for carbon, 
hydrogen and nitrogen were similar to the values expected. However, the product was 
found to be totally insoluble in all common solvents, including hot water, hot dmf and hot 
Me2SO. Even in hot aqua regia no solubility was observed! This total lack of solubility 
meant that any further analysis or purification was not possible.
2.2.4. The synthesis of 4,4t-dipyrazolylmethane, dpzm.
The synthesis of this compound was originally described by Trofimenko170 who 
obtained it in only 30% yield from the reaction of pyrazole and methylenebromide at 
200°C under pressure. Because of the low yield and the use of pressure to achieve the 
reaction a more convenient method was sought.
It was found that the hydrobromide salt of l,T-dipyrazolylmethane, which can be 
prepared in high yield by a method that uses phase transfer catalysis186, could be 
converted to dpzm by heating it at 200°C for just one hour. It was necessary to use the 
hydrobromide salt so as to limit the volatility of the l,r-dipyrazolylmethane, which 
would otherwise sublime. Also, the presence of bromide ions probably assists in 
stabilizing the carbonium ion intermediate that is believed to form during the reaction102. 
The only other product from the reaction that was detected in any appreciable quantity 
was 4-bromopyrazole, which was identified by gas-chromatography mass-spectrometry. 
This by-product is probably formed by nucleophilic attack of bromide on the pyrazole 
groups. The overall yield of this reaction approached 60%, which included sublimation of 
the dpzm product to give a sample of high purity.
Chapter Two 43
<Q)
N— N 
H2C +
Scheme 2.3. The isomerization o f 1 ,T-dipyrazolylmethane to 4 ,4 '-  
dipyrazolylmethane, via a proposed carbonium ion intermediate102.
2 .3 . FURTHER INVESTIGATIONS
Despite some very promising biological results, the lack of solubility in water 
represents a major obstacle to the advancement of dpzm-bridged dinuclear platinum 
complexes as anticancer agents. One of the main priorities of any future research on this 
class of compounds would be to address this problem. Better solubility may be gained by 
replacement of the chloro leaving groups with ligands that have a net ionic charge, such 
as the phosphonocarboxylates, for example. Another approach may be to derivatize the 
dpzm ligand with solubilizing functions, such as hydroxy groups on the methylene 
bridge, in the hope that better biological properties in the resulting complexes can be 
obtained.
Chapter Three
THE PREPARATION AND 
CHARACTERIZATION OF COMPLEXES 
CONTAINING THE BOROCAPTATE LIGAND
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3.1. INTRODUCTIO N
The borocaptate anion was first described in 1964136, but despite its usefulness as 
an agent in boron neutron capture therapy (BNCT) its chemistry has not been extensively 
explored. The original synthetic procedure for the preparation of borocaptate involved the 
reaction of the doso-dodecahydrododecaborate anion (B12H122-) with hydrogen sulfide 
at 100°C for 4 hours in a pressure vessel. The crude product was neutralized with cesium 
hydroxide and this precipitated the salt CS2B 12H 11SH. The yield from this preparation 
was moderate (28%) and the product was reported to be contaminated with other 
boranes139. Other synthetic procedures have been subsequently described. Tolpin et 
a/.139 used a synthetic route based on the reaction of A-methylbenzothiazole-2-thione 
with closo-B i2H ii2_. A similar method has been used by Nakagawa and Nagai187, who 
used N-methylthiopyrrolidone as the thiolating agent (Scheme 3.1).
Scheme 3.1. Preparative routes to the borocaptate anion. The closo- 
dodecahydrododecaborane anion has been thiolated with N -  
m ethylbenzothiazole-2-thione139, N-methylthiopyrrolidone187 or 
hydrogen sulfide1^ 6to produce the borocaptate anion. (Labelling of the 
B-H  groups has been omitted for clarity in this and subsequent 
schemes).
The crystal structure of cesium borocaptate has been described188. It is composed 
of a regular dodecahedron with boron atoms located at the vertices. Hydrogen atoms are 
projected directly out from the centre of the dodecahedron, as is the thiol substituent. No
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other structural studies involving the borocaptate anion have been reported.
The known chemistry of the borocaptate anion centres about the thiol group. This 
group is oxidised by atmospheric oxygen in aqueous solution to yield a disulfide. 
Subsequent oxidation in turn yields a thiosulfinate and a sulfinylsulfone189 (Scheme 3.2). 
The mechanism of these reactions has been studied by electron spin resonance 
spectroscopy and are believed to involve the formation of superoxide adducts190. Apart 
from oxygen other agents have been used to oxidize the borocaptate anion and these 
produce similar results139»1^ .  All the oxidation products can be converted back into the 
parent thiol by reduction with dithiothreitol under basic conditions139. The disulfide when 
dissolved in acidified organic solvents is converted to an intensely coloured free radical, 
with the electron apparently distributed about the two sulfur atoms. The stability of the 
radical is undoubtedly due to the high charge (4-) on the anion and the aromatic nature of 
the boron cage191.
Scheme 3 2 . The oxidation o f the borocaptate anion. Oxidizing agents, 
[O], that have been investigated include hydrogen p e r o x id e ^ , 2- 
chloroperbenzoic acid139, 2-iodosobenzoate191 and oxygen189 The 
actual product that can be isolated is dependent upon the conditions and 
the time allowed fo r  the reaction.
Electrophilic substitution reactions occur readily on the thiol group. The 
borocaptate anion reacts with trimethylsulfonium iodide to produce (B i2H nS(C H 3)2r
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(Scheme 3.3) which is the more stable sulfonium ion136. Disubstituted sulfonium salts 
are also produced when borocaptate is reacted with alkyl halides192. These are formed via 
the monosubstituted thioether (Scheme 3.4). Only when a bulky alkyl halide, such as 2 - 
iodopropane, is used can the reaction be halted at the monosubstituted thioether. The 
sulfonium salts produced are quite stable when compared to the corresponding alkyl 
sulfonium salts. They will only alkylate amines with great difficulty. Removal of an alkyl 
group from the sulfonium salt could only be achieved with the use of a strong base, such 
as tetramethylammonium hydroxide in acetonitrile, and then only with the bis(cyanoethyl) 
and bis(cyanomethyl) derivatives. A synthetic route for the production of thioether 
derivatives of borocaptate based on this reaction has been devised192.
Scheme 3.3. The reaction o f the borocaptate anion with the 
trimethylsulfonium cation.
Scheme 3.4. The synthesis of borocaptate derived sulfonium salts via a 
thioether intermediate. The reaction only halts at the thioether when a 
sterically demanding R group is used.
Thioesters of borocaptate with carboxylic acids are also remarkably stable against 
hydrolysis, with pseudo-first-order reaction rate constants similar to or smaller than those 
of carboxylic acid esters. The thioesters described192 have been prepared by the reaction 
of the corresponding acid chloride with the borocaptate anion(Scheme 3.5).
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The apparent stability of these organo-sulfur derivatives must be attributed to the 
strong electron donating properties of the c/öso-dodecaborane cage structure. This is also 
borne out in the unusually high pKa of the thiol group that has been determined to be 
13.4. Although Gabel et al,192 have attributed this to the “ the strong electron- 
withdrawing character of the borate cage”, this cannot be the case as electron withdrawal 
would decrease the strength of the S-H  bond and so produce a lower pKa. Electron 
withdrawal would also serve to destabilize sulfonium ions and thioesters. A species 
which has formally a charge of 2 -  cannot be viewed as electron deficient, and it would 
appear that a significant amount of this charge resides on the sulfur atom.
Scheme 3.5. The preparation o f thioester derivatives o f the borocaptate 
anion with acid chlorides (R = CH3, C^H^).
The coordination chemistry of thio ligands is extensive. There is nothing obvious 
to suggest that the sulfur of the borocaptate anion could not also act as a donor in metal 
complexes. In view of the known affinity a number of metal complexes have for DNA 
and the apparent need to develop boron compounds that display just this property, it is 
somewhat surprising that attempts to prepare borocaptate-metal complexes have not been 
reported previously. Additionally, there are no reports of any studies aimed at elucidating 
possible interactions the borocaptate anion may have with metal ions in patients receiving 
this drug, and thus, evidence for complex formation would be of interest.
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3.2. RESULTS AND DISCUSSION
Initial attempts to produce borocaptate complexes focused on platinum(II) and 
nickel(II) metal centres. The starting materials with which complexation was attempted 
were [PtCl(terpy)]Cl and [NiCl2(PEt3)2]. When mild reaction conditions were used only 
starting materials were returned. With more vigorous conditions, mixtures of solid 
materials, which could only be described as decomposition products, were obtained. 
When the borocaptate anion was reacted with the ruthenium(II) complex, cis- 
[RuCl2(Me2SO)4], a number of different water soluble species, which could not be 
satisfactorily purified, were formed. The use of ruthenium(III) species was more 
successful.
3.2.1. The synthesis and characterization of 
[Ru(SBI2Hn)(NH3)s]-2H20
The synthesis of [Ru(SBi2H n)(N H 3)5] has been achieved by the reaction of 
[RuCl(NH3)5]Cl2 with cesium borocaptate in a warm aqueous solution (Scheme 3.6). 
The reaction mixture quickly turned deep-blue and on standing, crystals of the product 
formed. The reaction probably proceeds via either the aquated species 
[Ru(NH3)5(OH2)]3+ or the hydroxo species [Ru(NH3>5(OH)]2+, both of which are 
known to be present in a neutral aqueous solution192. Substitution with the sulfur of 
borocaptate occurs with the loss of the thiol proton to give a neutral species. Because of 
the large pKa of the thiol group (13.4) it is expected that the loss of the proton occurs 
after substitution192.
The infrared spectrum of the complex is dominated by the very intense peak due to 
the v(B-H) band at 2475 cm-1. This peak is slightly lower in frequency than it is in the 
free borocaptate (2486 cm-1), which may be due to a lowering of the electron density of 
the boron cage with subsequent weakening of the B-H bonds. Other peaks and then- 
assignments are given in Table 3.1. The location of most of these peaks is very similar in 
the complex to their positions found in the spectra of the parent moieties. The exception is
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the band assigned to the NH3 rocking vibration (760 cm-1) which is significantly reduced 
in energy from that observed for [RuCl(NH3)5]Cl2 (801 cm-1). This band has been used 
as a measure of the strength of the M-N bond194. The reduction in frequency observed 
here suggests that there has been a weakening of the Ru-N bonds, which is probably due 
to the stronger electron donating effects of the borocaptate ligand over the chloro ligand.
Scheme 3 .6 . The preparation of [Ru(SBi2Hu)(NH3)5] in aqueous 
solution.
The changes in the ultraviolet and visible spectrum on complex formation are quite 
dramatic. From a pale-orange solution of [RuCl(NH3)5]Cl2 and a colourless solution of 
CS2B12H11SH is produced the intensely blue product, [Ru(SBi2Hn)(NH3)5]-2H20. 
The ultraviolet and visible spectrum of this complex was measured in Me2SO solution 
and this displayed two reasonably broad bands at 588 and 440 nm. The emax values for 
these absorptions are 1320 and 1190 M^cm-1 respectively. These relatively high values 
suggest that the bands are due to charge transfer. With formally a 3+ charge on the 
ruthenium centre and a 3- charge on the borocaptate ligand, the presence of charge 
transfer bands is hardly surprising and the transfer undoubtedly occurs from the ligand to 
the metal. With a large electron density thought to manifested on the sulfur atom, 
borocaptate must be viewed as a 7t-base ligand. Ruthenium(III) with its low-spin d5 
arrangement of electrons has a t2g orbital available for overlap with just such a ligand195 
and this promotes the formation of a stable complex. The solution spectrum of 
[Ru(SBi2Hh )(NH3)5]-2H20 in Me2SO remains unchanged after several days, which is 
an indication of the high stability of the complex.
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Table 3.1. Infrared bands o f the complex [Ru(SBj2H n)(^H ^)^]-2H2 0 , with 
comparisons to the parent compounds from which it is derived.
Assignment [Ru(SB12Hh )
(NH3)5]-2H20
[RuC1(NH3)5]C12 CS2B12H11SH
Va(N-H3) 3321 3300 n.a.
VS(N-H3) 3252 3200 n.a.
v(B-H) 2475 n.a. 2486
3a(H-N-H) 1609 1617 n.a.
3S(H-N-H) 1294 1297 n.a.
pr(NH3) 760 801 n.a.
[B 12H 11S-]2- 1055 n.a. 1053
[B 12H n s - ] 2- 963 n.a. 976
[B 12H 11S-)2- 840 n.a. 843
[Bi2Hn S—I2- 722 n.a. 718
n.a. = not applicable.
The cyclic voltammogram of [Ru(SBi2H n)(N H 3)5]*2H20 in dmf at a platinum 
electrode is shown in Figure 3.1. This shows a number of electrochemical processes. A 
tentative reaction scheme which may explain the nature of these couples is shown in 
Scheme 3.7.
- 0.6 - 0.8 - 1.0-0.2 -0.4
E/V
Figure 3.1. Cyclic voltammogram o f [Ru(SBj2H ]i)(N H s)^] in dmf, 
0.5 M NBU4BF4 and about 10~3 M in sample, run at 100 mV  W  in the 
range -1 .0-1.0 V vs Ag/AgCl at -20 °C.
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"[Ru(SB12H n )(NH3)5]2+" 
(+0.54 V)
"[Ru(SB1T2H 11)(NH3)5]+”
a
(+0.33 V)
[Ru(SB12H n )(NH3)5] 
(-0.30 V) 
"[Ru(SB12H 11)(NH3)5r "
[Ru(NH3)5(solv.)]3+ 
(-0.09 V)
[Ru(NH3)5(solv.)]2+
+
[SB12H n ]3-
Schem e 3.7. The oxidation  and reduction  chem istry o f  
[Ru(SB i 2H j i )(NH 3 )5]-2 H 2 0  as observed by cyclic voltammetry in 
dm f solution. Redox couples are referenced against the NHE according 
to the method o f D uff and Heath196. Arrows marked with a X indicate 
that the couple was not reversible in the direction indicated.
A cathodic process for [Ru(SBi2H n)(N H 3)5] is seen to occur at -0.30 V, relative 
to the normal hydrogen electrode (NHE). The relatively small intensity of this process 
suggests that it is an one electron reduction. Being a borohydride, the borocaptate anion is 
in a very reduced state. It is probable, therefore, that further reduction of this group 
would not occur at such a moderate potential. Hence, it is assumed that this reduction is 
associated with the metal centre and thus would correspond to the reduction of 
ruthenium(III) to ruthenium(II). Ruthenium(II), which is d6, does not have an available 
t2g orbital that can accept k electrons from the sulfur atom of the borocaptate ligand. 
Thus, the ruthenium(II)-borocaptate complex generated electrochemically, is unstable and 
dissociates irreversibly. The solvated ruthenium(XI) species so formed can be oxidised 
back to a ruthenium(III) species but only at a more positive potential.
Recent work by Lever197 has suggested that the redox potential, £ 7/2, of a couple 
M(n)/M(n -  1) for a complex species can be estimated according to the formula:
E 1/2 = Sm [££ l(L)] + / m
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where 5m and / m are values determined experimentally for the particular couple involved 
and £ l(L) is what is known as the ligand electrochemical parameter. While the 5m and 
7m values for the ruthenium(III)/ruthenium(II) couple are known (and are 0.97 and -0.04 
V respectively197) the £l(L) value for the borocaptate ligand has not been determined. 
The value £ l (SB i 2H h ) can be calculated from the experimental data, and by 
incorporating the known value of £ l(NH3) that has been quoted as 0.07 V197. That is:
-0.30 = 1.01(5 x 0.07 + £L(SBi2Hh )) -  0.063 
£l(SBi2Hh )« -0 .6 V
This value is quite similar to that obtained for the related thiophenolato ligand that 
has a stated £ l (SC6H5) = -0.53 V. This value is amongst the most negative of any 
determined thus far. This large negative value of £ l(SBi2Hh ) would make reductions of 
borocaptate complexes difficult. Conversely, high oxidation state complexes should be 
stabilized by the presence of the borocaptate ligand.
From the estimated value of £ l (SB i 2H h ) it is possible to estimate the 
which is given by Duff and Heath196 as:
£ l/2(RuIV/m) = 1.01 ZEl  + 1.523
Thus, £ i/2(RuIv^n) for [Ru(SBi2Hn)(NH3)5] is approximately 1.3 V. This was not 
observed in this experiment because at these potentials decomposition of the solvent dmf 
occurs. The unidentified anodic processes that are observed are assumed to be associated 
with the oxidation of the borocaptate ligand itself.
The magnetic moment, p, of the complex was determined by the Gouy method198. 
In order for the determination to be made, the molar magnetic susceptibility, %m, for the 
borocaptate anion had to be measured. This was found to be -204 x 10'6 cgs units. The 
magnetic moment of the complex was thus calculated to be 1.68 BM. This corresponds to 
a value due entirely to a spin-only low spin d5 system. That is, the paramagnetism 
observed is due to the one unpaired electron on the metal centre. It is not unusual for d5 
complexes of ruthenium to have a contribution to their magnetic moment attributable to
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spin-orbit coupling199, but this is not found in this borocaptate complex.
The n.m.r. spectrum was of little value in the determination of the structure of 
the complex. It featured a broad peak at 8.00 ppm that is due to the NH3 ligands and 
another broad peak at 3.64 ppm due to the B-H groups. The B-H protons of the 
borocaptate thioether, sulfonium salt and thioester derivatives, are seen as broad 
resonances between 0 and 2 ppm192. An effect due to metal coordination of the 
borocaptate anion is reflected in the downfield shift observed for the proton resonances of 
the boron cage in this complex.
Definitive proof as to the actual nature of the complex was obtained by a single 
crystal X-ray structure analysis (see Chapter Four).
3.2.2. The synthesis and characterization of
trsLns-[Ru(SBi2Hn)(en)2(OH2)]
The reaction of rratts-[RuCl2(en)2]Cl with CS2B12H11SH in water produced a pale 
yellow precipitate which was identified as the salt rr<ms-[RuCl2(en)2]2[Bi2HnSH]. 
Because of the ready formation of this salt an alternate procedure was required. The 
method used for this synthesis involved the preparation of the trifluoromethanesulfonato 
(triflato) intermediate200'202. The addition of trifluromethanesulfonic (triflic) acid to trans- 
[RuCl2(en)2]Cl proceeded with the liberation of hydrogen chloride gas and produced a 
dark-orange oil. The excess acid was removed and the triflato complex was dissolved in 
water. This was treated with CS2B12H11SH to produce the desired complex, which was 
obtained as an amorphous green-brown powder (Scheme 3.8).
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Scheme 3 .8. Preparative route to trans-[Ru(SB 12Hn)(en)2(OH2)] via 
the bis(triflato) intermediate.
A number of significant shifts in the infrared bands associated with the 
ethylenediamine ligand between the parent dichloro complex and the borocaptate complex 
are observed (Table 3.2). Molecular modelling studies indicate that there exists a great 
degree of steric crowding about the ruthenium centre in this borocaptate complex. This 
would have a direct influence on the ethylenediamine groups which is reflected in the 
higher frequencies obtained for a number of the bands. The v(B-H ) frequency is again 
somewhat lower than what is found in the free borocaptate anion, and is comparable to 
that found for [Ru(SBi2H n )(N H 3)5]. The presence of water can be seen in the broad 
v(0 -H 2) frequency at 3435 cm '1.
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Table 3 2 . Infrared bands of the complex tians-[Ru(SBi2Hi])(en)2(OH2)], with 
comparison to the parent compounds from which it is derived.
Assignment [Ru(SBi2Hn)(en)2
(OH2)]
fr<2ftf-[RuCl2(en)2]
Cl
Cs2B i2H i i SH
v(0 -H 2) 3435 n.a. n.a.
Va(N-H2) 3297 3247 n.a.
VS(N-H2) 3254 3178 n.a.
Va(C-H2) 2942 2981 n.a.
VS(C-H2) 2884 2946 n.a.
v(B-H) 2475 n.a. 2486
8(NH2) 1580 1595 n.a.
8(CH2) 1454 1445 n.a.
V a(C -N ) 1163 1123 n.a.
V s(C -N ) 1108 1101 n.a.
[B12H „S-]2- 1045 n.a. 1053
[B12Hu S-]2- 976 n.a. 976
[Bl2H „S-]2- 837 n.a. 843
[Bi2Hn S-]2- 718 n.a. 718
n.a. = not applicable.
The !H n.m.r. spectrum of rra>w-[Ru(SBi2H ii)(en)2(OH2)] in 0 7 -dm f is poorly 
resolved. This is probably due to the paramagnetism of the d^  ruthenium metal centre, but 
it could also be due to a solvolysis reaction. In Me2SO a blue solution is formed from the 
green-brown rra/i£-[Ru(SBi2H n )(en )2(OH2)]. Undoubtedly this is produced by a 
solvolysis reaction. The *H n.m.r. spectrum obtained in this solvent is again poorly 
resolved.
The magnetic moment, |i, of /ra/w-[Ru(SBi2Hn)(en)2(OH2)] was 1.08 BM. This 
value is much lower than the theoretical value expected for one unpaired electron in a low- 
spin d5 system of 1.73 BM199. The complex rrart5-[Ru(SBi2H ii)(N H 3)5] also has a 
relatively low value for its magnetic moment, which suggests that this may be a feature of 
borocaptate coordination to ruthenium(III). The poor solubility characteristics of the 
product have prevented further analysis.
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3 .2 .3 . The synthesis and characterization of 
[R u (SB 12Hu ) (terpy) (OH 2)2] -
The direct treatment of [R11CI3(terpy)] with CS2B12H11SH failed to give any 
reaction. Thus, it was necessary to convert [R.UCI3 (terpy)] to a more reactive 
intermediate. The procedure that was used to prepare [Ru(SBi2Hn)(terpy)(OH2)2] was 
via the tris(trifluoromethanesulfonato) complex (Scheme 3.9), in similar manner to that 
used to produce the ethylenediamine analogue203»204. In this case it was possible to 
actually isolate the triflato complex, [Ru(03SCF3)3(terpy)], as a dark-green crystalline 
solid. This compound was very air sensitive, but its infrared spectrum indicated the 
presence of terpyridine and triflate, and the absence of any peaks that were due to chloro 
ligands.
The triflato intermediate was dissolved in water and then reacted with the 
borocaptate anion which rapidly gave the product as a brown amorphous powder. 
Molecular modelling studies suggest that the aquo ligands would be in a cis geometry, 
with respect to each other, with the borocaptate ligand perpendicular to the plane formed 
by the terpyridine ligand. This would be necessary because of the extreme steric 
crowding that would result if the borocaptate was in the same plane as the terpyridine 
ligand; the borocaptate is far to bulky to occupy this position.
The infrared spectrum is a mixture of bands derived from both the terpyridine and 
the borocaptate ligands (Table 3.3). The band associated with the B -H  stretching mode is 
at a higher frequency than is observed in the free borocaptate anion, rather than at a lower 
frequency as observed in [Ru(SBi2H i i )(NH3)5] and [Ru(SBi2Hii)(en)2(OH2)]. This is 
most likely due to an effect associated with the presence of the aromatic terpyridine 
ligand. Bands associated with the terpyridine ligand are at essentially the same 
frequencies as they are in the parent complex [RUCI3(terpy)], with the exception of the 
band assigned to the out of plane wagging mode, co(C—H), which is found at a somewhat 
lower energy. If the borocaptate was having a direct steric effect on the terpyridine ligand 
then it is expected that this mode would be at a higher energy, being less favourable. As 
this is not the case it can be tentatively concluded that the borocaptate lies out of the plane
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of the terpyridine ligand, as is depicted in Scheme 3.9.
Scheme 3.9. The preparative route to [Ru(SB 12Hji)(terpy)(OH2)2l> 
via the tris(triflato) derivativ.
Table 3.3. Infrared bands of the complex [Ru(SB]2Hn)(terpy)(OH)2], with comparisons 
to the parent compounds from which it is derived.
Assignment [Ru(SB12Hh )(terpy)(OH2)2] [RuCl3 (terpy)] Cs2B i2H h SH
v(0-H 2) 3445 n.a. n.a.
v(C-H) 3078 3060 n.a.
v(B-H) 2500 n.a. 2486
v(C-C) 1601, 1468, 1449, 1595, 1468, 1445, n.a.
1388 1387
8(C-H) 1285, 1244, 1162 1280, 1233, 1156 n.a.
co(C-H) 767 783 n.a.
[Bi2HUS-]2- 1051 n.a. 1053
[B12H11S-]2- 963 n.a. 976
[B12H i i S-]2- 837 n.a. 843
[Bi2H h S-]2- 733 n.a. 718
n.a. = not applicable.
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The complex [Ru(SBi2Hn)(terpy)(OH2)2] is only soluble in Me2SO. Its iH 
n.m.r. spectrum indicates that this occurs with solvolysis as a number of species can be 
detected. The paramagnetism again makes the spectrum poorly resolved.
The magnetic moment, |i, of the solid was determined to be 1.31 BM. This value 
is again lower than that expected for a low spin d5 system, which is 1.73 BM 199. This 
low value is, however, in keeping with what has been observed for the other complexes 
of borocaptate described. With poor solubility further analyses were not possible.
3 .3 . CONCLUSIONS
It is possible to prepare metal complexes featuring the borocaptate anion as a 
ligand, albeit with some difficulty. Being a dianion, borocaptate has a strong tendency to 
form insoluble salts with a number of cationic metal complexes. With anionic metal 
complexes, there is a considerable electrostatic repulsion to be overcome before any kind 
of association can proceed. The sterically demanding size of the borocaptate ligand also 
makes coordination unfavourable.
While it is difficult to produce complexes with borocaptate, it is not impossible as 
the preceeding examples have demonstrated. Complexation has been found to be 
achievable with ruthenium(III) species. Other metals and oxidation states, which were 
tried but failed to give a reaction or a characterizable product, were platinum(II), nickel(II) 
and ruthenium(II).
Borocaptate has been found to coordinate in a monodentate fashion with formally, 
at least, a 3 - charge and is clearly a very electron rich ligand. This would favour charge 
transfer, which would occur from the ligand to the metal centre, in its complexes. This 
opens up the possibility that the borocaptate ligand may be effective in stabilizing 
unusually high oxidation states.
The possible coordination of borocaptate to a metal centre should not be ignored in 
any discussion of the in vivo action of the borocaptate anion, especially considering the
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variety of metal ions to be found in biological systems.
3 .4 . FURTHER INVESTIGATIONS
The poor aqueous solubilities observed for the borocaptate complexes represents a 
serious impediment to their further development as boron delivery agents for BNCT. 
However, the idea of using a metal complex to deliver boron specifically to the DNA of 
cancer cells is not without merit, if a suitable ligand with a high boron content is used. 
The general investigation of the borocaptate anion as a ligand may be warranted. 
Unusually high oxidation states of metal complexes are likely to be accessible when 
borocaptate is present.
Investigations into the possible in vivo coordination of the borocaptate anion may 
also produce some interesting results. Coordination studies which focus on metals 
commonly found in biological systems, such as iron(III), would be of interest in 
determining the possible fate of borocaptate within an organism, and whether that fate is 
linked to a metal centre.
Chapter Four
X-RAY STRUCTURE DETERMINATION OF 
PENTAAMMINE(l-THIOLATO-c/oso-UNDECA- 
HYDRODODECABORANE)RUTHENIUM(III) 
DIHYDRATE, [Ru(SBi2Hn)(NH3)5] 2H20
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4 .1. BACKGROUND
The scattering of X-rays by a crystal is produced by the interaction of the X-rays 
with the electrons of the atoms present. The scattering pattern formed discloses the atomic 
arrays associated with the crystals’ structure205. The scattering strength of an atom is 
proportional to the number of electrons it possesses, which is given by its atomic 
number. Because the distances between the electrons of an atom are about the same as the 
wavelength of the incident X-rays, the scattered waves interfere with one another, so the 
preceding statement is only strictly applicable for scattering in the forward direction. The 
total scattering amplitude in other directions decreases with increasing scattering angle 
because of the partially destructive interference produced by electrons scattering at 
different points within the atom. The ratio between the amplitude of the radiation scattered 
by an atom, Ea, and that of an isolated electron, Ee, (under identical conditions) is known 
as the atomic scattering factor f :
The sum of the scattering factors, with respect to the position of the J atoms 
(represented by fractional coordinates xj, y/, i f ) within the crystal unit cell gives the 
complex quantity Fhkl which is the structure factor:
Fhkl = /  ie ^ i  + f y t lih  + f $ e l<h  +....+ / je ^ J
where (j)j = 2n(hxj + Icyj + Izj)
This characterizes the diffraction maxima, or reflections, with indices hkl. Thus for 
a particular arrangement of atoms in a cell, there is a specific set of diffraction maxima
Fhkl-
A crystal structure solution is achieved by comparing the observed diffraction 
pattem with that calculated from a model of the structure206. The degree of agreement 
between the observed and calculated is indicative of the accuracy of the model. The 
observed intensity of a reflection I hkl is related to the structure factor of that reflection 
Fhkl as:
C h a p ter  F our 63
hkl 00 \Fhkl I2
For the purposes of computing structure factors it is more convenient to express 
them in terms of their real and imaginary components, that is:
Fhkl = IFhkl I cos <p + i 1Fhkl \ sin 0
= cos <f)j) + / ( £ / /  sin <pj)
j  j
As crystals are periodic structures, the electron density p at a point*, y, z in a unit 
cell of volume V can be represented by a three dimensional Fourier series:
Pxyz = fXXX \Fhkl\cos t2lz(hx + ky + /z) - al
h k l
where a  is the phase angle, defmed as:
% f j  sin <Pj
a  = tan*1 d ;-------------
ZJj  cos  
j
If the structure factor amplitude and phase angles for each reflection were known, 
then the electron density could be calculated for all values of x, y, z to give an electron 
density map with atomic nuclei located in regions of high electron concentration. 
Unfortunately, only the structure factor amplitudes can be determined from 
experimentally observed intensities. This is known as the phase problem.
If one or more atoms within a structure have an atomic number substantially greater 
than the majority of the atoms present, then these heavy atoms will dominate the 
scattering and the phase angle for the whole structure can by approximated to that of the 
heavy atoms alone. The positions of the heavy atoms can be located by using the 
Patterson function, which is a vectorial representation of the atomic composition of the 
unit cell and is expressed thus:
P UVw = y ' Z I , £  \ P m \2cos [27t + k v +  )] 
h k l
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The intensity of each peak in this three-dimensional contour representation is 
proportional to the product of the electron density of the two atoms which define the 
interatomic vector u, v, w.
Having identified the relative positions of the heavy atoms, a Fourier synthesis 
may be produced using the phase angles calculated from these positions and the observed 
structure factor amplitudes. New atom positions found by this synthesis are then added to 
the model structure and another Fourier synthesis is calculated. This procedure is repeated 
until all the atomic positions are located. An alternative approach is to use a difference 
Fourier synthesis, calculated as the difference between the observed electron density 
(Pobs) and the calculated density (pcalc)• A difference Fourier can reveal where 
insufficient or excessive electron density is included in the model structure and thus can 
be used to detect the positions of light atoms.
4 .2. X-RAY STRUCTURE DETERMINATION OF
[Ru(SB12H1I)(NH3)5]-2H20
The crystals used in this determination were obtained directly from the reaction of 
[RuCl(NH3 )5 ]Cl2  with CS2 B 12H 1 1SH in aqueous solution. The density of these crystals 
was determined by flotation in a mixture of chloroform and dibromomethane.
A needle-like crystal of approximate dimensions 0.20 x 0.05 x 0.01 mm was 
mounted lengthwise on a quartz glass fibre with Araldite adhesive. Preliminary X-ray 
photographic data was obtained on a Weissenberg camera using CuKa radiation. Results 
from a zero level Weissenberg photograph suggested a monoclinic crystal mounted on the 
unique axis. Systematic absences were noted on the hOl net when / was odd and on OkO 
axis when k was odd. This defines the space group P2i/c (Number 14). A first level 
Weissenberg photograph was taken in order that all the unit cell dimensions could be 
approximated using a geometric method207.
More accurate unit cell dimensions were obtained by a least squares calculation of 
the settings of 23 reflections (10° < 20 < 45°) centred on a Philips PW 1100/20
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diffractometer with graphite monochromated MoKa radiation. An intensity data set of 
2617 reflections, in the form +h, +k, ±/ was collected in the ranges 0 < / i < 8 , 0 < / : < 1 0  
and -10 < / < 10. Three standard reflections, 0 2 1,2 2 0 and 1 2  1, were measured 
every two hours in order to monitor variations in intensity. The intensities of these 
standard reflections dropped by 4.5, 2.6 and 4.9% respectively during the period of data 
acquisition.
A superior data set was collected on a Rigaku AFC6-R instrument using graphite 
monochromated CuKa radiation from a 12 kW rotating anode generator. Unit cell 
parameters were obtained from 25 high angle reflections (60° < 20 < 80°), while the data 
set consisted of a total 2884 reflections (2176 observed, 688 weak and 20 symmetry 
related). This data set was of the form +h, +k, ±1 and was collected in the ranges 0 <h<  
9, 0 < k < 16, -16 < / < 16. The standard reflections, 1 2 0, 0 2 2 and 1 2  1 were 
measured after every 75 reflections. Over the 29 hours required for the data to be acquired 
the standards dropped in intensity 2.2, 3.5 and 4.1% respectively.
4.2.1. Structure solution and refinement
The structure solution and refinement were performed on the RSC4 node of the 
Research School of Chemistry’s Minivax computer. The following computer programs 
from either the ANUCRYS208, SHELX-86, XTAL3.0 or XTAL3.2 program libraries were 
employed in the solution .
ABSORB - XTAL3.2: For the application of Gaussian, analytical and spherical
absorption corrections, by G. Davenport, N. Spadaccini and J. 
Stewart.
ADDREF - XTAL3.0/3.2: For the placement and reduction of reflection data onto a binary
file, by G. Davenport and S. Hall.
BONDAT - XTAL3.0/3.2: For generating atom coordinates from molecular geometry, by R.
Doherty, J. Stewart and H. Flack.
Chapter Four 66
BONDLA - XTAL3.0/3.2: For the calculation of bond lengths and angles, by W. Dreissig,
R. Doherty, J. Stewart and S. Hall.
CRYLSQ - XTAL3.0/3.2: For full-matrix least squares structure factor refinement, by R.
Olthof-Hazekamp.
CRYSTAL STRUCTURE SOLUTION - SHELX-86: For the Patterson heavy atom solution of
atomic coordinates, by G. M. Sheldrick.
DIFDAT - XTAL3.2: For the processing and scaling of diffraction data, by J. Stewart,
R. Merom, J. Holden, R. Doherty, S. Hall, T. Maslen and N. 
Spadaccini.
FOURR - XTAL3.0/3.2: For three-dimensional Fourier syntheses, by J. Stewart, J.
Holden, R. Doherty and S. Hall.
GENEV - XTAL3.2: For the normalization of structure factors, by S. Hall and V.
Subramanian.
HYDGEN83 - ANUCRYS: For the calculation of hydrogen atom positions208.
ORTEP - XTAL3.0/3.2: For calculating thermal ellipsoid data for plotting, by G.
Davenport, S. Hall and W. Dreissig.
PEAKPIK - XTAL3.0/3.2: For the location of electron density peaks in a Fourier map, by S.
Hall and R. Doherty.
PWDECO - ANUCRYS: For the analysis of standard reflections208.
PWREDU - ANUCRYS: For data reduction, application of Lorentz-polarization and decay
corrections208.
REGWT - XTAL3.2: For the estimation of least-squares weights, by B. Robertson and
H. Wang.
SORTRF - XTAL3.2: For the sorting and merging of reflection data, by S. Hall, N.
Spadaccini and J. Stewart.
The data obtained from the Philips instrument was corrected first for crystal 
degradation and Lorentz-polarization effects using the PWDECO and PWREDU programs. 
The integrated intensities, /, were corrected as follows:
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I =[cp -(tp I tb)(Bj +B2)
where cp = scan count, tp = scan time (s), tb -  background count time (s), and Bj and B2 
are the measured background counts either side of the peak. The correction for Lorentz- 
polarization (Lp), which was also applied, is given by:
cos229 + cos229m 
^  sin29(l + cos229m)
where 29 is the reflection angle and 9m is the monochromator angle. The final observed 
structure factor amplitudes, |F0|, are thus given by:
The reflections were then sorted and the mean of equivalent reflections calculated
by the SHELX-86 CRYSTAL STRUCTURE SOLUTION program. This gave a set 965 
reflections with |F0| > 4o(|F0|) that were used in the refinement. The structure was
solved by the Patterson heavy atom method. This located both the ruthenium and sulfur, 
atoms at 0.120, 0.198, 0.011 and 0.173, 0.067, -0.75 respectively.
The data was converted to XTAL3.0 format and, with the positions of the ruthenium
and sulfur atoms obtained from the Patterson solution, was used in a least-squares 
refinement. The selection criterion for observed reflections was set to |F0| > 2o(|F0|),
and this gave a set of 1382 reflections that were used for further refinement. The isotropic 
thermal parameters were arbitrarily set at 3.5 Ä2 for ruthenium and 5.0 Ä2 for sulfur. A 
difference Fourier was calculated and further atom positions were thus located. The 
function K was minimised in the least squares refinements:
*  = 2>(N -  |Fc|)2
where \FC\ = the calculated structure-factor amplitude and w = assigned weight, initially 
set to one.
The refinement process was repeated until all non-hydrogen atoms were found, 
including the oxygens due to the two waters of crystallization. The R-factor, which is a
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measure of the data quality and the correctness of the structure, was at this stage 0.169. 
This index is defined as:
Because the intensity of this data set was very weak, and thus a relatively small 
number of reflections were observed, further refinement could not be achieved. It was at 
this stage that the more intense data, obtained from the Rigaku instrument using CuKa 
radiation was introduced and used for further refinement.
The DIFDAT program was applied to the data in order to scale it according to the 
standard reflections and to present it in a form usable by XTAL3.2. A correction for crystal 
absorption effects was applied, using the analytical method described by Alcock209, 
available within the ABSORB program. The data was then sorted, using SORTRF, and 
equivalent reflections were merged. A correction for Lorentz-polarization was applied by 
the program ADDREF. The Lorentz-polarization was in this case given by:
sin 20
L p ~  (Tl + T2)
where Tl = (1 -  C)(B + (1 -  B)cos220cos220m)/(B + (1 -  B)cos226m)
T2 = C(B + (1 -  B)cos220cos228m)/(B + (1 -  B)cos220m) 
and B is the fraction of intensity with the electric field parallel to the plane of the 
monochromator and was set at 0.5, while C is the monochromator perfection factor and
this was also 0.5. The structure factors were calculated as described previously. This 
gave a set of 2196 reflections with |F0| > 2o(|F0|). A least-squares refinement of this
data set, using the atom positions already located with their corresponding isotropic 
thermal parameters, gave a R-factor of 0.080.
The program REGWT was used to produce a weighting scheme for least-squares 
refinement. The assigned weight, w, was given by:
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where p is the instrumental uncertainty. This scheme reduces the effect of very strong 
maxima on the residual R-factor and the minimisation function K.
Refmement was continued with anisotropic thermal parameters for all atoms except 
hydrogen. These parameters were satisfactory except for the oxygen of the second water 
molecule. Its thermal parameters were very large and this was thought to be due to partial 
occupancy of its site. Refinement of its population parameter gave a value of 0.90, which 
effectively indicates full occupancy. This refinement did, however, improve the R-factor 
and, therefore, the population parameter was not reset to 1.0. The large thermal 
parameters of this oxygen indicate that it is either statistically or thermally disordered.
The hydrogen atoms on each boron atom and on one of the solvent water 
molecules were located from difference Fourier synthesis. These hydrogens were 
included in the refinement with isotropic thermal parameters assigned arbitrarily as 0.06 
Ä2 for boron hydrogens and 0.10 Ä2 for water hydrogens. This resulted in a reduction of 
the R-factor to 0.053. The possible positions of the hydrogen atoms about the nitrogen 
atoms were calculated with HYDGEN83. Comparison of these values with difference 
Fourier contour maps gave approximately the correct positions for these atoms, which 
were included in the refinement with thermal parameters assigned as 0.10 Ä2.
Least-squares refinement with all atoms accounted for, except for the protons of 
the second water molecule, produced a R-factor of 0.041. The final difference Fourier 
synthesis revealed no residual electron density greater than 0.58 electrons / Ä3. The 
weighted residual factor Rw was calculated to be 0.053, where Rw is given by:
The standard deviation of an observation of unit weight or goodness of fit, S, is 
defined as:
where m = the number of unique reflections and n = the number of variables. This value
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should be very close to unity if the weighting scheme has been chosen correctly. The final 
S value in this case was found to be 1.294.
Figure 4.1. The molecular structure o f [Ru(SBi2Hu)(NHs)y], without hydrogen atoms. 
Thermal ellipsoids are represented at 30% probability.
N5
B12 B11
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Figure 4.2. The molecular structure of [Ru(SB]2Hu)(NHs)y] with hydrogen atoms 
present. Thermal ellipsoids are represented at 30% probability.
o
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Figure 4.3. Stereoscopic view of the unit cell contents of [Ru(SBj2Hjj)(NH^)y] -2H2Ö. 
Hydrogen atoms have been omitted for clarity.
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Table 4.1. Crystal data for [Ru(SB 12HU )(NH3 )5 ] -2H20
RuBi2H26N5S*2H20Chemical formula 
Formula weight 
Crystal dimensions 
Systematic absences
Space group
Unit cell dimensions (A) 
Photographic
Philips Diffractometer 
Rigaku Diffractometer 
Volume
Measured density, Dm
Calculated density, Dc
Boundary faces of crystal, hkl 
(distance to origin, mm)
Fooo
Formula units per cell, Z 
Linear absorption coefficient, [i 
(radiation used)
395.14
0.20 x 0.05 x 0.01 mm
hOl: l odd 
OkO: k odd
P2i/c
a = 7.97, b = 14.3, c = 15.0, ß = 99.6°
a = 8.069(1), b = 14.254(1), 
c = 15.185(4), ß = 98.371°
a = 8.056(1), b = 14.240(2),
c=  15.172(2) ß 
1721.3 A3 
1.50 gem-3 
1.52 g cm-3
= 98.48°
I  4 9 (0.021) 1 3 6(0.024)
0 1 0(0.034) 0 T 0 (0.027)
T 4 7 (0.024) 1 4 6 (0.027)
3 11(0.097) 3 1 3 (0.097)
804
4
10.03 cm-1 (Mo Ko) 
86.82 cm-1 (Cu K„i)
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Table 4.2. Summary of data collection for [Ru(SBj2Hj})(NH3)y]'2H20
Diffractometer used for data Philips PW1100/20 Rigaku AFC6-R
collection (graphite monochromator) (graphite monochromator)
Radiation used for data MoKa (K = 0.7107 Ä) C uK ai (X = 1.54051 Ä)
collection
Radiation Source Fine focus sealed tube 12 kW rotating anode
generator
Number of reflections used to 23 in the range 25 in the range
refine cell dimensions 10° < 20 < 30° 80* < 20 < 100°
Range of 20 in data collection
to1oTfr 3° -  120°
Form of data collected +h, +k, ±1 +/z, +k, ±1
Transmission factors: Max. 0.7160
Min. 0.5142
Monochromator 20 12.2° 26.50°
Dispersion factor (A) 0.34 tan 0 0.300 tan 0
Scan mode 20 -  co scan 20 -  co scan
Scan speed 1° /  minute 8° /  minute
Scan width 0.90 + 0.34 tan 0 1.260 + 0.300 tan 0
Total background count time 20 s Half the scan time
Standard reflections (% drop 0 2 1 (4 .5), 2 2 0(2.6), T  2 0 (2.2), 0 2 2 (3.5),
in intensity) 1 2 0(4.9) 1 2 1 (4.1)
Frequency standards were Every 2 hours Every 75 reflections
measured
Total number of reflections 2617 (2269 unique) 2889 (2551 unique)
measured
Number considered observed 1382 2196
|F 0|> 2 c r |F 0|
Instrumental uncertainty value 0.009
(p )
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Table 4.3. Summary of methods used in the structure solution and refinement of
[Ru(SB12H11)(NH3)5]-2H20
Method used to solve structure 
Least-squares refinement method 
Function minimised 
Initial weights
Final weights
Absorption correction method
Anomalous dispersion included for
Final R -factor
Final /^ -facto r
Final S (goodness of fit)
Observations (m): variables (n)
Ratio of maximum parameter shift to 
error in final cycle
Final difference map: highest peak 
deepest trough
Patterson heavy atom 
Full-matrix
k=2>(N - |^ c|)2
w = 1.0
1
02N  + p\Fo\2
Analytical method of Alcock209
Ru, S, N, O, B
0.041
0.053
1.294
2196: 191
0.07022
0.58 e/A3  
-0.29 e/A3
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Table 4.4. Atomic coordinates and site occupancy in the asymmetric unit of 
[Ru(SB12H11)(NH3)5]-2H20*
Atom x / a y / b z / c Population
Ru 0.87851(5) 0.30197(2) 0.51011(2)
S 0.8309(2) 0.43187(9) 0.4268(1)
N(l) 1.1364(6) 0.3110(4) 0.4921(3)
N(2) 0.6265(6) 0.2927(3) 0.5348(3)
N(3) 0.8213(6) 0.2112(3) 0.4011(3)
N(4) 0.9442(6) 0.1757(3) 0.5930(3)
N(5) 0.9401(6) 0.3870(3) 0.6237(3)
B(l) 0.6544(8) 0.4375(4) 0.3311(4)
B(2) 0.7015(9) 0.4834(4) 0.2272(4)
B(3) 0.5905(9) 0.5535(4) 0.2980(4)
B(4) 0.4531(8) 0.4801(4) 0.3467(4)
B(5) 0.4744(8) 0.3641(4) 0.3084(4)
B(6) 0.6273(9) 0.3657(4) 0.2327(4)
B(7) 0.5491(9) 0.4367(4) 0.1401(4)
B(8) 0.5270(9) 0.5536(4) 0.1799(4)
B(9) 0.3776(9) 0.5515(5) 0.2547(4)
B(10) 0.3023(9) 0.4347(5) 0.2603(5)
B ( l l ) 0.4101(9) 0.3631(4) 0.1898(4)
B(12) 0.3504(9) 0.4810(5) 0.1571(4)
0(1) 1.1238(7) 0.2201(4) 0.2873(3)
0(2) 0.842(1) 0.5952(7) 0.0449(5) 0.90(2)
* Estimated standard deviations shown in parentheses
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Table 4 5  Atomic coordinates and isotropic thermal parameters* of the hydrogen atoms of
[Ru(SB12H1i )(NH3)5]-2H20
Atom x / a y / b z / c U (k2)
H(2) 0.8409 0.4925 0.2138 0.060
H(3) 0.6422 0.6180 0.3308 0.060
H(4) 0.4160 0.4954 0.4138 0.060
H(5) 0.4542 0.3011 0.3449 0.060
H(6) 0.7218 0.3052 0.2351 0.060
H(7) 0.5889 0.4226 0.0731 0.060
H(8) 0.5687 0.6142 0.1366 0.060
H(9) 0.2799 0.6045 0.2584 0.060
H(10) 0.1779 0.4242 0.2767 0.060
H( l l ) 0.3534 0.2962 0.1557 0.060
H(12) 0.2483 0.4853 0.0985 0.060
H(1N1) 1.1459 0.2971 0.4324 0.100
H(2N1) 1.1752 0.3732 0.5063 0.100
H(3N1) 1.1996 0.2678 0.5309 0.100
H(1N2) 0.6090 0.3351 0.5811 0.100
H(2N2) 0.5518 0.3080 0.4822 0.100
H(3N2) 0.6036 0.2303 0.5526 0.100
H(1N3) 0.7600 0.1589 0.4177 0.100
H(2N3) 0.7572 0.2436 0.3531 0.100
H(3N3) 0.9233 0.1895 0.3828 0.100
H(1N4) 0.8616 0.1288 0.5776 0.100
H(2N4) 1.0506 0.1529 0.5828 0.100
H(3N4) 0.9490 0.1918 0.6541 0.100
H(1N5) 1.0048 0.3510 0.6698 0.100
H(2N5) 1.0043 0.4391 0.6097 0.100
H(3N5) 0.8407 0.4079 0.6438 0.100
H (lO l) 1.1240 0.1905 0.3438 0.100
H(201) 1.1824 0.2877 0.2969 0.100
* The isotropic thermal parameter is defined as:
r iso = -8 n 2£ ^ ^
where U = mean-square amplitude o f the atomic vibration-^1®.
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Table 4.6. Intramolecular bond lengths and angles fo r  the asymmetric unit o f 
[Ru(SB12Hn )(NH3)5]-2H20*
Bond Lengths (Ä) Bond Angles (°)
The ruthenium coordination sphere:
Ru-S 2.241(1) S-Ru-N(l) 88.1(1)
S-Ru-N(2) 93.6(1)
S-Ru-N(3) 93.7(1)
S-Ru-N(4) 176.1(1)
S-Ru-N(5) 89.2(1)
Ru-N(l) 2.139(5) N(l)-Ru-N(2) 177.2(2)
N(l)-Ru-N(3) 92.3(2)
N(l)-Ru-N(4) 88.1(2)
N(l)-Ru-N(5) 87.4(2)
Ru-N(2) 2.122(5) N(2)-Ru-N(3) 89.8(2)
N(2)-Ru-N(4) 90.2(2)
N(2)-Ru-N(5) 90.4(2)
Ru-N(3) 2.095(4) N(3)-Ru-N(4) 87.4(2)
N(3)-Ru-N(5) 177.0(2)
Ru-N(4) 2.214(5) N(4)-Ru-N(5) 89.7(2)
Ru-N(5) 2.104(4)
The sulfur atom:
S-B(l) 1.879(6) Ru-S-B(l) 121.2(2)
The boron cage environment:
Average B-B 1.78(2) Mean acute B-B-B 60.0(5)
Mean obtuse B-B-B 108.0(5)
Average B-H 1.12(3) Mean B-B-H 122(5)
The water o f crystallization:
0(1)-H(101) 0.955(5) H (101)-0(l)-H (201) 109.3(5)
0(1)-H(201) 1.073(5)
*  Estimated standard deviations shown in parentheses.
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Table 4.7. Selected dihedral angles for the asymmetric unit of 
[Ru(SB 12H 11)(NH3)5] '2H20*
B(l)-S-Ru-N(l) 130.4(3) B(l)-S-Ru-N(5) -142.2(3)
B(l)-S-Ru-N(2) -51.8(3) B(l)-S-Ru-N(3) 38.2(3)
B(5)-B(l)-S-Ru 18.0(6) B(2)-B(l)-S-Ru -132.7(3)
B(3)-B(l)-S-Ru 159.4(4) B(4)-B(l)-S-Ru 91.9(4)
B(6)-B(l)-S-Ru -61.6(6)
Table 4.8. Intramolecular bond distances of the boron cage of 
[Ru(SB12Hn )(NH3)5]-2H20*.
B(l)-B(2) 1.798(9) B(l)-B(4) 1.78(1) B(l)-B(6) 1.795(8)
B(l)-B(3) 1.779(8) B(l)-B(5) 1.778(9) B(2)-B(6) 1.786(9)
B(2)-B(3) 1.80(1) B(2)-B(7) 1.793(9) B(2)-B(8) 1.785(9)
B(3)-B(4) 1.76(1) B(3)-B(8) 1.789(9) B(3)-B(9) 1.74(1)
B(4)-B(5) 1.767(9) B(4)-B(9) 1.762(9) B(4)-B(10) 1.773(9)
B(5)-B(10) 1.779(9) B (5)-B (ll) 1.799(9) B(6)-B(7) 1.769(8)
B (6)-B (ll) 1.77(1) B(7)-B(8) 1.789(9) B (7)-B (ll) 1.78(1)
B(7)-B(12) 1.78(1) B(8)-B(9) 1.77(1) B(8)-B(12) 1.75(1)
B(9)-B(12)
B(ll)-B(12)
1.776(9)
1.796(9)
B (10)-B(ll) 1.79(1) B(10)-B(12) 1.79(1)
Table 4.9. Selected bond distances (A) and angles ( °)* for pentaammineruthenium(III)-
sulfur donor c o m p le x e s ^ '^ .
Atoms -S B 12H 1I -S R R ’ -SO(CH 3)2 -S SR u(NH3)5
D istances (A)
Ru-S 2.241(1) 2.374(9) 2.188(3) 2.193(3)
Ru—Nfjans 2.214(5) 2.12(2) 2.203(8) 2.183(6)
mean Ru-Naxial 2.12(2) 2.108(5) 2.155(2) 2.125(7)
A ngles (°)
Ru-S-Ntrans 176.1(1) 176.2(3) 175.4(2) 180
R u -S -X t 121.2(2) 112(3) 116(2) 111.1(5)
t  X is the substituent atom on sulfur
* Estimated standard deviations shown in parentheses.
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Table 4.10. Bond angles in the boron cage of [Ru(SB 1 2 Hii)(NHs)§]-2H20*.
S-B(l)-B(2) 117.4(4)
S-B(l)-B(5) 128.8(4)
B(2)-B(l)-B(4) 107.9(4)
B(3)-B(1>B(4) 59.3(4)
B(4>B(1>B(5) 59.6(4)
B(1>B(2>B(3) 59.3(3)
B(1>B(2>B(8) 107.4(5)
B(3>B(2)-B(8) 59.9(4)
B(7>B(2>B(8) 60.0(4)
B(1>B(3>B(8) 108.1(4)
B(2>B(3>B(8) 59.7(4)
B(4)-B(3>B(9) 60.4(4)
B(1>B(4>B(5) 60.2(4)
B(3>B(4>B(5) 108.6(5)
B(5>B(4)-B(9) 108.6(4)
B(1>B(5>B(4) 60.2(4)
B(4)-B(5>B(10) 60.0(4)
B(1)-B(6>B(2) 60.3(3)
B(2>B(6>B(7) 60.6(3)
B(2>B(7>B(6) 60.2(3)
B(2)-B(7>B(12) 107.2(5)
B(6)-B(7>B(12) 108.1(5)
B(11)-B(7>B(12) 60.7(4)
B(2>B(8>B(9) 107.6(4)
B(3>B(8>B(9) 58.6(4)
B(7)-B(8>B(12) 60.2(4)
B(3>B(9>B(8) 61.2(4)
B(4>B(9>B(8) 109.2(5)
B(8)-B(9)-B(10) 108.3(5)
B(4)-B(10)-B(5) 59.7(4)
B(4)-B(10>B(12) 107.4(5)
B(5)-B(10)-B(12) 108.2(5)
B(11)-B(10)-B(12) 60.1(4)
B(5)-B(11>B(10) 59.4(4)
B(6)-B(11>B(10) 107.9(4)
B(7)-B(11>B(12) 59.6(4)
B(7)-B(12)-B(9) 108.5(5)
B(8)-B(12)-B(9) 60.2(4)
B(9)-B(12>B(10) 59.8(4)
S-B(l)-B(3) 114.4(4)
S-B(l)-B(6) 127.1(4)
B(2>B(1)-B(5) 108.4(4)
B(3>B(1)-B(5) 107.3(4)
B(4>B(1)-B (6) 107.7(4)
B(l)-B(2)-B(6) 60.1(3)
B(3>B(2)-B(6) 107.0(5)
B(6>B(2)-B(7) 59.3(3)
B(l)-B(3)-B(2) 60.4(4)
B(l)-B(3)-B(9) 108.7(5)
B(2>B(3)-B(9) 108.3(4)
B(8)-B(3)-B(9) 60.2(4)
B(1>B(4)-B(9) 107.8(5)
B(3>B(4)-B(9) 59.3(4)
B(5>B(4)-B(10) 60.3(4)
B(1>B(5)-B(10) 108.1(4)
B(4>B(5)-B(11) 108.0(4)
B(1>B(6)-B(7) 108.6(4)
B(2>B(6)-B(11) 108.7(4)
B(2>B(7)-B(8) 59.8(4)
B(6>B(7)-B(8) 107.8(4)
B(8>B(7)-B(11) 107.8(5)
B(2>B(8)-B(3) 60.4(4)
B(2>B(8)-B(12) 108.5(4)
B(3>B(8)-B(12) 107.5(5)
B(9)-B(8)-B(12) 60.5(4)
B(3>B(9)-B(10) 108.6(5)
B(4>B(9)-B(10) 60.1(4)
B(8>B(9)-B(12) 59.3(4)
B(4>B(10>B(9) 59.5(4)
B(5>B(10>B(9) 107.3(5)
B(9)-B(10>B(11) 107.7(5)
B(5>B(11>B(6) 60.6(4)
B(5)-B(11>B(12) 107.1(4)
B(6)-B(11>B(12) 107.0(4)
B(10)-B(ll)-B(12) 59.9(4)
B(7)-B(12>B(10) 108.1(5)
B(8)-B(12>B(10) 108.5(4)
B(9)-B(12>B(11) 107.7(4)
S-B(1>B(4) 120.8(4)
B(2)-B(1>B(3) 60.4(4)
B(2)-B(1>B(6) 59.6(3)
B(3)-B(1>B(6) 107.5(4)
B(5)-B(l)-B(6) 60.6(4)
B(1)-B(2>B(7) 107.5(5)
B(3)-B(2)-B(7) 107.4(5)
B(6)-B(2>B(8) 107.2(5)
B(1)-B(3>B(4) 60.3(4)
B(2)-B(3)-B(4) 108.7(4)
B(4)-B(3>B(8) 108.5(5)
B(1)-B(4>B(3) 60.4(4)
B(1>B(4>B(10) 108.4(5)
B(3>B(4>B(10) 108.1(4)
B(9>B(4>B(10) 60.4(4)
B(1)-B(5>B(11) 107.7(5)
B(10)-B(5)-B(l 1) 60.1(4)
B(1>B(6>B(11) 108.0(5)
B(7>B(6>B(11) 60.3(4)
B(2>B(7>B(11) 108.2(4)
B(6>B(7>B(11) 60.0(4)
B(8>B(7>B(12) 58.9(4)
B(2)-B(8>B(7) 60.2(4)
B(3)-B(8>B(7) 108.0(4)
B(7)-B(8>B(9) 108.2(5)
B(3)-B(9>B(4) 60.3(4)
B(3>B(9>B(12) 108.6(5)
B(4>B(9>B(12) 108.6(5)
B(10)-B(9)-B(12) 60.6(4)
B(4)-B(10)-B(ll) 108.0(5)
B(5>B(10)-B(11) 60.5(4)
B(9>B(10)-B(12) 59.6(4)
B(5>B(11)-B(7) 108.2(4)
B(6>B(11)-B(7) 59.7(4)
B(7>B(11)-B(10) 108.0(4)
B(7>B(12)-B(8) 60.9(4)
B(7>B(12)-B(11) 59.7(4)
B(8>B(12)-B(11) 108.6(5)
B(10>B(12>B(11) 59.9(4)
Estimated standard deviations shown in parentheses.
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Table 4 .11. Anisotropic thermal-parameters* o f the non-hydrogen atoms in the 
asymmetric unit o f [Ru(SB J2Ü j ])(NH 3)3] -21120^
Atom U 1 1 U 2 2 U 3 3 U 1 2 U 1 3 U 2 3
RU(1) .0406(3) .0366(3) .0329(3) -.0032(2) .0048(2) .0012(1)
S(l) .064(1) .0443(7) .0463(7) -.0154(7) -.0097(7) .0100(6)
N (l) .042(3) .074(4) .054(3) -.003(2) .009(2) -.004(2)
N(2) .044(3) .049(3) .051(3) -.002(2) .013(2) .007(2)
N(3) .057(3) .036(2) .050(3) -.005(2) .003(2) -.009(2)
N(4) .048(3) .055(3) .049(3) .002(2) .007(2) .011(2)
N(5) .054(3) .051(2) .036(2) -.006(2) .010(2) -.003(2)
B (l) .048(4) .036(3) .037(3) -.000(3) .003(3) .003(2)
B(2) .053(4) .043(3) .038(3) .001(3) .008(3) .007(3)
B(3) .067(5) .035(3) .037(3) -.003(3) .003(3) -.001(2)
B(4) .049(4) .045(3) .040(3) .007(3) .011(3) -.001(3)
B(5) .041(4) .039(3) .042(3) .003(3) .004(3) .002(2)
B(6) .053(4) .039(3) .036(3) .006(3) .003(3) .001(2)
B(7) .064(5) .046(3) .033(3) .006(3) .000(3) .000(3)
B(8) .058(4) .046(3) .037(3) .009(3) .007(3) .002(3)
B(9) .069(5) .047(4) .043(4) .017(3) .014(3) .005(3) •
B(10) .049(4) .053(4) .049(4) .001(3) .009(3) .005(3)
B (ll) .055(4) .039(3) .046(4) .006(3) -.002(3) .001(3)
B(12) .057(4) .052(3) .040(3) .014(3) -.004(3) .006(3)
0(1) .087(4) .094(3) .076(3) -.018(3) .013(3) -.014(3)
0(2) •23(1) •21(1) .088(5) -.114(8) .062(6) -.024(6)
* The anisotropic thermal parameter is defined as:
Taniso = uh^a*^ + U22^b*^ + U33X^0*  ^+ 2U]2hka*b* cosy* + 2Uj3hla*c*cos$* +
2U23klb*c* cosa*)
where Ua expresses the mean square amplitudes of vibration axes and Uij (i *  j) represents the ellipsoid 
orientation210.
t Estimated standard deviations shown in parentheses.
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4 .3 . RESULTS AND DISCUSSION
The crystal structure of the title complex consists of discrete molecules 
[Ru(5Bi2Hn)(NH3)5] separated by normal Van der Waals contacts. Also present are 
two molecules of water per molecule of complex, which are also separated by normal Van 
der Waals contacts. Figure 4.1 shows an ORTEP view of the non-hydrogen atoms of the 
complex with atom labelling scheme. Another ORTEP view of the complex with all atoms 
present is shown in Figure 4.2. A stereoscopic view of the unit cell contents is presented 
in Figure 4.3. Summaries of crystal data, data collection, and structure solution and 
refinement are given in Tables 4.1, 4.2 and 4.3. The atomic coordinates of the non­
hydrogen atoms of [Ru(SBi 2Hh )(NH3)5]-2H20 are given in Table 4.4, while the 
coordinates of the hydrogen atoms are given in Table 4.5. Tables 4.6, 4.7, 4.8 and 4.10 
present bond distances and bond angles and Table 4.11 gives the anisotropic thermal 
parameters of the non-hydrogen atoms. A comparison of selected bond distances and 
angles found for pentaammineruthenium(III)-sulfur donor ligand type complexes, which 
have been determined by X-ray crystallography, is shown in Table 4.9.
The structure of [Ru(SBi2 Hn)(NH 3 )5 ] is composed of the borocaptate ligand 
linked to ruthenium by the sulfur atom with five nitrogen atoms completing a distorted 
octahedron. The borocaptate ligand consists of a regular icosahedron with boron atoms 
occupying the vertices in a cage-like structure. Each boron has a hydrogen atom, which 
projects directly away from the centre of the cage, except for B(l) which is bonded to 
sulfur. Boron to boron distances within the cage structure (average 1.78 A) do not vary 
significantly from one another (a = 0.02) and are in good agreement with those reported 
for the free ligand (1.77 A)18**. Bond angles (Table 4.9) are also close in value to each 
other and do not vary significantly from the ideal values of 60° and 108°. This uniformity 
in bond distances and angles probably reflects the three-dimensional delocalization of the 
c/oso-dodecaborate structure214. The boron to hydrogen distances found in this study are 
essentially the same as those reported188 for the free ligand (1.12 A compared with 1.2 
A), as is the boron to sulfur distance (1.879 A compared to 1.90 A).
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The boron icosahedron is positioned between the N(2) and N(3) atoms, with B(5) 
situated between these two atoms at distances of about 3.7 and 3.6 Ä respectively (Figure 
4.4). The dihedral angle Ru-S-B(l)-B(5) is 18° and this puts B(6) 3.6 Ä away from 
N(3). The sulfur atom in turn is moved away from N(2) and N(3), toward N (l) and 
N(5), so as to reduce the trans N(4)-Ru-S angle to 176°. The angle about the sulfur atom, 
Ru-S-B(l), of 121° is significantly greater than the tetrahedral angle of 109.5° expected. 
This is probably a result of steric interactions, but possible electronic factors can not be 
wholly discounted. The B (l)-S  bond does not sit at 122° with respect to the B(2), B(3), 
B(4), B(5) and B(6) atoms as expected but is distorted away from B(5) and B(6) and 
towards B(3) by about 7°. All of these effects combine to minimise steric interactions 
between the boron cage and the ammonia ligands.
N(3)
I *  3.6
3.6 ■ V
Figure 4.4. Non-bonding distances (A) between the boron cage and
ammonia ligands
The ammonia ligands are also perturbed from an ideal octahedral arrangement. It 
was expected that the N(2)-Ru-N(3) angle would be greater than 90° due to the effect of 
the interposing B(5), but this is not the case. It is in fact the N (l)-R u-N (3) angle that is 
opened up to 92.3°, with the N (l)-R u-N (5) angle reduced to 87.4°. No obvious steric 
effects are available to account for this observation.
The complex [Ru(SBi2 H n)(N H 3 )5 ] is not only the first structurally characterized 
compound featuring borocaptate coordinated to a metal centre but it also appears to be the 
first pentaammineruthenium(III)-thiolate to be so characterized. Similar compounds such 
as pentaammineruthenium(III)-thioethers211, pentaammineruthenium(III)-Me2S0212 and
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bis(pentaammineruthenium(III))-disulfide213 have been characterized structurally (see 
Table 4.9.). The bond distances for ruthenium to sulfur atoms give an indication as to the 
degree of 7t-bonding between the metal and the ligand. The thioether complexes appear to 
have little or no 7t orbital interaction, while those of the disulfide and Me2 SO display 
considerably shorter bond distances and hence strong interactions. The borocaptate 
complex also displays a relatively short ruthenium to sulfur distance when compared to 
the thioether complexes but it is somewhat longer than that of the other two. This 
probably reflects the bulkiness of the borocaptate ligand rather than any diminished ability 
at 7t interaction. Strong k interactions also produce an obvious trans effect which is 
reflected in the distance between ruthenium and the nitrogen atom in the position directly 
opposite the sulfur. For the thioether complexes this distance is essentially the same as the 
ruthenium to nitrogen distances for the ammine ligands in the axial positions, however for 
the Me2 SO and disulfide ligands it is much longer. For the borocaptate ligand this length 
is at its longest (2.214 A), but the distance for the Me2 SO ligand is only marginally 
shorter (2.203 A).
There also appears to be a somewhat less noticeable cis effect. The average bond 
lengths of the ruthenium to the axial nitrogen atoms in the borocaptate and disulfide 
complexes are marginally longer than those in the thioether complexes, while in the 
Me2 SO complex the corresponding distances are much longer. This may indicate that the 
nature of the 7t interaction between these ligands and the ruthenium centre is different.
A general decrease in the angle between sulfur, ruthenium and the trans nitrogen 
atoms to 176° most probably reflects steric interactions. In the case of the unhindered 
disulfide this angle is 180°, which is as expected. The ruthenium-sulfur-substituent atom 
angles also increase depending on the bulkiness or on the number of substituents.
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DNA BINDING STUDIES
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5.1. I N T R O D U C T I O N
It is generally believed that the in vivo target of cisplatin and a number of other 
anticancer agents, is the DNA of the cancerous cells (see Chapter One). Thus, study of 
the interactions between potential agents and DNA can provide insights into the 
usefulness of such compounds as anticancer treatments215.
Bacterial cells may contain accessory chromosomes, called plasmids, that replicate 
independently of the host chromosome216. Plasmids generally are a covalently closed 
circle of duplex DNA217. They are relatively small in size consisting of only a few 
thousand base-pairs and often confer antibiotic resistance to their host cell216. A feature 
of all circular DNA molecules is that the absolute number of times the two strands of the 
double-helix twist about each other cannot be altered. As a result, the formation of an 
appropriate number of supercoils in the opposite direction is produced in the DNA 
molecule when the average number of base pairs per helical turn is altered. Supercoiling 
is then the further twisting of the duplex DNA molecule into a more condensed tertiary 
structure218' 220. The condensed supercoiled DNA is known as Form I DNA. 
Supercoiling may be present in either the positive (right-handed) or negative (left-handed) 
direction and it is due to the overwinding (positive) or underwinding (negative) of the 
DNA duplex. If a duplex molecule is overwound the topological constraints involved in 
such a structure result in the number of positive supercoils exactly equalling the number 
of subtracted twists of the double helix caused by a decreased rotation angle. Similarly, if 
the duplex is underwound the number of negative supercoils exactly equals the number of 
added twists brought about by an increased rotation angle. The cutting, or nicking, of a 
single strand of the duplex molecule relieves these constraints, removing the supercoiling. 
The resulting relaxed circular DNA is known as Form II DNA. The cutting of both of the 
DNA strands results in the formation of linear or Form HI DNA (see Figure 5.1). Form I 
DNA is much more compact or more dense than Form II DNA. Form ID DNA is not as 
constrained as Form II, but it is likewise not as compact as Form I and so its density is 
intermediate. These density changes are translated directly into differences in the physical 
properties of the various forms.
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Figure 5.1. A schematic representation o f the various forms o f DNA 
(not drawn to the same sca/e)218.
The constraints can also be removed by the interaction of the DNA with certain 
chemical agents. The dye ethidium bromide (Figure 5.2), which intercalates between the 
base pairs of DNA, can cause local untwisting of the double helix. A sufficiently high 
concentration will completely untwist the the molecule leaving it as the fully relaxed Form 
Io DNA. The addition of more ethidium bromide will promote twisting in the opposite 
direction causing the duplex to writhe into an oppositely orientated supercoil. These 
structural changes are directly translated into density changes that can be easily observed 
by sedimentation by an ultracentrifuge or gel electrophoresis (see Figure 5.3.)218. 
Cisplatin also promotes the untwisting of DNA and similar results have been 
obtained63«221' 224. However, cisplatin does not intercalate with DNA as ethidium 
bromide does, but rather it binds covalently to the nucleoside bases226'227.
It has been proposed228 that on reaction with DNA, platinum complexes alter the 
electronic distribution within the coordinated bases. This causes a change in the 
orientation of the phosphodiester backbone, which produces localised denaturation of the
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duplex. The torsion that results from this non-separative denaturation can unwind and 
subsequently rewind the DNA helix. The time that is required for Form I DNA to 
comigrate with Form II DNA reflects the effectiveness of the particular platinum complex 
as an unwinding agent22**.
JU
' ----- < Br* CH2CH3
Figure 5.2. The structure o f ethidium bromide (3,8-diamino-5-ethyl-6 - 
phenylphenanthridinium bromide)
INCREASING CONCENTRATION OF ETHIDIUM BROMIDE
Figure 5.3. The effect o f adding ethidium bromide to supercoiled DNA, 
as demonstrated by the changes in sedimentation velocity with 
increasing ethidium bromide concentration. The changes to the structure 
o f  DNA which are shown have been confirmed by electron  
microscopy^S.
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Electrophoresis involves the movement of charged species through a medium, such 
as agarose gel, under the influence of an electric potential. The rate at which a species 
moves is dependent on its overall charge, structure and density229. As the various forms 
of DNA have effectively the same charge, separation by electrophoresis is based mainly 
upon density differences that are a direct result of structural differences. With a time 
dependent experiment the rate at which an agent interacts with DNA can be followed to 
give a profile that is characteristic of the binding. As any structural change is translated 
into a density change, this sort of experiment provides a useful probe into the nature of 
the interactions the agent may have with DNA. It should be noted, however, that the fact 
that a complex binds to DNA does not necessarily imply that it will be an active anticancer 
agent. For instance trans-[PtCl2(NH3)2] binds readily to DNA, but it is not regarded as 
cytotoxic74.
In this chapter the binding or the reaction of the com pounds cis-  
[ {PtCl2(NH3) }2(/i-dpzm)]9 trans-[ {PtCl2(Me2SO)}2(/*-dpzm)], cis-[ {PtCl2(Me2SO)}2- 
Gu-dpzm)], Cs2B i2H h SH, [Ru(SB i2H i i )(NH3)5] and [Ru(SBi2H ii)(en )2(OH2)] to 
plasmid DNA is discussed and compared with the binding of the known anticancer agent 
cisplatin. The particular plasmid used in these experiments is known as pUC9, which is 
derived from the well known pBR322 plasmid230. The studies involved are known as 
time-dependent binding experiments and involve the sampling of mixtures of DNA and 
complex, which have been incubated for varying times, and then observing the changes 
that have occurred in the DNA by gel electrophoresis. The results of these experiments 
provide insights into the interaction of the complex with DNA and also the rate at which 
these interactions occur.
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5.2. RESULTS AND DISCUSSION
5.2.1. The binding to DNA of cisplatin.
Time-dependent DNA binding experiments were performed with Form I pUC9 
DNA which contained a small amount of Form II DNA. All the reactions conducted were 
maintained at a constant temperature of 36.0°C. It is pertinent to compare the DNA 
binding abilities of any potential anticancer complex with the well established effects of 
cisplatin63’222-224. Thus, an experiment involving cisplatin was performed so that direct 
comparisons could be made.
The main feature of the binding of cisplatin to Form I DNA is the gradual 
unwinding of the supercoil to give the relaxed Form Io DNA that comigrates with Form II 
DNA. The unwinding of the supercoils is accompanied by a progressive broadening of 
the band, which probably reflects statistical differences in the binding between individual 
DNA molecules. Further binding of cisplatin results in supercoiling in the opposite 
direction that causes the divergence of Form I and Form II DNA bands.
o 0 .9-
E 0 .8-
Time (hours)
Figure 5.4. Plot of the electrophoretic mobility of closed Form I (M) 
and nicked Form / /  pUC9 DNA through agar gel after reaction with
cis-[PtCl2(NFl3)2] for various times. The Rf values have been 
normalized against that of the Form I control and thus represent 
migration from bottom to top.
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Form II DNA is also affected by the binding of cisplatin, though not as 
dramatically. What is observed is that with increased binding its mobility also increases. 
This can be attributed to the shortening of the macromolecule due to localized denaturing 
or microloop formation induced by platinum crosslinks that may serve to disrupt the 
hydrogen-bonding between the base pairs of DNA222. Thus, single stranded regions of 
DNA that are produced would collapse, and reduce the overall length of the DNA 
molecule222. Binding is generally believed to involve the addition of Pt(NH3)22+ 
adducts. Thus, platinum binding should serve to reduce the net charge on the DNA 
molecule, reducing its electrophoretic mobility. Clearly, the structural effects of complex 
binding predominate over the electrostatic effects, as the binding of platinum adducts is 
seen to increase the mobility of the plasmid.
Under the conditions of the experiment, the comigration of Form I with Form II 
occurred after 5 hours. This is comparable to what has been determined previously102. 
This time-dependence of the electrophoretic mobilities of the plasmid reflects the kinetics 
of the reaction of the complex with DNA.
5.2.2 . The binding to DNA of cis-[{PtCl 2 (NH 3 )} 2 (p -dpzm)]
A similar binding study, conducted with the complex c/s-[{ PtCl2(NH3)}2(^ - 
dpzm)] under identical conditions (Figure 5.5), produced a profile that was similar to that 
of cisplatin. That is, an untwisting of the supercoiled structure produced relaxed circular 
DNA Form Io. Further binding produced a DNA structure that is supercoiled in the 
opposite direction. The major difference between the two was that c/s-[{PtCl2(NH3)}2- 
(^-dpzm)] caused the comigration of Form I with Form II DNA after only two hours, 
compared to five hours with cisplatin binding. It should be noted that at equivalent 
concentrations c/s-[{PtCl2(NH3))2(M-dpzm)] has twice the platinum, and thus twice the 
coordination sites available, than what cisplatin has. Even allowing for this cis- 
[{PtCl2(NH3)}2(/x-dpzm)] displays a much faster binding with DNA than its parent 
complex does. Hence, it can be regarded as a superior unwinding agent. This may be due
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to either kinetic or stereochemical reasons. For instance, ds-[{PtCl2(NH3)}2 (jU-dpzm)] 
may have better kinetic properties, such as the rate with which it binds to DNA, which 
increases its binding or that once bound to DNA it may exert a greater influence on the 
tertiary structure of DNA, so that each molecule bound produces a greater degree of 
unwinding. Since the amount of platinum bound to DNA has not been determined it is not 
possible to attribute the differences in the experiments to either of these mechanisms.
It is almost certain that the effects observed when ris-[{PtCl2(NH3)}2(/i-dpzm)] 
binds to DNA are due to covalent binding, similar to that seen with cisplatin binding. 
Ionic or hydrogen-bonding interactions that may occur would be reversed under the high 
salt concentration used to quench the reaction. Positively charged platinum species, which 
are weakly bound, would be separated from the DNA molecule during electrophoresis. A 
mode involving the intercalation of the complex cannot entirely be ruled out. This could 
occur through n-stacking non-covalent interactions between the base-pairs of DNA with 
the pyrazole rings and square-planar platinum centres of the complex. However, 
molecular modelling studies suggest that this would not be a favourable mode. For the 
pyrazole rings of dpzm to achieve the necessary coplanarity unfavourable steric 
interactions between the H3 or H5 and H3' or H5' protons would occur. The cutting or 
nicking of DNA is not observed with this complex. Redox type behaviour of the complex 
with DNA can be thus ruled ou t
With tetrafunctional binding modes possible c/s-[{PtCl2(NH3)}2(/*-dpzm)] can 
produce a greater number of different adducts when bound to DNA than cisplatin, which 
is at best only bifunctional. It appears possible that ri£-[{PtCl2(NH3)}2(M-dpzm)] could 
form both interstrand and intrastrand crosslinks that could bridge a number of 
nucleotides. DNA-protein crosslinks could also be formed. Unlike the dinuclear- 
dibridged platinum-dpzm complexes that have shown anticancer activity1^ -101, cis- 
[{PtCl2(NH3)}20w-dpzm)] possesses coordinated ammonia groups, which are regarded 
as a definite advantage in producing anticancer properties231-236. It is not constrained into 
a 16-membered ring system as the dibridged analogues are, and thus has a greater degree 
of freedom to form unique adducts when bound to DNA. It still retains a pyrazole type
C h a p te r  F ive 93
N -H  group, which allows possible binding to d(GpA) sequences of DNA; a mode that is 
not accessible to cisplatin79, but is accessible to ß-[Cl2 Pt(|i-dpzm)2 PtCl2 ] 102.
When compared to the dinuclear-monobridged complexes described by Farrell et 
a l.92,93} cis-[{PtCl2(NH3)}2(/i- dpzm)] is more constrained. Adducts formed between 
DNA and c/s-[{PtCl2 (NH3 )}2 (/*-dpzm)] would be more rigidly held. This is likely to 
produce a greater effect on the tertiary structure of DNA, which may maximise cytotoxic 
effects; if it is assumed that the more affected the DNA molecule is, the less the replication 
mechanisms are able to function. The bridging ligand used by Farrells group that 
produced the greatest cytotoxic effect was 1,4—diaminobutane98. It is of interest to note 
that the maximum distances possible between the coordination sites of 1,4-diaminobutane 
and dpzm are about the same (~6 Ä). It seems likely that the distance between platinum 
centres in dinuclear complexes would be important in determining the degree of activity.
Time (hours)
Figure 5.5. Plot o f the electrophoretic mobility o f closed Form I  (M) 
and nicked Form II (%) pUC9 DNA through 1.5% agarose gel after 
reaction with cis-[{PtCl2(NH3)}2([i-dpzm)] fo r  various times. The R f 
values have been normalized against that o f the Form I  control and thus 
represent migration from bottom to top.
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The preliminary nature of the studies presented makes the assignment of definite 
binding modes difficult. However, the DNA binding experiments performed do indicate 
that ci5-[{PtCl2(NH3)}2(/i-dpzm)] has a large effect on plasmid DNA when compared to 
the known anticancer agent cisplatin. These results do not specify the actual usefulness of 
ci5-[{PtCl2(NH3)}2(^-dpzm)] as an anticancer drug, as many other factors are involved 
beside that of simple DNA binding. However, it is expected that this complex should 
show, in relatively simple in vitro systems, at least similar activity to that of cisplatin.
5.2.3. The binding to DNA o f  cis- and trans- 
[ {P tC l2(M  e 2S O) } 2( \ i - d p z m ) ] .
An interesting comparison between two similar complexes has been obtained with 
the results of the binding studies conducted with cis- and trans-[{PtCl2(Me2SO)}2(M~ 
dpzm)] (Figures 5.6 and 5.7). The trans isomer certainly binds to DNA with Form I 
comigrating with Form II after 3 to 4 hours, however, the two forms do not seem to 
separate with longer reaction times. It appears that either further binding of this complex 
with DNA does not promote further twisting of the DNA molecule or more probably a 
competing reaction occurs with the buffer solution, which inactivates the complex with 
respect to its DNA binding.
The cis isomer on the other hand shows only very marginal binding with DNA. 
Form I DNA does not comigrate with Form II over the period of the experiment (14 
hours). *H n.m.r. studies (Chapter Two) have shown that the cis isomer quickly 
undergoes a solvolysis reaction in dmf and this is probably the major factor that disrupts 
its binding to DNA. It is probable that the solvolysis products formed do not readily react 
with DNA and/or do not give adducts that alter the structure of DNA and produce 
untwisting.
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Figure 5.6. Plot o f the electrophoretic mobility o f closed Form I (M) 
and nicked Form II ( • )  pUC9 DNA through 1.5% agarose gel after 
reaction with trans-[{P tC l2(Me2SO)}2(\t-dpzm)] fo r  various times. 
The Rf values have been normalized against that o f the Form I  control 
and thus represent migration from bottom to top.
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Figure 5.7. Plot o f the electrophoretic mobility o f closed Form I (M) 
and nicked Form II pUC9 DNA through 1.5% agarose gel after 
reaction with cis-[{P tC l2(Me2SO))2(\x-dpzm)] fo r  various times. The 
Rf values have been normalized against that o f the Form I control and 
thus represent migration from bottom to top.
Chapter Five 96
It is probable from these results that neither isomer will show significant anticancer 
activity. The trans isomer would not because its binding to DNA appears to be deactivated 
after about five hours incubation and also because trans isomers rarely show anticancer 
properties. The slow rate of binding does not necessarily rule out the cis isomer as an 
anticancer agent. Carboplatin, for example, is also known to have a very slow rate of 
binding to DNA when it is studied in similar experiments40. However, the loss of 
structural integrity that is observed in the cis isomer when it is in solution would suggest 
that it would not be active.
5.2.4. The reaction of DNA with borocaptate complexes.
The effects that the borocaptate anion and transition metal complexes of this anion 
have on plasmid DNA have been investigated.
Time (hours)
Figure 5.8. Plot of the electrophoretic mobility of closed Form I (M), 
nicked Form II and linear Form III (A.) pUC9 DNA through 1.5% 
agarose gel after reaction with CsfBnHijSHfor various times. The Rf 
values have been normalized against that of the Form I control and thus 
represent migration from bottom to top.
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The time-dependent reaction of the borocaptate anion with DNA produced an 
electrophoresis profile that showed no variation in the mobilities of the different forms of 
DNA over the course of the reaction (Figure 5.8). This indicates that no binding has 
occurred. What is observed is the sequential cutting of supercoiled Form I DNA to 
produce the relaxed circular Form II, which is further cut to produce the linear Form in 
DNA. The initially intense Form I DNA band faded over the period of the reaction, while 
the Form II DNA band increased in intensity to a maximum after about 8 hours after 
which it started to decrease again. After 5 hours a band attributable to Form HI DNA was 
discernible and this increased in intensity during the remainder of the experiment.
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Figure 5.9. Plot of the electrophoretic mobility of closed Form I  (■), 
nicked Form II ( • )  and linear Form III (A) pUC9 DNA through 1.5% 
agarose gel after reaction with [Ru(SB]2Hu)(NHs)5] for various 
times. The Rf values have been normalized against that of the Form I 
control and thus represent migration from bottom to top.
The strand scission reaction that is involved is probably mediated by an oxygen 
species, most probably the superoxide radical, which has been implicated in the reaction 
mechanisms of other agents that give similar effects with DNA, such as bleomycin237,238 
streptonigrin239 and bis(phenanthroline)copper(II)2^9,241 An electron spin resonance
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study of the auto-oxidation o f the borocaptate anion has shown that superoxide radicals 
are generated. In order to confirm the actual involvement o f superoxide in the borocaptate 
mediated cutting of DNA, further experiments in oxygen free systems or in the presence 
of the enzyme superoxide dismutase, which destroys superoxide as it is formed, would 
need to be conducted. These experiments were beyond the scope o f the present 
investigation.
The ruthenium-borocaptate complexes, [R u(SBi2 H n )(N H 3 )5] (Figure 5.9) and 
[R u(SB i2 H n )(e n )2 (OH2 )] (Figure 5.10), display profiles similar to the borocaptate 
anion, in that no binding occurs but rather the cutting of DNA is observed. The time taken 
for the appearance of Form HI DNA is the same for both complexes and is about 9 hours. 
This is much slower than that found for the free ligand and probably indicates that on 
coordination there is a lowering o f the reduction potential o f the borocaptate group.
Time (hours)
Figure 5.10. Plot of the electrophoretic mobility of closed Form I (M), 
nicked Form II ( 0)  and linear Form III (A) pUC9 DNA through 1.5% 
agarose gel after reaction with [Ru(SBi2Hjj)(en)2(OH2)I for various 
times. The Rf values have been normalized against that o f the Form I 
control and thus represent migration from bottom to top.
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5.3. DNA BINDING AND IN VITRO CYTOTOXICITY  
STUDIES
In vitro cytotoxicity studies have been conducted on the platinum complexes 
described (see Appendix One). These results were obtained from Me2SO solutions of the 
various complexes with P388 murine tumour, L1210 murine leukemia and L1210 
cisplatin resistant murine leukemia cell lines.
The results of the in vitro studies conducted with c/s-[{PtCl2(NH3)}2(/i-dpzm)] 
show that it is highly active against P388 tumour cells and is also active against both 
L1210 cell lines. These results agree with those obtained from the DNA binding studies, 
assuming that activity is directly related to DNA binding. It appears, in this case at least, 
that DNA binding studies can be used as a convenient means of determining the potential 
of DNA targeted anticancer drugs.
As predicted from its poor DNA binding d5,-[{PtCl2(Me2SO)}2(/i-dpzm)] shows 
very little activity in all the cancer cell screens analysed. Surprisingly however,, the trans 
isomer showed no activity whatsoever. This could have been due to the use of Me2SO as 
the solvent in the in vitro studies. Results from n.m.r. experiments (Chapter Two) 
suggest that a rapid solvolysis of this complex occurs in Me2SO. This demonstrates that 
M e2SO is inappropriate for use as solvent in biological assays involving platinum 
complexes, and that comparisons between different assays, which use different solvents, 
should not be made.
5.4. FURTHER STUDIES
The results from the time-dependent DNA binding studies and the in vitro 
anticancer screens suggest that czs-[{PtCl2(N H 3)} 2(/i-dpzm )] warrants further 
investigation. The next logical stage of biological testing is in vivo screening against 
murine cancer systems. The behaviour of this complex in animal models would be of
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interest considering that it has shown at least as impressive results as any dinuclear 
platinum anticancer agent reported to date.
Conversely, cis-[ {PtCl2(Me2SO)}2(M~dpzm)] has shown only poor DNA binding 
and only slight cytotoxicity toward cancer cells. Thus, further testing of this compound is 
not warranted.
The complex trans-[ {PtCl2(Me2SO)} 2(M~dpzm)] has shown some ability to bind 
with DNA, but has given no cytotoxic activity against the in vitro screens. This may be 
due to the use of Me2SO as the solvent in the in vitro experiments. It would be of interest 
to know whether fra/u-[{PtCl2(Me2SO)}2(/*-dpzm)] still gives the same results when a 
poorly coordinating solvent, such as dmf, is used in the experiment Results of biological 
studies on platinum anticancer drugs that have been conducted in Me2SO should be 
viewed with caution.
Chapter Six
EXPERIMENTAL DETAILS
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6.1. GENERAL
Elemental analyses were measured by the Australian National University 
Microanalytical Service. Carbon, hydrogen and nitrogen analyses were obtained using a 
Carlo Erba 1106 automatic analyser. Chlorine and sulfur analyses were performed on a 
QIC instrument.
*H n.m.r. spectra were obtained in 0 7 -dmf from either Varian Gemini-300 
spectrometer (*H at 300 MHz) or a Varian CFT-20 spectrometer (*H at 80 MHz) with 
tms internal reference using 5mm quartz tubes, unless otherwise noted.
IR spectra were recorded on a Perkin-Elmer 683 Grating Infrared spectrometer 
and also on a Perkin-Elmer Series 1600 FT-IR as KBr disks, unless specified otherwise.
Gas chromatography-mass spectrometry (g.c.-m.s.) analyses were conducted on a 
Hewlett-Packard 5970 Series Mass Selective Detector, coupled to a 5980A Series Gas 
Chromatograph, using an Ultra 2 non-polar column and a column head pressure of 5 kpa. 
The temperature program used was: 0-2 min. 100°C; 2-10 min. ramp at 15°C / min. to 
220°C; 10-15 min. hold at 220°C.
X-ray powder diffraction patterns were obtained using a Philips PW 1049 Counter 
Diffractometer (Philips PW 1010 generator) using Ni-filtered CuKa (h = 1.5418 Ä)
radiation.
Ultraviolet-visible spectra were recorded on a Shimadzu UV-160 
spectrophotometer with the solvent as specified.
Magnetic susceptibilities were measured by the Gouy method in the solid state, at 
the temperature specified. The corrections for the diamagnetism of the ligands are as 
given in the literature242.
Mass spectra were obtained using the fast atom bombardment (f.a.b.-m.s.) 
technique (Research School of Chemistry, Australian National University, Canberra, 
Australia). The samples were dissolved in Me2SO prior to application onto the sample 
stage. Glycerol was used as the matrix.
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Electrophoresis gels were illuminated from beneath with an ultraviolet lamp and 
then photographed with a Polaroid MP-4 camera using Polaroid type 55 positive-negative 
film and a red filter.
Cyclic voltammetric measurements made for [Ru(SB 12H11 )(NH3)5] -2H20  were 
performed with E.G. & G. Model 173 potentiostat/galvanostat, Model 179 Digital 
Coulometer, Model 178 electrometer and Model 175 universal programmer, using a non- 
aqueous Ag/AgCl reference electrode196, a platinum working micro-electrode and a 
platinum wire counter electrode. Electrochemical solutions were 0.5 M NBU4BF4 in 
anhydrous dmf with a sample concentration of about 10"3 M. All solutions were purged 
and maintained under a nitrogen atmosphere. Scan rate was 100 mVs-1. Cell temperatures 
were maintained by immersion in a constant temperature bath and were monitored by a 
digital thermometer probe within the cell solution.
6.2. SYNTHETIC PROCEDURES
6.2.1. Materials and Methods
Tetraphenylphosphonium bromide, [Ru(NH3)ö]C13 (Aldrich Chemical Co.) and 
cesium borocaptate (Boron Biologicals) were obtained commercially. 
Trifluoromethanesulfonic (triflic) acid was kindly supplied by Dr. L. M. Rendina 
(Research School of Chemistry, ANU). Other chemicals; l , l ’-Dipyrazolylmethane186, 
c /5 -[P tC l2 (N H 3)2]243, K[PtCl3(N H 3) ] 172j K[PtCl3 (M e 2 SO)] 178, cis- 
[PtCl2(Me2SO)2]244, [Pt(mal)(Me2SO)2] 185, [RuCl3(terpy)]-l/2H20 245, trans- 
[RuCl2(en)2]Cl246, [NiCl2(PEt3)2]247, [PtCl(terpy)]Cl248 and ris-[RuCl2(Me2SO)4]249 
were all prepared according to literature methods. Milli-Q ultra-high purity water was 
used. All other reagents and organic solvents were of analytical grade or better and were 
used with no further purification, unless otherwise noted.
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6.2.2. Preparation of tetraphenylphosphonium
amminetrichloroplatinum(II), [PPI14][PtCl3 (NH3)]
A solution of c/s-[PtCl2(NH3)2] (0.35 g, 1.17 mmol) in concentrated hydrochloric 
acid (15 mL) was heated at reflux with powdered platinum metal catalyst (0.03 g) for 2 
hours, whereupon an orange solution with a quantity of a yellow precipitate was formed. 
The precipitate, consisting of platinum metal and unreacted c/s-[PtCl2(NH3)2], was 
filtered off and washed with cold water (60 mL). To the combined filtrates was added 
[PPh4]Br (0.48 g, 1.15 mmol). This mixture was stirred for two hours and then cooled 
to 5°C. The pale yellow precipitate that formed was collected, washed with water, ethanol 
and ether, and dried under vacuum. The solid was dissolved in dichloromethane and a 
small amount of green precipitate was removed. Ether was added to precipitate the 
product, which was collected and then dissolved in dmf. A small volume of chloroform 
was added and the brown crystals of [PPh4 ][PtCl4 ] that formed on cooling were 
removed. The volume of the filtrate obtained was decreased by rotary-evaporation under 
reduced pressure. A small amount of ethyl acetate was added to promote the precipitation 
of the pale-orange product. The mixture was cooled at 5°C and the product was again 
collected, washed with ether and dried in a vacuum (yield 0.40 g, 52%). Anal. Calc, for 
PtC24H23NCl3P: C, 43.82; H, 3.52; N, 2.13. Found: C, 44.06; H, 3.76; N, 2.04. IR 
(cm-1): 3322(w), 3252(m), 3187(sh), 3074(sh), 3053(m), 3019(w), 1585(m), 1481(m), 
1440(sh), 1435(s), 1338(w), 1315(w), 1291(m), 1190(m), 1160(m), 1109(s), 1073(w), 
1026(w), 994(m), 759(m), 749(sh), 724(s), 691(s), 616(w), 527(s), 457(w), 435(w), 
332(sh), 320(m).
6.2.3. Preparation of 4,4f-dipyrazolylmethane, dpzm
l,l'-Dipyrazolylmethane (1.00 g, 6.75 mmol) was converted to its’ hydrobromide 
salt by dissolving it in concentrated hydrobromic acid (5 ml). The excess acid solution 
was removed by rotary evaporation to leave an off white crystalline mass. Acetone (10
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ml) was added and the salt was collected, washed further with a small quantity of acetone 
and dried at the pump.
This salt was heated in a sublimation apparatus at 200°C for 1 hour. A dark oily 
residue that deposited on the cooler surfaces was identified by g.c.-m.s. as being 4- 
bromopyrazole. Rt 2.3 min, m/z- 148(100%), 146(100%), 121(15%), 119(23%), 
94(12%), 92(12%), 40(48%), 38(24%).
The solid residual mass was neutralised with excess potassium carbonate solution. 
The off white precipitate was collected and dried in a vacuum. By g.c.-m.s. analysis, this 
was identified as 4,4’-dipyrazolylmethane. Rt 8.4 min, m/z- 148(100%), 147(84%), 
120(24%), 119(16%), 94(18%), 93(17%), 81(12%), 66(14%), 54(16%), 39(24%). The 
compound was further purified by sublimation under reduced pressure at 200°C. (Yield 
0.57 g, 57%). Anal. Calc, for C7H8N4 requires: C, 56.74; H, 5.44; N, 37.81. Found: 
C, 57.02; H, 5.52; N, 38.07. IR: 3137(br), 3054(sh), 2952(s), 2844(sh), 1570(w), 
1507(m), 1443(m), 1393(s), 1349(s), 1297(w), 1267 (m), 1220(w), 1184(w), 1036(s), 
1059(sh), 1044(m), 999(s), 956(s), 926(m), 917(m), 870(s), 815(s), 742(s), 707(m), 
655(m), 649(sh), 642(sh), 615(m), 607(m), 330(w), 317(w). *H n.m.r.: 12.66 ppm 
(br, 2 H, N -H ), 7.49 ppm (s, 4 H, Pz-H), 3.71 ppm (s, 2 H, -CH2-)
6.2.4. Preparation of [SV-4-2]-(\i-4,4'-dipyrazolylmethane-  
N,N')bis(amminedichloroplatinum), 
cis-[(PtCl2 (NH 3)}2 (\L-dpzm)]
The salt [PPh4 ][P tC l3 (N H 3)] (0.36 g, 0.55 mmol) was dissolved in 
dichloromethane (30 ml). To it was added a solution of dpzm in ethanol (3 ml). The 
cloudy mixture was stirred overnight. The yellow product that formed was collected, 
washed with dichloromethane, water, ethanol and ether, and dried in a vacuum (yield 
0.18 g, 0.25 mmol, 92% yield). Anal. Calc, for Pt2C7H i4N6Cl4 requires: C, 11.77; H, 
1.98; N, 11.77. Found: C, 11.92; H, 2.16; N, 11.90. IR: 3267(br s), 3180(s), 
3125(sh), 3117(s), 2974(m), 2860(sh), 1477(m), 1437(m), 1409(s), 1367(w), 1308(s),
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1245(w), 1140(s), 1080(s), 1010(m), 1000(sh), 975(w), 859(m), 827(m), 747(m), 
682(w), 586(m), 504(w), 333(m), 322(sh). n.m.r.: 13.7 ppm (br, 1 H, N -H ), 7.91
ppm (s, 1 H, Pz-H5), 7.84 ppm (s, 1 H, Pz-H 3), 4.43 ppm (br, 3 H, Pt-NH3), 3.77 
ppm (s, 2 H, -CH2 -). X-ray powder diffraction data [20 angle (relative intensity)]: 
Amorphous.
6.2.5. Preparation of [S¥-4-l]-( \ i-4 ,49-dipyrazolylmethane- 
N,N')bis(dichloro(S-dimethylsulfoxide)platinum), 
tranS‘[{PtCl2 (Me2SO)}2 (\L-dpzm)]
The salt K[PtCl3 (Me2 SO)] (0.33 g, 0.79 mmol) was dissolved in water (5 ml). 
Ethanol (5 ml) was added and the solution was stirred magnetically. The ligand, dpzm 
(0.39 mmol, 0.058 g) dissolved in 1:1 ethanol-water (2 ml), was added dropwise over a 
10 minute period. After 1 minute the solution became cloudy. The reaction was left to 
proceed overnight. The yellow solid that formed was filtered off from the colourless 
mother liquor and was then washed with ethanol and ether, and dried at the pump (yield 
0.30 g, 92% yield). Anal. Calc, for Pt2CiiH2oN4Cl4S202  requires: C, 15.80; H, 2.41; 
N, 6.70; S, 7.67; Cl 16.96. Found: C, 16.22; H, 2.43; N, 6.60; S, 7.19; Cl, 17.59. IR: 
3548(br m), 3328(s), 3127(br s), 3071(sh), 3001(s), 2913(sh), 2875(w), 1623(w), 
1574(w), 1521(w), 1476(m), 1440(m), 1409(s), 1374(sh), 1345(sh), 1316(m), 
1297(m), 1238(w), 1120(br s), 1080(s), 1024(s), 1000(sh), 975(s), 933(sh), 921(m), 
878(m), 867(sh), 833(m), 749(s), 719(sh), 698(m), 613(m), 585(m), 506(w), 440(s), 
375(m), 340(s), 320(sh). lH n.m.r.: 8.07 ppm (s, 2 H, Pz-H5), 8.02 ppm (s, 1 H, Pz- 
H3), 7.95 ppm (s, 1 H, Pz-H 3), 3.86 ppm (s, 2 H, -C H 2-) ,  3.50 ppm (s, 12 H, 
OS(CH3)2 ). X-ray powder diffraction data {20 angle (relative intensity)}: 11.6 (35), 
12.0 (100), 12.3 (77), 12.7 (42), 13.3 (88), 14.9 (99), 16.5 (44), 18.3 (59), 19.0 (72), 
19.8 (61), 20.3 (31), 20.9 (37), 22.0 (87), 23.4 (42), 24.4 (58), 25.0 (25), 25.6 (28), 
26.7 (38), 27.2 (35), 28.9 (49), 29.8 (57), 30.2 (35), 30.5 (32), 32.5 (26), 33.2 (21),
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34.4 (33), 34.9 (22), 35.7 (28), 38.4 (33), 39.0 (44), 39.6 (35), 40.7 (32), 41.7 (51),
43.4 (30), 44.8 (26), 45.4 (29), 48.0 (33).
6.2.6. Preparation of [SP-4-2]-([i-4,4f-
dipyrazolylmethane-N,N')bis(dichloro(S-
dim e thy Is ulfoxide)platinum) , cis-[{PtCl2(Me2SO)}2-
(\i-dpzm)].
M ethod A: The complex c/.y-[PtCl2(Me2SO)2] (0.43 g, 1.02 mmol) was 
dissolved in warm water (15 ml). To this was added dropwise dpzm (0.075 g, 0.51 
mmol) dissolved in warm water (5 ml). A pale yellow precipitate formed immediately. 
The mixture was left for 2 hours and the precipitate was collected. It was washed with 
water, ethanol and finally ether, and dried in a vacuum (yield 0.39 g, 0.47 mmol, 91% 
yield). Anal. Calc, for Pt2CiiH2oN4Cl4S202 requires: C, 15.80; H, 2.41; N, 6.70; S, 
7.67; Cl 16.96. Found C, 15.90; H, 2.40; N, 6.70; S, 6.66; Cl, 15.56. IR: 3509 (br s), 
3298(br s), 3123(sh), 3004(s), 2915(s), 1624(br m), 1477(m), 1405(m), 1317(m), 
1298(m), 1249(w), 1132(s), 1083(s), 1025(s), 1007(sh), 976(m), 930(sh), 920(m), 
869(m), 842(sh), 749(m), 727(sh), 694(m), 594(m), 505(w), 439(m), 377(m), 336(m).
Method B: A small quantity of rra/i.s-[{PtCl2 (Me2 SO)}2 (/*-dpzm)] (0.10 g, 0.12 
mmol) was dissolved in Me2 SO (3 ml). To this was added 0.1 M hydrochloric acid (1.5 
ml) and the resulting mixture was left for 3 days. The precipitate that formed was 
collected, washed with water, ethanol and chloroform, and dried at the pump. The 
product was identical analytically and spectroscopically to that obtained by Method A.
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6.2.7. Attempted preparation of [SP-4-3]-(\i-4,4'- 
dipyrazolylmethane-N,N')bis(malonato(S- 
dimethylsulfoxide)platinum), 
[{Pt(mal)(Me2SO)}2 (\L-dpzm)].
To a stirred solution of [Pt(mal)(Me2SO)2] (0.36 g, 0.79 mmol) in water (10 ml) 
was added dpzm (0.06g, 0.40mmol) dissolved in water (3ml). A white precipitate was 
formed immediately and the mixture was stirred for a further 8 hours. The precipitate 
(0.33 g, 0.37 mmol) was collected washed with water, ethanol and ether, and dried at the 
pump. The product was totally insoluble in hot water, hot dmf, hot Me2SO and aqua 
regia. Anal. Calc, for Pt2CnH23N40ioS2 requires: C, 22.75; H, 2.58; N, 6.24. Found: 
C, 19.71; H, 2.42; N, 6.90. IR: 3432(br s), 3119(sh), 3004(m), 2916(m), 1635(br s), 
1589(s), 1387(br), 1355(br), 1250(m), 1132(s), 1083(s), 1024(s), 976(m), 922(m), 
826(m), 746(m), 697(m), 620(w), 440(m), 375(m).
6.2.8. Preparation of pentaamminechlororuthenium(III) 
chloride, [RuCl(NH3)5]Cl2
Commercial red [Ru(NH3)ö]C13 (4.00 g, 12.9 mmol) was refluxed in 6 M 
hydrochloric acid (120 ml) for 3 hours whereupon a buff precipitate was observed. 
Precipitation was completed by cooling at 4°C for 16 hours. The solid was collected and 
then dissolved in hot 0.1M hydrochloric acid. A dark insoluble material was removed by 
filtration at this stage. The filtrate was cooled at 4°C for 16 hours and the yellow-orange 
crystals of [RuCl(NH3)5]Cl2 that formed were collected, washed with ethanol and ether, 
and dried at the pump (yield 3.2 g, 85%). IR (cnr1): 3222(br), 1617(s), 1297(s), 801(s), 
488(m), 466(m), 455(m), 295(s), 255(s).
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6.2.9 . Preparation of pentaammine(l-thiolato-c\oso- 
undecahydrododecaborane)ruthenium(III) 
dihydrate, [Ru(SBi2Hu)(NH3)s]*2 H2 0
A warm solution of CS2B 12H 11SH (0.20 g, 0.45 mmol) in water (5 ml) was 
filtered through a 45 |im syringe filter unit. To this was added dropwise through a 45 |im 
syringe filter unit [RuCl(NH3)5]Cl2 in warm (~40°C) water (5ml). After about 5 seconds 
an intense deep-blue formed, and shortly after, a crystalline precipitate was evident. The 
mixture was left at room-temperature for 15 minutes and was then cooled at 5°C for 1 
hour. The product was collected, washed with water, ethanol-water (1:1) and ethanol, 
and dried under vacuum. The product consisted of fine dark-blue needles (yield 0.14 g, 
87% yield). Anal. Calc, for RuB i2H26N5S-2H20  requires: H, 7.65; N, 17.72; S, 8.11. 
Found: H, 6.85; N, 16.69; S, 7.52. IR: 3611(m), 3423(m), 3321(s), 3252(s), 3181(sh), 
2475(s), 1609(m), 1294(s), 1313(sh), 1055(m), 963(m), 840(m), 806(w), 760(m br), 
722(m), 455(w), 402(w), 330(w). lH n.m.r. 8.00ppm (br, NH3), 3.64ppm (br, 
B12H 11). Ultraviolet-visible spectrum (Me2SO, 9.9 x 10-5 M): 583nm (e = 1300 M-1cm- 
!), 440nm (e = 1200 M ^cnr1). Magnetic susceptibility (19.8°C); Xg = 2.25 x 10-6 cgs. 
Cyclic voltammetry couples vs. Ag/AgCl (V): +0.29(+0.39), +0.08(+0.18), (-0.55), - 
0.24(-0.34). X-ray powder diffraction data {20 angle (relative intensity)}: 9.50 (23), 
12.00(37), 12.90(15), 14.70(40), 15.30(59), 19.00(100), 20.00(25), 22.30(19), 
23.10(12), 24.00(31), 25.80(11), 27.60(13), 29.70(14), 30.40(13), 32.70(13), 
33.80(11), 35.20(14), 35.60(12), 36.30(11), 38.70(11), 41.40(12), 42.00(9).
6.2.10. Preparation of tris(trifluromethanesulfanato)
(2,29,5 ',2"-tripyridine)ruthenium(III),
[Ru(Ö3SCF 3)3 (terpy)]
Into a three-necked round bottom flask (50ml), flushed with nitrogen, was placed 
[R uC l3(terpy)]-1/2H 2 0  (0.20 g, 0.45 mmol). To this was added dropwise 
trifluoromethanesulfonic (triflic) acid (1.2 ml). This gave a deep-green solution that was
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heated for 3 hours, after which time the nitrogen effluent gave a negative AgNC>3 test for 
chloride. The mixture was left at room-temperature for a further 16 hours. Ether was 
added, producing a dark-green crystalline precipitate. This product was collected, washed 
thoroughly with ether (3 x 20 ml), and dried in a vacuum (Yield 0.34 g, 96% yield). The 
product hydrolysed rapidly in air to give a dark-purple solid. Anal. Calc, for 
RUC18H 11N3F9O9S3 3H2O (after hydrolysis) requires: C, 25.87; H, 2.05; N, 4.92. 
Found: C, 25.63; H, 1.67; N, 4.92. IR: 3406(br), 3093(m), 1602(m), 1476(m), 
1453(m), 1354(s), 1313(sh), 1235(s), 1202(s), 1099(sh), 1055(sh), 1027(s), 956(s), 
903(sh), 825(w), 776(s), 732(m), 518(m), 461(m), 348(w).
6.2.11. Preparation of (OC-6-23)-diaquo(l-thiolato-c\oso-  
undecahydrododecaborane)(2,2f5 ',2 
tripyridine)ruthenium(III),
[Ru(SB12H 11)(terpy)(OH2)2]
The complex [Ru(C>3SCF3)3(terpy)] (0.29 g, 0.37 mmol) was placed in water (5 
ml) and heated at 60°C for 1 hour, giving a dark aqua-green solution. This was filtered 
through a 45 Jim syringe filter unit. To this solution was added a similarly filtered 
solution of CS2B12H 11SH (0.18 g, 0.40 mmol) in water (5 ml), which caused a rapid 
colour change to dark maroon. A dark precipitate became evident within 5 minutes. The 
mixture was left for 16 hours and the precipitate was collected, washed with water and 
acetone, and dried in a vacuum at 60°C for 5 hours (Yield 0.17 g, 85% yield). The 
complex dissolves readily in base and can be reprecipitated with acid. Anal. Calc, for 
RUB12C15H26N3O2S requires: C, 33.16; H, 4.82; N, 7.74. Found: C, 31.68; H, 4.67; 
N, 7.05. IR: 3445(br), 3078(sh), 2500(s), 1691(m), 1601(m), 1468(m), 1449(s), 
1388(m), 1285(m), 1244(m), 1162(m), 1093(w), 1051(m), 963(m), 837(m), 767(s), 
733(sh), 669(w), 647(w), 574(w), 527(w), 494(w). Magnetic susceptibility (20.4°C); 
Xg = 0.598 x 10' 6 cgs.
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6.2.12. Preparation of (OC-6-23)-aquobis(l ,2- 
ethanediamine)(l-thiolato-c\oso- 
undecahydrododecaborane)ruthenium(III), 
tT2Lns-[Ru(SBi2Hu)(en)2(OH2)]
In a three-necked round bottom flask, equipped with a nitrogen bubbler, was 
placed rrans-[RuCl2(en)2]Cl (0.29 g, 0.89 mmol). To this was added triflic acid (2 ml), 
which caused some vigorous bubbling, and produced a dark orange solution. This was 
left for 20 minutes at room temperature and then heated at 110*C for 16 hours. After 
cooling back to room-temperature, ether (20 ml) was added giving a dark orange-brown 
oil and an ether layer. The ether layer was discarded and fresh ether was added and mixed 
with the oil. The ether was again discarded and the washing was repeated.
The residual oil was dissolved in water (20 ml), giving a dark tea-coloured 
solution. To this was added CS2B12H11SH (0.39 g, 0.89 mmol) dissolved in water (10 
ml). This mixture was set aside for 2 hours. The brown precipitate that had formed was 
collected, washed with water and ethanol, and dried in a vacuum (yield 0.26 g, 93% 
yield). Anal. Calc, for RUB12C4H29N4OS requires: C, 10.44; H, 6.35; N, 12.18. 
Found: C, 10.96; H, 6.58; N, 11.18. IR: 3579(br), 3425(br), 3297(s), 3254(s), 
3156(sh), 2942(m), 2884(m), 2475(s), 1580(s), 1454(m), 1396(w), 1365(w), 1316(w), 
1284(m), 1163(m), 1108(m), 1045(s), 1003(w), 976(m), 900(w), 837(m), 718(m), 
578(w), 534(w). Magnetic susceptibility (20.6°C); Xg = 0.512 x 10-6 cgs.
6.2.13. Preparation of bis(tetrabutylammonium)
1-mer capto-c\oso-undecahydrodode cab orate (2-), 
[N(Bu)4]2[B12H u SH]
To a solution of CS2B12H11SH (0.20 g, 0.45 mmol) in water (2 ml) was added 
dropwise a solution of tetrabutylammonium bromide in water (2 ml). The white 
precipitate that formed was collected. It was then dissolved in methylene chloride (10 ml)
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and this solution was dried with anhydrous MgSC>4 . The MgSC>4 was removed and the 
solvent was evaporated off to leave the product as a white powder (0.11 g, 0.30 mmol, 
64% yield). This product was used without any further purification. IR: 2961 (s), 
2873(s), 2732(w), 2478(s), 1988(w), 1845(w), 1470(s), 1420(w), 1380(m), 1362(w), 
1319(w), 1283(w), 1243(w), 1169(m), 1151(m), 1108(m), 1060(sh), 1043(s), 978(sh), 
865(m), 925(w), 882(m), 848(w), 835(m), 803(w), 740(m), 717(m), 668(w), 618(w).
6.2 .14. The reaction of [NiCl2(PEt3)2] with 
[NBu4][B12H u S H ]
No reaction was observed when [NBu4]2[Bi2HnSH] (0.38 g, 0.57 mmol) was 
dissolved with [NiCl2 (PEt3)2] in refluxing benzene, only starting materials were 
returned.
6.2.15. The reaction of [PtCl(terpy)]Cl with Cs2 B i j H j2 S H
To [PtCl(terpy)]Cl (0.223 g, 0.428 mmol) dissolved in water (20 ml) was added 
dropwise AgNC>3 (0.144 g, 0.845 mmol) in water (10 ml). This mixture was stirred in 
the dark, under a nitrogen atmosphere, for 16 hours. This was then heated on a hot water 
bath to dissolve the orange precipitate that was formed. The white AgCl precipitate that 
remained was removed by centrifugation at 5000 r.p.m..
To the mother liquor was added CS2B11H12SH (0.185 g, 0.422 mmol) in water (5 
ml). The solution imediatedly went brown with a flocculent precipitate present. This was 
stirred at room-temperature overnight under a nitrogen atmosphere.
The red-brown precipitate that had formed was collected by centrifugation at 5000 
r.p.m.. The pellet that was isolated was dried in a vacuum overnight, to give a black flaky 
solid. The solid was not soluble in dmf or Me2SO. IR (peaks generally poorly resolved): 
3580(s br), 3073(m), 2457(s br), 1597(m), 1519(w), 1473(m), 1450(m), 1440(m), 
1395(m), 1313(m), 1248(m), 1162(m), 1137(w), 1093(w), 1045(m), 1028(m), 955(m), 
823(m), 769(s), 721(m), 658(w), 616(w), 450(m).
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6.2.16. The reaction of cis-[RuCl2 (Me2SO)4] with 
Cs2B12Hu SH
To a stirred solution of cis-[RuCl2(Me2SO)4] (0.58 g, 1.20 mmol) in water (25 
ml) was added CS2B 12H 11SH (0.50 g, 1.19 mmol) in water (25 ml). The resulting 
yellow solution was stirred at room temperature for 16 hours.
The clear brown solution that formed was evaporated under reduced pressure to a 
small volume (~10 ml), whereupon precipitation occurred. Absolute ethanol (50 ml) was 
added and the precipitate was collected. A further quantity of product was obtained by 
adding more ethanol and cooling the mixture at 5°C overnight (yield 0.70 g). Anal. Calc, 
for R.UB12CSC4H29O5S3 (i.e. Cs[Ru(SBi2Hn)(OH2)3(Me2SO)2]) requires: C, 7.78; H, 
4.74; N, 0.00. Found: C, 7.71; H, 4.88; N, 0.00. IR: 3595(br s), 3433(br s), 3013(m), 
2924(m), 2496(s), 1617(brm), 1412(m), 1314(m), 1295(m), 1096(s), 1016(s), 971(m), 
928(m), 837(m), 720(m), 680(m), 494(w), 423(m), 384(w), 372(sh). F.a.b.-m.s.: 
709(5%), 619(9%), 617(8%), 600(15%), 543(8%), 541(16%), 540(8%), 539(15%), 
538(10%), 463(9%), 461(8%), 451(8%), 450(7%), 439(9%), 419(15%), 355(18%), 
312(24%), 301(21%), 292(19%), 287(14%), 286(100%), 245(11%), 211(40%).
6.3 . PLASMID DNA-BINDING EXPERIMENTS
6.3.1. Materials and Methods
Plasmid pUC9 DNA in sterile water was kindly supplied by Dr. N. Dixon 
(Research School of Chemistry, ANU). Tris(hydroxymethyl)aminomethane (Tris) 
(Sigma Chemical Co.), agarose (standard low-mr) (Bio-Rad), and 3,8-diamino-5-ethyl-6- 
phenylphenanthridium bromide (ethidium bromide) (Aldrich Chemical Co.) were 
obtained commercially. The metal complexes used were prepared as described in Section 
6.2. All other reagents were of analytical grade or better.
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6 .3 .2. Preparation of saline-phosphate buffer
Sodium chloride (1.75 g, 29.4 mmol) was dissolved in a mixture of KH2PO4 (0.1 
M, 21.8 ml) and K2HPO4 (0.1 M, 78.2 ml). An 100-fold dilution of this gave a buffer 
solution with pH = 7.4 at 20°C ([CP] = 3 mM and [PO43"] = 1 mM).
6 .3 .3. Plasmid DNA-binding experiments
To a freshly prepared solution of ris-[PtCl2(NH3)2] (0.067 mM, 100 |il) in NaCl 
(4.5 mM) and phosphate (1.5 mM) buffer was added pUC9 DNA (200 fig / ml, 50 fil) 
and this stock solution was incubated at 37.0°C ± 0.1°C. At various times (0, 1, 2, 3, 4, 
5, 6 , 7, 8 , 9, 10, 12 and 14 hours) a sample (10 p.1) was removed, the reaction was 
quenched by the addition of NaCl (1 M, 2.5 p.1), and the sample was stored at -5°C.
To the samples was added tracking dye (0.2% (w/v) bromophenol blue and 53% 
(w/v) glycerol, 6 p.1), and gel electrophoresis was carried out in a horizontal slab gel 
composed of agarose (1.5% (w/v)) and TBE buffer (90 mM Tris, 90 mM boric acid and 
2.2 mM Na2H2edta-2H2 0 , pH = 8.3 at 22°C), loaded with 14 jil of sample per well. 
This was run at 30 V for 24 hours at room temperature. The gel was stained with TBE 
buffer containing ethidium bromide (0.5 pg / ml) for 12 hours and photographed as 
described previously.
The above procedure was repeated with the mole equivalent of cis- 
[ {PtCl2(NH3)} 2(/x~dpzm)], trans- [ {PtCl2(Me2SO)} 2(/*-dpzm)], cis-[ {PtCl2(Me2S O)} 2- 
(/i-dpzm)], CS2B 12H 11SH, [Ru(SBi 2H h )(NH3)5]-2H2 0  and rra/w-[Ru(SBi2H n)- 
(en)2(OH2)]
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A l . l .  RESULTS OF IN VITRO ANTICANCER STUDIES
The platinum complexes described (Chapter Two) have been screened against a 
number of cancer cell lines in vitro by Dr. L. K. Webster at the Andrew Durant Drug 
Testing Facility (Experimental Chemotherapy and Pharmacology Unit), Peter MacCallum 
Cancer Institute, Melbourne, Australia. These results are presented in Table A l.l  along 
with those obtained for cisplatin, which was used as a positive reference.
Table A l . l .  In vitro screens o f platinum complexes, expressed as IC5 0 * (fiM)for a 48
hour continuous exposure o f the cells to the compound dissolved in Me2SO followed by
counting using a Coulter counter.
Compound P388 L1210 L1210/cisplatinresistant
cw-[ {PtC l2(N H 3) } 2 (M p z m )] 0.4
2.0
1.1
1.7
5.2 4.6
6.2
cis-[ {PtCl2(Me2SO)} 2(^-dpzm)] >20
>100
>20 >20
>50
trans- [ {PtCl2(Me25 O)} 2 
(/t-dpzm)]
Not determined No response up 
to 100|ig/ml
Not determined
cis- [PtCl2(NH3)2] 0.5 (saline or 
Me2SO)
0.8 (saline) 6.2 (saline) 
12.4 (Me2SO)
s|c
IC50 is defined as the concentration (jiM) required to produce of 50% inhibition of growth in the culture.
A1.2. DISCUSSION
The complex cis- [ {PtCl2(NH3) } 2(/t-dpzm)] displays activity that is comparable to 
cisplatin in P388 murine tumour cells. In the L1210 murine leukemia cell line this activity 
is somewhat reduced in comparison. In the L I210 cell line, which is resistant to the 
effects of cisplatin, the activity of ris-[{PtCl2(NH3)}2(/x-dpzm)] remains essentially the 
same as it is in the normal cell line. The resistance factor98, calculated as the ratio IC50 
cisplatin resistant /  IC50 normal cell line, for this complex is 1.03. Thus, it can be seen 
that m -[{PtC l2(NH3)}2(/t-dpzm)] is as toxic toward cisplatin resistant L1210 cells as it
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is to normal L1210 cells. To achieve this the complex must have a mode of action that is 
quite unlike that of cisplatin.
The other complexes screened, cis- and rra/is-[{PtCl2(Me2.SO)}2(M-dpzm)] have 
not shown any significant activity in the cell lines tested. This may be due to the use of 
Me2SO as the solvent for these complexes. It is known from !H n.m.r. studies (Chapter 
Two) that rapid solvolysis reactions occur when these complexes are dissolved in this 
solvent, which may lead to a complete loss of structural integrity.
The use of Me2SO as the solvent for cis- [{PtCl2(NH3))2(/t-dpzm)] may explain 
the variability in the results obtained for this complex, as it too will undergo a rapid 
solvolysis in Me2SO. If a solvent that does not give such dramatic solvolysis effects was 
used, such as dmf for instance, then even better cytotoxicities might be observed. 
Clearly, the lack of solubility in water is an impediment to the biological effectiveness of 
these complexes and further efforts should be directed at overcoming this problem.
In light of the good cytotoxicity cis-[{PtCl2(NH3))2(^-dpzm)] has displayed, 
particularly against P388 tumour cells, further in vitro and in vivo testing of this 
compound is warranted, despite the fact that it may be necessary to use Me2SO as the 
solvent in these assays.
Appendix Two
OBSERVED AND CALCULATED STRUCTURE 
FACTOR AMPLITUDES FOR 
[Ru(SB i2H ii)(NH3)5] 2H20
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h k 1 Fobs Fcal h k 1
0 0 2 131 119 0 4 12
0 0 4 149 136 0 4 13
0 0 6 90 87 0 4 14
0 0 8 78 75 0 4 15
0 0 10 68 67 0 4 16
0 0 12 67 66 0 5 1
0 0 14 41 41 0 5 2
0 0 16 26 24 0 5 3
0 1 1 99 92 0 5 4
0 1 2 10 9 0 5 5
0 1 3 67 62 0 5 6
0 1 4 42 41 0 5 7
0 1 5 31 29 0 5 8
0 1 6 23 22 0 5 9
0 1 7 25 24 0 5 10
0 1 8 61 63 0 5 11
0 1 9 18 18 0 5 12
0 1 10 63 62 0 5 13
0 1 11 29 29 0 5 14
0 1 12 43 44 0 5 15
0 1 13 23 21 0 5 16
0 1 14 37 37 0 6 0
0 1 15 23 22 0 6 1
0 1 16 30 29 0 6 2
0 2 0 88 85 0 6 3
0 2 1 43 38 0 6 4
0 2 2 219 195 0 6 5
0 2 3 21 19 0 6 6
0 2 4 139 131 0 6 7
0 2 5 11 10 0 6 8
0 2 6 100 98 0 6 9
0 2 7 32 33 0 6 10
0 2 8 90 86 0 6 11
0 2 9 57 59 0 6 12
0 2 10 86 86 0 6 13
0 2 11 56 55 0 6 14
0 2 12 24 23 0 6 15
0 2 13 22 22 0 7 1
0 2 14 16 16 0 7 2
0 2 15 6 11 0 7 3
0 2 16 13 12 0 7 4
0 3 1 126 120 0 7 5
0 3 2 12 11 0 7 6
0 3 3 159 154 0 7 7
0 3 4 86 88 0 7 8
0 3 5 144 141 0 7 9
0 3 6 62 63 0 7 10
0 3 7 122 122 0 7 11
0 3 8 44 49 0 7 12
0 3 9 60 61 0 7 13
0 3 10 13 13 0 7 14
0 3 11 38 38 0 7 15
0 3 12 19 19 0 8 0
0 3 13 25 26 0 8 1
0 3 14 28 28 0 8 2
0 3 15 25 24 0 8 3
0 3 16 20 19 0 8 4
0 4 0 40 35 0 8 5
0 4 1 40 37 0 8 6
0 4 2 27 23 0 8 7
0 4 3 74 68 0 8 8
0 4 4 46 43 0 8 9
0 4 5 54 52 0 8 10
0 4 6 37 35 0 8 11
0 4 7 44 39 0 8 12
0 4 8 27 26 0 8 13
0 4 9 39 39 0 8 14
0 4 10 11 9 0 9 1
0 4 11 17 18 0 9 2
Fcal h k 1 Fobs Fcal
16 0 9 3 17 18
31 0 9 4 14 13
13 0 9 5 3 7
48 0 9 6 16 15
7 0 9 7 43 42
116 0 9 8 47 46
59 0 9 9 11 10
191 0 9 10 38 38
22 0 9 11 4 7
146 0 9 12 38 37
13 0 9 13 5 6
118 0 10 0 67 68
18 0 10 1 10 9
52 0 10 2 96 97
22 0 10 3 35 34
41 0 10 4 62 63
4 0 10 5 11 12
28 0 10 6 64 63
11 0 10 7 18 17
25 0 10 8 66 66
2 0 10 9 12 12
19 0 10 10 41 43
16 0 10 11 8 8
41 0 10 12 24 24
23 0 10 13 6 2
44 0 11 1 31 31
50 0 11 2 22 22
56 0 11 3 27 27
43 0 11 4 26 26
40 0 11 5 27 27
20 0 11 6 32 31
30 0 11 7 26 25
60 0 11 8 22 22
14 0 11 9 22 21
43 0 11 10 16 16
5 0 11 11 14 14
20 0 11 12 15 15
113 0 12 0 58 60
7 0 12 1 7 7
101 0 12 2 29 31
19 0 12 3 23 23
74 0 12 4 45 45
31 0 12 5 21 20
28 0 12 6 42 43
13 0 12 7 17 16
37 0 12 8 30 30
28 0 12 9 12 10
33 0 12 10 26 25
24 0 12 11 7 8
42 0 13 1 42 43
25 0 13 2 11 12
15 0 13 3 43 43
137 0 13 4 3 2
36 0 13 5 47 49
112 0 13 6 5 6
18 0 13 7 45 44
73 0 13 8 17 18
11 0 13 9 36 35
44 0 14 0 31 32
18 0 14 1 8 8
38 0 14 2 2 4
23 0 14 3 4 7
40 0 14 4 6 7
26 0 14 5 11 10
47 0 14 6 4 3
15 0 14 7 16 15
27 0 14 8 6 6
7 0 15 1 51 50
7 0 15 2 5 8
Fobs
15
32
10
48
6
116
62
199
22
148
12
120
18
50
22
41
5
28
11
26
3
19
21
42
24
45
53
56
43
41
19
30
60
15
42
3
19
112
7
100
20
73
33
28
14
37
30
32
24
41
24
17
136
38
110
19
73
10
44
17
39
24
40
24
47
14
27
6
6
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h k 1 Fobs Fcal h k 1
0 15 3 40 41 1 2 -2
0 15 4 4 5 1 2 -1
0 15 5 32 31 1 2 0
0 16 0 35 34 1 2 1
1 0 -16 3 2 1 2 2
1 0 -14 3 4 1 2 3
1 0 -12 6 7 1 2 4
1 0 -10 15 15 1 2 5
1 0 -8 40 37 1 2 6
1 0 -6 60 50 1 2 7
1 0 -4 70 73 1 2 8
1 0 -2 262 238 1 2 9
1 0 0 101 94 1 2 10
1 0 2 239 213 1 2 11
1 0 4 75 69 1 2 12
1 0 6 92 88 1 2 13
1 0 8 115 112 1 2 14
1 0 10 152 156 1 2 15
1 0 12 60 61 1 2 16
1 0 14 62 64 1 3 -16
1 0 16 30 29 1 3 -15
1 1 -17 3 5 1 3 -14
1 1 -16 34 34 1 3 -13
1 1 -15 11 12 1 3 -12
1 1 -14 44 45 1 3 -11
1 1 -13 3 5 1 3 -10
1 1 -12 77 78 1 3 -9
1 1 -11 10 9 1 3 -8
1 1 -10 65 64 1 3 -7
1 1 -9 19 17 1 3 -6
1 1 -8 95 97 1 3 -5
1 1 -7 41 39 1 3 -4
1 1 -6 10 16 1 3 -3
1 1 -5 36 37 1 3 -2
1 1 -4 59 61 1 3 -1
1 1 -3 49 51 1 3 0
1 1 -2 147 137 1 3 1
1 1 -1 79 71 1 3 2
1 1 0 147 133 1 3 3
1 1 1 44 40 1 3 4
1 1 2 127 121 1 3 5
1 1 3 1 3 1 3 6
1 1 4 29 30 1 3 7
1 1 5 12 12 1 3 8
1 1 6 44 40 1 3 9
1 1 7 31 29 1 3 10
1 1 8 24 22 1 3 11
1 1 9 55 54 1 3 12
1 1 10 16 13 1 3 13
1 1 11 30 31 1 3 14
1 1 12 4 0 1 3 15
1 1 13 36 35 1 3 16
1 1 14 3 6 1 4 -16
1 1 15 15 14 1 4 -15
1 1 16 11 9 1 4 -14
1 2 -16 20 20 1 4 -13
1 2 -15 30 28 1 4 -12
1 2 -14 3 1 1 4 -11
1 2 -13 28 26 1 4 -10
1 2 -12 14 13 1 4 -9
1 2 -11 54 54 1 4 -8
1 2 -10 34 35 1 4 -7
1 2 -9 39 42 1 4 -6
1 2 -8 26 28 1 4 -5
1 2 -7 54 55 1 4 -4
1 2 -6 27 29 1 4 -3
1 2 -5 20 20 1 4 -2
1 2 -4 36 34 1 4 -1
1 2 -3 48 50 1 4 0
Fcal h k 1 Fobs Fcal
13 1 4 1 7 5
150 1 4 2 25 19
178 1 4 3 99 94
53 1 4 4 45 43
61 1 4 5 74 72
70 1 4 6 46 43
92 1 4 7 41 41
56 1 4 8 5 5
130 1 4 9 54 55
3 1 4 10 31 31
92 1 4 11 11 13
34 1 4 12 12 12
51 1 4 13 18 16
5 1 4 14 11 10
56 1 4 15 8 7
4 1 5 -16 9 8
39 1 5 -15 13 11
8 1 5 -14 6 7
33 1 5 -13 6 7
25 1 5 -12 12 12
2 1 5 -11 18 19
14 1 5 -10 7 9
4 1 5 -9 15 15
8 1 5 -8 3 4
9 1 5 -7 26 26
36 1 5 -6 15 16
33 1 5 -5 76 72
54 1 5 -4 42 41
44 1 5 -3 32 35
90 1 5 -2 12 12
60 1 5 -1 31 38
96 1 5 0 24 21
45 1 5 1 57 60
57 1 5 2 66 61
51 1 5 3 197 187
28 1 5 4 8 9
76 1 5 5 137 132
66 1 5 6 7 5
129 1 5 7 108 111
13 1 5 8 32 33
118 1 5 9 64 65
35 1 5 10 3 0
107 1 5 11 54 56
31 1 5 12 4 5
65 1 5 13 56 57
19 1 5 14 4 0
57 1 5 15 43 44
1 1 6 -15 47 47
46 1 6 -14 12 13
20 1 6 -13 51 51
38 1 6 -12 7 6
19 1 6 -11 45 44
0 1 6 -10 23 23
35 1 6 -9 55 56
3 1 6 -8 31 30
38 1 6 -7 56 56
1 1 6 -6 15 14
45 1 6 -5 67 69
20 1 6 -4 6 4
65 1 6 -3 88 88
4 1 6 -2 11 9
103 1 6 -1 61 62
9 1 6 0 21 20
154 1 6 1 93 92
62 1 6 2 56 53
52 1 6 3 56 58
3 1 6 4 58 56
50 1 6 5 66 63
6 1 6 6 46 47
Fobs
15
158
191
50
60
73
94
62
132
2
93
30
50
2
57
3
38
8
34
24
3
14
5
10
10
34
33
51
44
87
61
100
42
60
51
37
77
69
130
13
123
34
108
32
66
20
56
5
43
18
38
19
4
36
4
38
2
42
19
60
3
100
9
158
71
45
4
49
4
Appendix Two
h k 1 Fobs 'Fcal h k 1
1 6 7 21 22 1 9 -13
1 6 8 24 26 1 9 -12
1 6 9 15 15 1 9 -11
1 6 10 16 17 1 9 -10
1 6 11 10 9 1 9 -9
1 6 12 18 18 1 9 -8
1 6 13 8 7 1 9 -7
1 6 14 16 16 1 9 -6
1 6 15 17 16 1 9 -5
1 7 -15 10 11 1 9 -4
1 7 -14 34 34 1 9 -3
1 7 -13 3 2 1 9 -2
1 7 -12 35 36 1 9 -1
1 7 -11 4 3 1 9 0
1 7 -10 26 26 1 9 1
1 7 -9 25 24 1 9 2
1 7 -8 36 36 1 9 3
1 7 -7 45 44 1 9 4
1 7 -6 39 40 1 9 5
1 7 -5 0 5 1 9 6
1 7 -4 59 61 1 9 7
1 7 -3 71 76 1 9 8
1 7 -2 57 56 1 9 9
1 7 -1 69 70 1 9 10
1 7 0 57 55 1 9 11
1 7 1 58 58 1 9 12
1 7 2 42 43 1 9 13
1 7 3 43 44 1 10 -13
1 7 4 34 36 1 10 -12
1 7 5 54 52 1 10 -11
1 7 6 5 2 1 10 -10
1 7 7 38 39 1 10 -9
1 7 8 7 7 1 10 -8
1 7 9 62 62 1 10 -7
1 7 10 11 11 1 10 -6
1 7 11 59 61 1 10 -5
1 7 12 5 2 1 10 -4
1 7 13 49 50 1 10 -3
1 7 14 12 12 1 10 -2
1 8 -14 4 3 1 10 -1
1 8 -13 23 24 1 10 0
1 8 -12 4 2 1 10 1
1 8 -11 24 26 1 10 2
1 8 -10 4 4 1 10 3
1 8 -9 31 30 1 10 4
1 8 -8 3 9 1 10 5
1 8 -7 11 11 1 10 6
1 8 -6 24 22 1 10 7
1 8 -5 46 50 1 10 8
1 8 -4 54 53 1 10 9
1 8 -3 43 43 1 10 10
1 8 -2 87 84 1 10 11
1 8 -1 49 49 1 10 12
1 8 0 72 73 1 11 -12
1 8 1 35 35 1 11 -11
1 8 2 59 60 1 11 -10
1 8 3 25 25 1 11 -9
1 8 4 50 50 1 11 -8
1 8 5 23 24 1 11 -7
1 8 6 44 43 1 11 -6
1 8 7 10 12 1 11 -5
1 8 8 59 58 1 11 -4
1 8 9 4 12 1 11 -3
1 8 10 67 69 1 11 -2
1 8 11 10 10 1 11 -1
1 8 12 56 59 1 11 0
1 8 13 3 2 1 11 1
1 8 14 36 36 1 11 2
1 9 -14 38 39 1 11 3
Fcal h k 1 Fobs Fcal
0 1 11 4 32 33
50 1 11 5 29 29
6 1 11 6 23 25
58 1 11 7 26 26
28 1 11 8 27 27
37 1 11 9 25 24
1 1 11 10 11 10
58 1 11 11 17 16
11 1 12 -11 14 14
31 1 12 -10 6 4
32 1 12 -9 33 34
65 1 12 -8 17 17
4 1 12 -7 44 43
75 1 12 -6 14 14
15 1 12 -5 38 36
74 1 12 -4 11 13
46 1 12 -3 36 36
27 1 12 -2 27 29
4 1 12 -1 21 20
25 1 12 0 16 15
21 1 12 1 12 13
3 1 12 2 37 37
6 1 12 3 11 12
4 1 12 4 32 32
4 1 12 5 15 15
5 1 12 6 39 38
4 1 12 7 21 21
12 1 12 8 40 41
3 1 12 9 12 12
10 1 12 10 26 25
20 1 13 -9 14 14
14 1 13 -8 18 20
14 1 13 -7 20 20
5 1 13 -6 14 13
19 1 13 -5 18 18
8 1 13 -4 1 4
32 1 13 -3 14 14
0 1 13 -2 18 18
18 1 13 -1 23 22
8 1 13 0 29 29
77 1 13 1 36 38
43 1 13 2 34 36
51 1 13 3 44 45
13 1 13 4 6 11
64 1 13 5 46 46
5 1 13 6 2 4
75 1 13 7 41 40
18 1 13 8 2 3
58 1 13 9 31 32
16 1 14 -8 4 6
51 1 14 -7 28 28
2 1 14 -6 3 6
36 1 14 -5 32 33
15 1 14 -4 12 13
2 1 14 -3 39 38
43 1 14 -2 23 23
6 1 14 -1 31 32
57 1 14 0 4 3
0 1 14 1 34 34
37 1 14 2 2 2
19 1 14 3 21 22
62 1 14 4 6 5
20 1 14 5 18 18
43 1 14 6 3 0
18 1 14 7 12 12
30 1 15 -5 15 14
21 1 15 -4 7 7
16 1 15 -3 29 28
23 1 15 -2 12 9
Fobs
5
47
8
57
29
37
3
58
12
32
34
66
3
75
16
75
44
27
0
26
21
4
5
3
4
3
2
13
3
10
21
15
15
5
19
8
34
4
19
8
79
44
49
14
64
8
75
17
59
17
51
5
34
17
3
44
4
56
2
39
19
64
21
44
20
28
22
16
25
Appendix Two
h k 1 Fobs Fcal h k 1
1 15 -1 35 34 2 2 -2
1 15 0 3 3 2 2 -1
1 15 1 29 29 2 2 0
1 15 2 3 4 2 2 1
1 15 3 24 24 2 2 2
1 15 4 3 1 2 2 3
1 15 5 23 25 2 2 4
2 0 -16 32 32 2 2 5
2 0 -14 32 33 2 2 6
2 0 -12 73 75 2 2 7
2 0 -10 43 42 2 2 8
2 0 -8 59 59 2 2 9
2 0 -6 6 2 2 2 10
2 0 -4 12 9 2 2 11
2 0 -2 39 38 2 2 12
2 0 0 22 14 2 2 13
2 0 2 6 4 2 2 14
2 0 4 81 73 2 2 15
2 0 6 87 83 2 3 -16
2 0 8 63 63 2 3 -15
2 0 10 62 63 2 3 -14
2 0 12 51 50 2 3 -13
2 0 14 24 23 2 3 -12
2 1 -16 28 27 2 3 -11
2 1 -15 8 13 2 3 -10
2 1 -14 37 36 2 3 -9
2 1 -13 18 18 2 3 -8
2 1 -12 56 56 2 3 -7
2 1 -11 47 49 2 3 -6
2 1 -10 77 77 2 3 -5
2 1 -9 8 11 2 3 -4
2 1 -8 59 59 2 3 -3
2 1 -7 3 5 2 3 -2
2 1 -6 66 67 2 3 -1
2 1 -5 44 43 2 3 0
2 1 -4 67 70 2 3 1
2 1 -3 17 18 2 3 2
2 1 -2 179 173 2 3 3
2 1 -1 9 7 2 3 4
2 1 0 121 115 2 3 5
2 1 1 19 23 2 3 6
2 1 2 74 76 2 3 7
2 1 3 35 35 2 3 8
2 1 4 9 9 2 3 9
2 1 5 14 16 2 3 10
2 1 6 80 81 2 3 11
2 1 7 24 23 2 3 12
2 1 8 72 72 2 3 13
2 1 9 39 39 2 3 14
2 1 10 66 65 2 3 15
2 1 11 28 29 2 4 -16
2 1 12 45 46 2 4 -15
2 1 13 5 4 2 4 -14
2 1 14 25 24 2 4 -13
2 1 15 3 4 2 4 -12
2 2 -16 33 33 2 4 -11
2 2 -15 25 25 2 4 -10
2 2 -14 32 32 2 4 -9
2 2 -13 29 30 2 4 -8
2 2 -12 14 14 2 4 -7
2 2 -11 10 8 2 4 -6
2 2 -10 31 33 2 4 -5
2 2 -9 49 47 2 4 -4
2 2 -8 13 14 2 4 -3
2 2 -7 22 21 2 4 -2
2 2 -6 67 64 2 4 -1
2 2 -5 60 59 2 4 0
2 2 -4 6 3 2 4 1
2 2 -3 53 58 2 4 2
Fcal h k 1 Fobs Fcal
17 2 4 3 96 100
101 2 4 4 2 0
12 2 4 5 143 140
84 2 4 6 25 24
27 2 4 7 88 88
67 2 4 8 3 0
46 2 4 9 33 35
43 2 4 10 3 1
19 2 4 11 31 32
33 2 4 12 7 6
9 2 4 13 30 31
36 2 4 14 16 16
29 2 4 15 5 9
22 2 5 -16 3 5
26 2 5 -15 36 37
32 2 5 -14 3 7
36 2 5 -13 27 28
23 2 5 -12 6 0
3 2 5 -11 37 36
28 2 5 -10 8 6
9 2 5 -9 28 27
45 2 5 -8 19 18
42 2 5 -7 32 33
20 2 5 -6 14 13
21 2 5 -5 50 55
58 2 5 -4 3 0
69 2 5 -3 44 44
12 2 5 -2 16 17
57 2 5 -1 30 26
26 2 5 0 6 4
41 2 5 1 2 2
27 2 5 2 4 8
43 2 5 3 24 28
2 2 5 4 14 15
15 2 5 5 61 61
14 2 5 6 26 26
79 2 5 7 23 24
35 2 5 8 6 7
79 2 5 9 22 21
32 2 5 10 3 0
58 2 5 11 33 33
16 2 5 12 12 12
61 2 5 13 49 49
44 2 5 14 12 12
22 2 5 15 30 30
23 2 6 -15 31 34
11 2 6 -14 17 18
29 2 6 -13 36 38
0 2 6 -12 5 3
36 2 6 -11 38 39
14 2 6 -10 4 0
19 2 6 -9 37 38
12 2 6 -8 20 20
24 2 6 -7 67 68
4 2 6 -6 20 22
51 2 6 -5 112 112
17 2 6 -4 40 40
90 2 6 -3 57 63
1 2 6 -2 12 11
113 2 6 -1 95 96
12 2 6 0 21 22
113 2 6 1 61 62
30 2 6 2 34 33
57 2 6 3 100 96
29 2 6 4 31 30
16 2 6 5 63 65
28 2 6 6 4 2
76 2 6 7 23 23
4 2 6 8 2 2
Fobs
18
96
12
83
23
65
49
44
19
31
10
35
28
21
25
30
35
22
3
28
11
45
42
19
22
55
69
10
55
25
40
29
41
3
15
12
79
32
77
32
56
16
60
45
19
22
12
28
2
35
14
19
11
23
3
51
18
88
3
114
11
113
31
55
34
26
32
76
3
Appendix Two
h k 1 Fobs Fcal h k 1
2 6 9 57 58 2 9 -8
2 6 10 3 0 2 9 -7
2 6 11 40 41 2 9 -6
2 6 12 19 20 2 9 -5
2 6 13 27 28 2 9 -4
2 6 14 17 17 2 9 -3
2 7 -15 23 22 2 9 -2
2 7 -14 21 21 2 9 -1
2 7 -13 38 38 2 9 0
2 7 -12 26 27 2 9 1
2 7 -11 33 32 2 9 2
2 7 -10 27 26 2 9 3
2 7 -9 10 9 2 9 4
2 7 -8 19 18 2 9 5
2 7 -7 26 27 2 9 6
2 7 -6 44 48 2 9 7
2 7 -5 25 26 2 9 8
2 7 -4 62 63 2 9 9
2 7 -3 5 8 2 9 10
2 7 -2 54 56 2 9 11
2 7 -1 14 14 2 9 12
2 7 0 66 65 2 10 -13
2 7 1 18 20 2 10 -12
2 7 2 59 59 2 10 -11
2 7 3 26 26 2 10 -10
2 7 4 39 38 2 10 -9
2 7 5 27 26 2 10 -8
2 7 6 36 35 2 10 -7
2 7 7 43 43 2 10 -6
2 7 8 35 33 2 10 -5
2 7 9 32 32 2 10 -4
2 7 10 33 33 2 10 -3
2 7 11 40 39 2 10 -2
2 7 12 19 21 2 10 -1
2 7 13 20 21 2 10 0
2 7 14 17 17 2 10 1
2 8 -14 33 33 2 10 2
2 8 -13 18 19 2 10 3
2 8 -12 40 39 2 10 4
2 8 -11 23 24 2 10 5
2 8 -10 35 36 2 10 6
2 8 -9 23 23 2 10 7
2 8 -8 21 22 2 10 8
2 8 -7 28 27 2 10 9
2 8 -6 15 16 2 10 10
2 8 -5 31 32 2 10 11
2 8 -4 4 7 2 10 12
2 8 -3 38 38 2 11 -12
2 8 -2 8 8 2 11 -11
2 8 -1 49 50 2 11 -10
2 8 0 12 10 2 11 -9
2 8 1 47 46 2 11 -8
2 8 2 11 9 2 11 -7
2 8 3 29 29 2 11 -6
2 8 4 5 0 2 11 -5
2 8 5 35 34 2 11 -4
2 8 6 32 33 2 11 -3
2 8 7 27 25 2 11 -2
2 8 8 37 37 2 11 -1
2 8 9 21 20 2 11 0
2 8 10 37 39 2 11 1
2 8 11 23 23 2 11 2
2 8 12 28 30 2 11 3
2 8 13 18 17 2 11 4
2 9 -13 3 0 2 11 5
2 9 -12 34 36 2 11 6
2 9 -11 8 7 2 11 7
2 9 -10 41 40 2 11 8
2 9 -9 4 2 2 11 9
Fcal h k 1 Fobs Fcal
50 2 11 10 20 19
19 2 11 11 3 9
32 2 12 -11 26 28
30 2 12 -10 9 8
68 2 12 -9 31 29
32 2 12 -8 12 12
94 2 12 -7 39 39
27 2 12 -6 5 6
76 2 12 -5 30 31
32 2 12 -4 5 1
53 2 12 -3 23 25
10 2 12 -2 12 10
63 2 12 -1 23 23
11 2 12 0 5 7
22 2 12 1 32 30
24 2 12 2 5 3
54 2 12 3 35 35
0 2 12 4 10 10
41 2 12 5 41 43
3 2 12 6 18 18
37 2 12 7 39 40
6 2 12 8 10 9
16 2 12 9 17 17
2 2 13 -9 5 10
34 2 13 -8 4 5
15 2 13 -7 14 15
20 2 13 -6 13 13
5 2 13 -5 20 21
23 2 13 -4 24 23
1 2 13 -3 16 17
20 2 13 -2 37 34
16 2 13 -1 4 2
2 2 13 0 23 22
27 2 13 1 15 16
3 2 13 2 17 16
13 2 13 3 16 16
23 2 13 4 17 17
13 2 13 5 14 15
19 2 13 6 10 10
13 2 13 7 12 12
15 2 13 8 7 5
9 2 14 -7 31 32
29 2 14 -6 9 10
2 2 14 -5 33 36
21 2 14 -4 21 20
13 2 14 -3 43 42
19 2 14 -2 4 9
35 2 14 -1 44 44
17 2 14 0 4 7
33 2 14 1 38 38
21 2 14 2 15 15
53 2 14 3 34 33
13 2 14 4 8 9
57 2 14 5 31 33
9 2 14 6 13 12
35 2 15 -5 5 0
2 2 15 -4 8 8
34 2 15 -3 4 3
0 2 15 -2 10 10
46 2 15 -1 5 5
1 2 15 0 4 4
53 2 15 1 3 1
3 2 15 2 2 2
34 2 15 3 3 2
16 2 15 4 5 12
63 3 0 -16 49 46
15 3 0 -14 69 70
46 3 0 -12 64 63
9 3 0 -10 104 105
Fobs
50
18
30
29
69
31
95
27
77
32
53
9
65
12
24
22
53
2
41
3
36
8
15
6
33
15
19
6
26
5
21
16
4
26
6
14
23
14
18
13
16
8
31
3
22
13
18
35
17
31
20
52
13
56
10
35
5
34
3
46
4
53
3
34
14
61
15
46
10
Appendix Two
h k 1 Fobs Fcal h k 1
3 0 -8 56 57 3 2 9
3 0 -6 80 79 3 2 10
3 0 -4 110 113 3 2 11
3 0 -2 217 205 3 2 12
3 0 0 129 134 3 2 13
3 0 2 61 60 3 2 14
3 0 4 0 14 3 3 -16
3 0 6 33 33 3 3 -15
3 0 8 15 14 3 3 -14
3 0 10 15 14 3 3 -13
3 0 12 5 6 3 3 -12
3 0 14 7 6 3 3 -11
3 1 -16 7 7 3 3 -10
3 1 -15 19 20 3 3 -9
3 1 -14 6 4 3 3 -8
3 1 -13 37 39 3 3 -7
3 1 -12 12 10 3 3 -6
3 1 -11 28 27 3 3 -5
3 1 -10 3 6 3 3 -4
3 1 -9 32 34 3 3 -3
3 1 -8 28 30 3 3 -2
3 1 -7 11 10 3 3 -1
3 1 -6 52 51 3 3 0
3 1 -5 13 13 3 3 1
3 1 -4 69 68 3 3 2
3 1 -3 45 44 3 3 3
3 1 -2 180 170 3 3 4
3 1 -1 49 50 3 3 5
3 1 0 96 91 3 3 6
3 1 1 43 46 3 3 7
3 1 2 52 56 3 3 8
3 1 3 27 26 3 3 9
3 1 4 58 63 3 3 10
3 1 5 3 4 3 3 11
3 1 6 45 48 3 3 12
3 1 7 18 15 3 3 13
3 1 8 99 97 3 3 14
3 1 9 10 9 3 4 -16
3 1 10 53 53 3 4 -15
3 1 11 2 6 3 4 -14
3 1 12 46 47 3 4 -13
3 1 13 15 16 3 4 -12
3 1 14 33 33 3 4 -11
3 1 15 2 6 3 4 -10
3 2 -16 27 27 3 4 -9
3 2 -15 3 0 3 4 -8
3 2 -14 36 38 3 4 -7
3 2 -13 17 16 3 4 -6
3 2 -12 56 57 3 4 -5
3 2 -11 4 2 3 4 -4
3 2 -10 77 78 3 4 -3
3 2 -9 5 5 3 4 -2
3 2 -8 75 77 3 4 -1
3 2 -7 30 28 3 4 0
3 2 -6 103 104 3 4 1
3 2 -5 41 40 3 4 2
3 2 -4 94 92 3 4 3
3 2 -3 58 60 3 4 4
3 2 -2 43 46 3 4 5
3 2 -1 48 52 3 4 6
3 2 0 75 74 3 4 7
3 2 1 61 63 3 4 8
3 2 2 6 9 3 4 9
3 2 3 24 24 3 4 10
3 2 4 55 56 3 4 11
3 2 5 47 48 3 4 12
3 2 6 15 14 3 4 13
3 2 7 50 49 3 4 14
3 2 8 44 45 3 5 -15
Fcal h k 1 Fobs Fcal
48 3 5 -14 3 2
4 3 5 -13 55 55
37 3 5 -12 2 2
5 3 5 -11 43 44
30 3 5 -10 17 17
15 3 5 -9 80 81
10 3 5 -8 4 2
30 3 5 -7 118 120
2 3 5 -6 17 17
38 3 5 -5 102 103
12 3 5 -4 28 28
80 3 5 -3 64 69
33 3 5 -2 12 13
75 3 5 -1 70 72
2 3 5 0 18 17
99 3 5 1 58 61
26 3 5 2 19 19
89 3 5 3 45 48
17 3 5 4 21 22
85 3 5 5 40 39
41 3 5 6 4 5
54 3 5 7 36 38
38 3 5 8 6 7
56 3 5 9 5 2
81 3 5 10 5 5
49 3 5 11 7 3
77 3 5 12 7 7
56 3 5 13 6 3
69 3 5 14 6 7
7 3 6 -15 10 10
10 3 6 -14 13 13
16 3 6 -13 5 2
22 3 6 -12 22 21
1 3 6 -11 8 5
16 3 6 -10 20 19
6 3 6 -9 31 28
18 3 6 -8 39 39
12 3 6 -7 23 21
6 3 6 -6 53 54
13 3 6 -5 81 83
5 3 6 -4 49 49
18 3 6 -3 79 77
12 3 6 -2 17 16
16 3 6 -1 39 40
36 3 6 0 2 4
38 3 6 1 82 80
62 3 6 2 7 9
30 3 6 3 66 69
43 3 6 4 20 21
10 3 6 5 53 55
23 3 6 6 34 34
9 3 6 7 49 50
58 3 6 8 25 25
18 3 6 9 44 46
99 3 6 10 4 8
4 3 6 11 46 50
115 3 6 12 5 8
3 3 6 13 45 45
105 3 7 -14 5 2
9 3 7 -13 45 44
43 3 7 -12 3 4
6 3 7 -11 44 43
36 3 7 -10 3 2
12 3 7 -9 46 46
35 3 7 -8 7 13
6 3 7 -7 35 34
29 3 7 -6 14 15
3 3 7 -5 40 40
42 3 7 -4 32 33
Fobs
46
6
37
3
28
16
11
32
3
36
12
78
34
74
4
102
27
87
18
83
39
55
35
53
82
49
75
54
70
0
10
14
20
3
16
3
18
13
6
14
6
19
13
15
37
36
64
29
45
11
22
6
62
19
98
4
116
4
105
8
43
2
36
10
35
3
29
3
42
Appendix Two
h k 1 Fobs Fcal h k 1
3 7 -3 83 83 3 10 -12
3 7 -2 46 46 3 10 -11
3 7 -1 19 20 3 10 -10
3 7 0 33 35 3 10 -9
3 7 1 60 63 3 10 -8
3 7 2 36 34 3 10 -7
3 7 3 50 51 3 10 -6
3 7 4 44 44 3 10 -5
3 7 5 15 16 3 10 -4
3 7 6 32 32 3 10 -3
3 7 7 10 9 3 10 -2
3 7 8 35 36 3 10 -1
3 7 9 10 9 3 10 0
3 7 10 37 37 3 10 1
3 7 11 11 9 3 10 2
3 7 12 30 31 3 10 3
3 7 13 3 1 3 10 4
3 8 -14 47 47 3 10 5
3 8 -13 4 2 3 10 6
3 8 -12 47 46 3 10 7
3 8 -11 3 0 3 10 8
3 8 -10 42 42 3 10 9
3 8 -9 11 14 3 10 10
3 8 -8 49 50 3 10 11
3 8 -7 14 15 3 11 -11
3 8 -6 45 46 3 11 -10
3 8 -5 21 21 3 11 -9
3 8 -4 58 57 3 11 -8
3 8 -3 25 27 3 11 -7
3 8 -2 74 74 3 11 -6
3 8 -1 45 44 3 11 -5
3 8 0 66 69 3 11 -4
3 8 1 46 48 3 11 -3
3 8 2 48 50 3 11 -2
3 8 3 25 24 3 11 -1
3 8 4 15 14 3 11 0
3 8 5 25 27 3 11 1
3 8 6 5 4 3 11 2
3 8 7 25 24 3 11 3
3 8 8 2 0 3 11 4
3 8 9 29 28 3 11 5
3 8 10 9 8 3 11 6
3 8 11 24 24 3 11 7
3 8 12 4 3 3 11 8
3 9 -13 6 8 3 11 9
3 9 -12 4 6 3 11 10
3 9 -11 11 10 3 12 -10
3 9 -10 4 3 3 12 -9
3 9 -9 11 8 3 12 -8
3 9 -8 4 5 3 12 -7
3 9 -7 28 29 3 12 -6
3 9 -6 32 34 3 12 -5
3 9 -5 18 20 3 12 -4
3 9 -4 61 63 3 12 -3
3 9 -3 5 1 3 12 -2
3 9 -2 47 47 3 12 -1
3 9 -1 4 1 3 12 0
3 9 0 63 69 3 12 1
3 9 1 24 24 3 12 2
3 9 2 46 45 3 12 3
3 9 3 17 18 3 12 4
3 9 4 22 21 3 12 5
3 9 5 29 31 3 12 6
3 9 6 55 54 3 12 7
3 9 7 13 13 3 12 8
3 9 8 51 49 3 13 -8
3 9 9 4 2 3 13 -7
3 9 10 50 49 3 13 -6
3 9 11 7 7 3 13 -5
Fcal h k 1 Fobs Fcal
49 3 13 -4 27 27
8 3 13 -3 32 34
49 3 13 -2 19 19
14 3 13 -1 24 25
59 3 13 0 14 15
7 3 13 1 15 14
50 3 13 2 11 10
17 3 13 3 17 17
53 3 13 4 14 13
18 3 13 5 19 20
46 3 13 6 6 8
2 3 13 7 19 20
42 3 14 -6 2 4
11 3 14 -5 21 22
25 3 14 -4 6 6
4 3 14 -3 26 25
32 3 14 -2 4 6
5 3 14 -1 27 28
15 3 14 0 13 14
13 3 14 1 28 28
18 3 14 2 10 10
6 3 14 3 28 29
4 3 14 4 4 9
11 3 14 5 25 25
22 3 15 -2 6 7
27 3 15 -1 30 27
26 3 15 0 7 7
20 3 15 1 26 25
24 4 0 -16 21 21
18 4 0 -14 35 35
17 4 0 -12 45 48
11 4 0 -10 56 57
11 4 0 -8 21 24
47 4 0 -6 83 85
29 4 0 -4 167 171
36 4 0 -2 136 142
21 4 0 0 174 169
44 4 0 2 79 86
17 4 0 4 70 71
60 4 0 6 57 58
10 4 0 8 90 89
47 4 0 10 44 44
10 4 0 12 40 38
24 4 0 14 24 24
1 4 1 -16 22 22
23 4 1 -15 8 8
35 4 1 -14 34 33
15 4 1 -13 5 6
27 4 1 -12 41 42
11 4 1 -11 19 18
33 4 1 -10 28 29
4 4 1 -9 18 21
26 4 1 -8 38 40
7 4 1 -7 17 18
25 4 1 -6 15 14
21 4 1 -5 39 40
20 4 1 -4 6 12
30 4 1 -3 61 65
12 4 1 -2 10 9
40 4 1 -1 61 59
9 4 1 0 25 22
35 4 1 1 34 34
13 4 1 2 5 9
24 4 1 3 16 14
2 4 1 4 25 27
12 4 1 5 7 9
38 4 1 6 53 56
19 4 1 7 17 18
41 4 1 8 43 44
Fobs
47
9
49
14
59
9
52
17
52
18
46
4
42
12
26
3
31
3
15
14
18
2
3
11
22
27
26
23
25
18
19
11
11
45
30
35
20
45
15
57
10
47
10
22
3
23
34
15
28
6
34
4
26
3
25
21
20
29
12
40
10
34
15
22
3
11
39
20
42
Appendix Two
h k 1 Fobs Fcal h k 1
4 1 9 15 16 4 4 -10
4 1 10 42 43 4 4 -9
4 1 11 27 26 4 4 -8
4 1 12 30 30 4 4 -7
4 1 13 18 18 4 4 -6
4 2 -16 13 12 4 4 -5
4 2 -15 14 14 4 4 -4
4 2 -14 31 29 4 4 -3
4 2 -13 26 25 4 4 -2
4 2 -12 36 36 4 4 -1
4 2 -11 34 35 4 4 0
4 2 -10 50 50 4 4 1
4 2 -9 20 18 4 4 2
4 2 -8 76 78 4 4 3
4 2 -7 5 7 4 4 4
4 2 -6 59 59 4 4 5
4 2 -5 12 10 4 4 6
4 2 -4 79 82 4 4 7
4 2 -3 17 17 4 4 8
4 2 -2 107 104 4 4 9
4 2 -1 6 7 4 4 10
4 2 0 91 97 4 4 11
4 2 1 3 0 4 4 12
4 2 2 69 68 4 4 13
4 2 3 6 5 4 5 -15
4 2 4 89 93 4 5 -14
4 2 5 25 27 4 5 -13
4 2 6 81 81 4 5 -12
4 2 7 48 47 4 5 -11
4 2 8 40 37 4 5 -10
4 2 9 34 35 4 5 -9
4 2 10 36 37 4 5 -8
4 2 11 22 23 4 5 -7
4 2 12 8 9 4 5 -6
4 2 13 5 8 4 5 -5
4 3 -15 19 20 4 5 -4
4 3 -14 9 6 4 5 -3
4 3 -13 27 26 4 5 -2
4 3 -12 4 2 4 5 -1
4 3 -11 38 39 4 5 0
4 3 -10 22 23 4 5 1
4 3 -9 67 67 4 5 2
4 3 -8 35 33 4 5 3
4 3 -7 86 84 4 5 4
4 3 -6 29 28 4 5 5
4 3 -5 60 63 4 5 6
4 3 -4 37 36 4 5 7
4 3 -3 94 97 4 5 8
4 3 -2 14 13 4 5 9
4 3 -1 79 80 4 5 10
4 3 0 5 6 4 5 11
4 3 1 102 105 4 5 12
4 3 2 32 34 4 5 13
4 3 3 111 111 4 6 -14
4 3 4 51 49 4 6 -13
4 3 5 61 61 4 6 -12
4 3 6 4 8 4 6 -11
4 3 7 67 68 4 6 -10
4 3 8 23 23 4 6 -9
4 3 9 18 19 4 6 -8
4 3 10 3 2 4 6 -7
4 3 11 24 27 4 6 -6
4 3 12 24 24 4 6 -5
4 3 13 26 26 4 6 -4
4 4 -15 27 29 4 6 -3
4 4 -14 7 8 4 6 -2
4 4 -13 27 26 4 6 -1
4 4 -12 5 8 4 6 0
4 4 -11 25 27 4 6 1
Fcal h k 1 Fobs Fcal
21 4 6 2 36 38
21 4 6 3 7 2
10 4 6 4 38 40
60 4 6 5 49 49
43 4 6 6 36 38
24 4 6 7 32 33
31 4 6 8 23 24
8 4 6 9 37 36
13 4 6 10 3 6
5 4 6 11 35 34
31 4 6 12 3 2
36 4 7 -14 18 17
33 4 7 -13 20 20
57 4 7 -12 11 12
18 4 7 -11 25 25
21 4 7 -10 4 11
13 4 7 -9 22 22
18 4 7 -8 22 22
18 4 7 -7 51 51
18 4 7 -6 15 16
8 4 7 -5 75 74
32 4 7 -4 3 5
3 4 7 -3 53 52
39 4 7 -2 13 13
18 4 7 -1 95 99
2 4 7 0 3 3
27 4 7 1 55 56
5 4 7 2 7 6
44 4 7 3 37 39
0 4 7 4 14 15
64 4 7 5 37 39
4 4 7 6 18 19
92 4 7 7 31 29
35 4 7 8 18 19
80 4 7 9 31 29
15 4 7 10 23 22
81 4 7 11 35 33
2 4 7 12 19 19
71 4 8 -13 15 15
34 4 8 -12 27 26
115 4 8 -11 14 15
23 4 8 -10 24 24
124 4 8 -9 4 6
9 4 8 -8 26 28
85 4 8 -7 21 20
13 4 8 -6 60 60
43 4 8 -5 8 11
11 4 8 -4 84 85
46 4 8 -3 3 0
4 4 8 -2 78 81
27 4 8 -1 8 2
3 4 8 0 77 77
16 4 8 1 15 15
9 4 8 2 57 59
25 4 8 3 10 8
17 4 8 4 32 32
30 4 8 5 6 7
23 4 8 6 34 33
39 4 8 7 18 17
34 4 8 8 43 42
0 4 8 9 30 27
37 4 8 10 39 41
26 4 8 11 18 18
23 4 9 -12 28 27
2 4 9 -11 8 11
23 4 9 -10 31 29
13 4 9 -9 19 18
20 4 9 -8 21 20
25 4 9 -7 16 16
Fobs
21
21
10
58
41
23
30
8
12
6
29
37
34
59
19
21
13
20
19
18
5
31
5
39
18
3
29
5
43
4
65
3
92
33
82
13
80
2
70
35
114
22
124
10
84
13
43
11
45
4
28
2
17
9
28
18
30
25
37
34
4
38
26
24
5
23
12
20
27
Appendix Two
h k 1 Fobs 1Fcal h k 1
4 9 -6 6 4 4 12 3
4 9 -5 4 3 4 12 4
4 9 -4 14 14 4 12 5
4 9 -3 24 26 4 12 6
4 9 -2 15 16 4 12 7
4 9 -1 5 8 4 13 -7
4 9 0 14 14 4 13 -6
4 9 1 17 16 4 13 -5
4 9 2 3 0 4 13 -4
4 9 3 26 27 4 13 -3
4 9 4 25 24 4 13 -2
4 9 5 14 14 4 13 -1
4 9 6 25 26 4 13 0
4 9 7 12 12 4 13 1
4 9 8 33 33 4 13 2
4 9 9 4 1 4 13 3
4 9 10 32 30 4 13 4
4 10 -11 9 9 4 13 5
4 10 -10 42 42 4 14 -4
4 10 -9 9 10 4 14 -3
4 10 -8 39 40 4 14 -2
4 10 -7 5 7 4 14 -1
4 10 -6 44 46 4 14 0
4 10 -5 14 16 4 14 1
4 10 -4 46 47 4 14 2
4 10 -3 5 6 5 0 -14
4 10 -2 67 69 5 0 -12
4 10 -1 18 16 5 0 -10
4 10 0 57 59 5 0 -8
4 10 1 24 22 5 0 -6
4 10 2 59 62 5 0 -4
4 10 3 6 5 5 0 -2
4 10 4 49 51 5 0 0
4 10 5 12 12 5 0 2
4 10 6 56 56 5 0 4
4 10 7 5 5 5 0 6
4 10 8 30 30 5 0 8
4 10 9 12 11 5 0 10
4 11 -10 22 21 5 0 12
4 11 -9 20 19 5 1 -15
4 11 -8 19 18 5 1 -14
4 11 -7 14 13 5 1 -13
4 11 -6 24 22 5 1 -12
4 11 -5 19 18 5 1 -11
4 11 -4 13 12 5 1 -10
4 11 -3 19 20 5 1 -9
4 11 -2 8 7 5 1 -8
4 11 -1 24 25 5 1 -7
4 11 0 23 23 5 1 -6
4 11 1 27 28 5 1 -5
4 11 2 22 21 5 1 -4
4 11 3 22 23 5 1 -3
4 11 4 21 21 5 1 -2
4 11 5 22 23 5 1 -1
4 11 6 4 7 5 1 0
4 11 7 6 8 5 1 1
4 11 8 27 26 5 1 2
4 12 -9 19 16 5 1 3
4 12 -8 31 32 5 1 4
4 12 -7 17 16 5 1 5
4 12 -6 27 26 5 1 6
4 12 -5 15 15 5 1 7
4 12 -4 37 37 5 1 8
4 12 -3 5 8 5 1 9
4 12 -2 29 29 5 1 10
4 12 -1 6 5 5 1 11
4 12 0 38 35 5 1 12
4 12 1 12 13 5 2 -15
4 12 2 27 26 5 2 -14
Fcal h k 1 Fobs Fcal
14 5 2 -13 27 27
36 5 2 -12 14 14
5 5 2 -11 28 30
24 5 2 -10 20 21
9 5 2 -9 13 13
33 5 2 -8 5 2
3 5 2 -7 24 24
34 5 2 -6 18 19
6 5 2 -5 28 30
30 5 2 -4 44 45
7 5 2 -3 37 39
34 5 2 -2 25 26
7 5 2 -1 46 48
34 5 2 0 51 52
2 5 2 1 44 45
38 5 2 2 74 76
8 5 2 3 10 11
41 5 2 4 49 50
12 5 2 5 5 8
6 5 2 6 53 52
10 5 2 7 7 6
1 5 2 8 47 49
13 5 2 9 2 3
4 5 2 10 33 32
3 5 2 11 5 8
3 5 2 12 22 23
3 5 3 -15 3 7
6 5 3 -14 20 18
37 5 3 -13 6 2
21 5 3 -12 17 17
58 5 3 -11 8 12
84 5 3 -10 24 24
53 5 3 -9 22 22
6 5 3 -8 46 46
70 5 3 -7 16 14
93 5 3 -6 38 38
67 5 3 -5 29 32
66 5 3 -4 7 9
42 5 3 -3 5 11
2 5 3 -2 35 38
35 5 3 -1 64 67
8 5 3 0 5 5
46 5 3 1 53 56
3 5 3 2 28 29
42 5 3 3 65 66
1 5 3 4 25 26
40 5 3 5 64 63
25 5 3 6 19 19
38 5 3 7 38 36
21 5 3 8 23 24
81 5 3 9 40 40
29 5 3 10 4 5
53 5 3 11 37 36
20 5 3 12 21 21
49 5 4 -14 4 11
2 5 4 -13 27 25
38 5 4 -12 5 2
7 5 4 -11 49 47
14 5 4 -10 9 0
17 5 4 -9 69 68
27 5 4 -8 6 14
31 5 4 -7 47 49
0 5 4 -6 8 9
31 5 4 -5 59 59
3 5 4 -4 18 17
20 5 4 -3 20 21
2 5 4 -2 6 0
22 5 4 -1 35 38
5 5 4 0 20 20
Fobs
13
38
4
25
3
32
3
31
3
32
8
33
9
35
2
37
9
41
12
5
4
2
13
3
4
4
6
5
35
23
56
83
53
1
65
91
68
67
41
3
34
6
46
5
43
4
40
26
37
21
77
27
51
20
48
4
38
4
13
16
27
27
3
28
3
20
4
24
6
Appendix Two
h k 1 Fobs Fcal h k 1
5 4 1 17 20 5 7 -7
5 4 2 10 9 5 7 -6
5 4 3 58 60 5 7 -5
5 4 4 30 31 5 7 -4
5 4 5 31 31 5 7 -3
5 4 6 17 16 5 7 -2
5 4 7 19 17 5 7 -1
5 4 8 5 7 5 7 0
5 4 9 4 4 5 7 1
5 4 10 10 11 5 7 2
5 4 11 5 6 5 7 3
5 4 12 15 14 5 7 4
5 5 -14 5 3 5 7 5
5 5 -13 6 0 5 7 6
5 5 -12 6 5 5 7 7
5 5 -11 17 17 5 7 8
5 5 -10 9 9 5 7 9
5 5 -9 17 17 5 7 10
5 5 -8 15 14 5 8 -12
5 5 -7 35 34 5 8 -11
5 5 -6 11 12 5 8 -10
5 5 -5 17 14 5 8 -9
5 5 -4 4 5 5 8 -8
5 5 -3 29 28 5 8 -7
5 5 -2 14 14 5 8 -6
5 5 -1 40 40 5 8 -5
5 5 0 15 16 5 8 -4
5 5 1 69 73 5 8 -3
5 5 2 3 2 5 8 -2
5 5 3 83 86 5 8 -1
5 5 4 16 17 5 8 0
5 5 5 56 55 5 8 1
5 5 6 12 13 5 8 2
5 5 7 50 52 5 8 3
5 5 8 4 6 5 8 4
5 5 9 39 37 5 8 5
5 5 10 5 7 5 8 6
5 5 11 43 42 5 8 7
5 6 -13 36 35 5 8 8
5 6 -12 5 4 5 8 9
5 6 -11 25 24 5 9 -11
5 6 -10 6 9 5 9 -10
5 6 -9 31 32 5 9 -9
5 6 -8 6 5 5 9 -8
5 6 -7 56 58 5 9 -7
5 6 -6 4 3 5 9 -6
5 6 -5 40 40 5 9 -5
5 6 -4 6 5 5 9 -4
5 6 -3 42 42 5 9 -3
5 6 -2 17 17 5 9 -2
5 6 -1 46 47 5 9 -1
5 6 0 25 26 5 9 0
5 6 1 57 59 5 9 1
5 6 2 33 35 5 9 2
5 6 3 9 6 5 9 3
5 6 4 27 28 5 9 4
5 6 5 17 18 5 9 5
5 6 6 14 16 5 9 6
5 6 7 3 3 5 9 7
5 6 8 11 11 5 9 8
5 6 9 6 6 5 9 9
5 6 10 12 11 5 10 -10
5 6 11 4 4 5 10 -9
5 7 -13 5 5 5 10 -8
5 7 -12 17 17 5 10 -7
5 7 -11 5 3 5 10 -6
5 7 -10 21 20 5 10 -5
5 7 -9 6 10 5 10 -4
5 7 -8 27 25 5 10 -3
Fcal h k 1 Fobs Fcal
30 5 10 -2 27 28
37 5 10 -1 15 16
23 5 10 0 44 43
33 5 10 1 17 17
46 5 10 2 40 39
26 5 10 3 4 6
20 5 10 4 41 42
28 5 10 5 12 12
33 5 10 6 38 39
17 5 10 7 10 9
35 5 11 -9 5 2
11 5 11 -8 33 32
24 5 11 -7 5 5
9 5 11 -6 32 31
44 5 11 -5 7 8
8 5 11 -4 22 23
47 5 11 -3 16 15
0 5 11 -2 26 26
1 5 11 -1 11 12
17 5 11 0 13 14
5 5 11 1 17 19
18 5 11 2 18 18
12 5 11 3 14 15
11 5 11 4 21 24
32 5 11 5 14 14
26 5 11 6 11 12
39 5 12 -7 24 23
23 5 12 -6 13 13
42 5 12 -5 20 20
21 5 12 -4 4 10
30 5 12 -3 14 15
12 5 12 -2 17 18
24 5 12 -1 7 10
26 5 12 0 15 16
34 5 12 1 11 12
10 5 12 2 26 27
46 5 12 3 16 16
2 5 12 4 26 25
48 5 13 -4 25 24
0 5 13 -3 16 17
15 5 13 -2 3 8
29 5 13 -1 19 20
5 5 13 0 22 23
28 5 13 1 30 29
5 6 0 -14 28 28
36 6 0 -12 34 33
5 6 0 -10 13 14
30 6 0 -8 6 14
3 6 0 -6 17 17
54 6 0 -4 15 15
27 6 0 -2 22 22
32 6 0 0 15 13
13 6 0 2 21 20
28 6 0 4 5 3
13 6 0 6 40 38
15 6 0 8 39 40
8 6 0 10 26 25
4 6 1 -14 27 28
7 6 1 -13 17 16
3 6 1 -12 36 37
1 6 1 -11 6 11
13 6 1 -10 30 32
3 6 1 -9 8 3
9 6 1 -8 38 38
2 6 1 -7 3 2
9 6 1 -6 64 62
7 6 1 -5 4 0
30 6 1 -4 60 60
15 6 1 -3 10 6
Fobs
32
36
25
32
44
26
21
30
33
17
35
7
25
7
44
9
49
3
3
18
4
19
10
6
31
27
38
22
42
22
28
14
24
26
35
6
47
5
48
3
14
31
8
30
4
37
5
33
4
53
25
33
14
28
12
13
8
3
5
4
3
12
4
9
4
6
5
27
15
Appendix Two
h k 1 Fobs Fcal h k 1
6 1 -2 79 80 6 4 -6
6 1 -1 5 9 6 4 -5
6 1 0 33 30 6 4 -4
6 1 1 3 11 6 4 -3
6 1 2 37 38 6 4 -2
6 1 3 6 0 6 4 -1
6 1 4 40 40 6 4 0
6 1 5 17 17 6 4 1
6 1 6 41 41 6 4 2
6 1 7 21 21 6 4 3
6 1 8 39 38 6 4 4
6 1 9 7 12 6 4 5
6 1 10 29 28 6 4 6
6 2 -14 16 13 6 4 7
6 2 -13 17 17 6 4 8
6 2 -12 18 18 6 4 9
6 2 -11 21 22 6 4 10
6 2 -10 26 25 6 5 -13
6 2 -9 27 27 6 5 -12
6 2 -8 17 15 6 5 -11
6 2 -7 21 22 6 5 -10
6 2 -6 15 13 6 5 -9
6 2 -5 37 36 6 5 -8
6 2 -4 3 8 6 5 -7
6 2 -3 45 45 6 5 -6
6 2 -2 13 13 6 5 -5
6 2 -1 40 41 6 5 -4
6 2 0 18 18 6 5 -3
6 2 1 20 22 6 5 -2
6 2 2 4 0 6 5 -1
6 2 3 31 29 6 5 0
6 2 4 18 17 6 5 1
6 2 5 19 19 6 5 2
6 2 6 15 14 6 5 3
6 2 7 18 17 6 5 4
6 2 8 6 6 6 5 5
6 2 9 24 24 6 5 6
6 2 10 16 16 6 5 7
6 3 -13 22 24 6 5 8
6 3 -12 27 27 6 5 9
6 3 -11 20 23 6 6 -12
6 3 -10 25 26 6 6 -11
6 3 -9 18 16 6 6 -10
6 3 -8 32 32 6 6 -9
6 3 -7 11 11 6 6 -8
6 3 -6 18 18 6 6 -7
6 3 -5 26 26 6 6 -6
6 3 -4 32 32 6 6 -5
6 3 -3 5 10 6 6 -4
6 3 -2 2 7 6 6 -3
6 3 -1 5 4 6 6 -2
6 3 0 37 36 6 6 -1
6 3 1 14 14 6 6 0
6 3 2 39 40 6 6 1
6 3 3 15 14 6 6 2
6 3 4 32 32 6 6 3
6 3 5 11 10 6 6 4
6 3 6 31 31 6 6 5
6 3 7 16 15 6 6 6
6 3 8 15 14 6 6 7
6 3 9 20 20 6 6 8
6 3 10 4 0 6 6 9
6 4 -13 33 34 6 7 -11
6 4 -12 5 4 6 7 -10
6 4 -11 36 35 6 7 -9
6 4 -10 11 11 6 7 -8
6 4 -9 59 59 6 7 -7
6 4 -8 7 1 6 7 -6
6 4 -7 46 49 6 7 -5
Fcal h k 1 Fobs Fcal
0 6 7 -4 34 32
35 6 7 -3 3 4
9 6 7 -2 25 28
31 6 7 -1 7 3
7 6 7 0 26 26
43 6 7 1 7 7
2 6 7 2 24 23
75 6 7 3 4 7
18 6 7 4 26 25
53 6 7 5 24 22
8 6 7 6 20 21
44 6 7 7 19 18
2 6 7 8 25 24
29 6 8 -11 13 14
0 6 8 -10 17 17
19 6 8 -9 18 17
10 6 8 -8 13 10
17 6 8 -7 16 16
9 6 8 -6 6 5
16 6 8 -5 25 25
2 6 8 -4 4 2
24 6 8 -3 19 19
2 6 8 -2 9 10
20 6 8 -1 27 26
2 6 8 0 10 10
1 6 8 1 24 23
0 6 8 2 5 4
22 6 8 3 11 12
7 6 8 4 16 16
17 6 8 5 18 17
6 6 8 6 21 20
13 6 8 7 13 12
11 6 9 -10 26 24
22 6 9 -9 5 4
16 6 9 -8 34 30
9 6 9 -7 7 5
6 6 9 -6 38 38
13 6 9 -5 3 3
5 6 9 -4 46 46
18 6 9 -3 6 8
2 6 9 -2 46 46
34 6 9 -1 20 21
11 6 9 0 41 40
35 6 9 1 11 11
21 6 9 2 25 26
47 6 9 3 3 1
17 6 9 4 22 23
50 6 9 5 10 10
6 6 9 6 28 30
40 6 10 -8 12 11
7 6 10 -7 2 4
50 6 10 -6 5 7
12 6 10 -5 8 8
39 6 10 -4 5 5
9 6 10 -3 7 8
38 6 10 -2 10 8
2 6 10 -1 15 14
30 6 10 0 3 6
3 6 10 1 3 4
22 6 10 2 6 6
2 6 10 3 5 5
29 6 10 4 9 10
8 6 10 5 5 3
19 6 11 -6 19 19
5 6 11 -5 4 0
25 6 11 -4 36 35
1 6 11 -3 5 7
34 6 11 -2 21 19
3 6 11 -1 3 1
Fobs
3
37
5
33
3
42
4
73
19
54
5
46
7
30
3
19
9
17
4
17
4
24
4
20
3
3
4
22
6
17
5
15
5
22
15
9
6
15
7
19
5
33
12
34
22
45
13
50
6
40
7
50
8
38
3
37
4
31
4
19
4
30
4
21
8
24
4
33
4
Appendix Two
h k 1 Fobs Fcal h k 1
6 11 0 32 30 7 3 0
6 11 1 5 1 7 3 1
6 11 2 33 32 7 3 2
6 11 3 3 3 7 3 3
7 0 -12 32 33 7 3 4
7 0 -10 42 40 7 3 5
7 0 -8 39 39 7 3 6
7 0 -6 45 45 7 3 7
7 0 -4 67 71 7 3 8
7 0 -2 38 37 7 4 -11
7 0 0 33 33 7 4 -10
7 0 2 23 24 7 4 -9
7 0 4 7 5 7 4 -8
7 0 6 4 3 7 4 -7
7 0 8 2 7 7 4 -6
7 1 -12 3 4 7 4 -5
7 1 -11 11 11 7 4 -4
7 1 -10 12 11 7 4 -3
7 1 -9 7 7 7 4 -2
7 1 -8 17 17 7 4 -1
7 1 -7 6 13 7 4 0
7 1 -6 31 32 7 4 1
7 1 -5 20 19 7 4 2
7 1 -4 48 50 7 4 3
7 1 -3 25 26 7 4 4
7 1 -2 39 40 7 4 5
7 1 -1 17 18 7 4 6
7 1 0 31 33 7 4 7
7 1 1 5 10 7 5 -11
7 1 2 30 31 7 5 -10
7 1 3 5 0 7 5 -9
7 1 4 41 40 7 5 -8
7 1 5 3 5 7 5 -7
7 1 6 42 42 7 5 -6
7 1 7 3 1 7 5 -5
7 1 8 37 37 7 5 -4
7 2 -12 33 31 7 5 -3
7 2 -11 4 5 7 5 -2
7 2 -10 43 40 7 5 -1
7 2 -9 19 17 7 5 0
7 2 -8 36 36 7 5 1
7 2 -7 13 13 7 5 2
7 2 -6 42 44 7 5 3
7 2 -5 23 24 7 5 4
7 2 -4 21 23 7 5 5
7 2 -3 22 23 7 5 6
7 2 -2 28 30 7 5 7
7 2 -1 23 23 7 6 -10
7 2 0 22 20 7 6 -9
7 2 1 20 21 7 6 -8
7 2 2 15 15 7 6 -7
7 2 3 17 17 7 6 -6
7 2 4 21 21 7 6 -5
7 2 5 27 26 7 6 -4
7 2 6 15 16 7 6 -3
7 2 7 29 26 7 6 -2
7 2 8 5 2 7 6 -1
7 3 -12 6 7 7 6 0
7 3 -11 33 32 7 6 1
7 3 -10 8 5 7 6 2
7 3 -9 43 43 7 6 3
7 3 -8 7 9 7 6 4
7 3 -7 37 37 7 6 5
7 3 -6 20 20 7 6 6
7 3 -5 30 30 7 7 -9
7 3 -4 4 5 7 7 -8
7 3 -3 41 42 7 7 -7
7 3 -2 31 33 7 7 -6
7 3 -1 23 23 7 7 -5
Fcal h k 1 Fobs Fcal
27 7 7 -4 17 16
28 7 7 -3 32 30
35 7 7 -2 16 14
22 7 7 -1 24 25
25 7 7 0 19 19
13 7 7 1 11 10
14 7 7 2 20 19
2 7 7 3 6 5
8 7 7 4 19 19
21 7 7 5 4 4
11 7 8 -8 31 31
10 7 8 -7 8 10
13 7 8 -6 29 29
21 7 8 -5 13 15
8 7 8 -4 36 35
19 7 8 -3 25 25
10 7 8 -2 33 33
29 7 8 -1 18 18
7 7 8 0 25 26
44 7 8 1 18 17
9 7 8 2 5 10
60 7 8 3 10 11
5 7 8 4 7 6
38 7 9 -6 24 24
5 7 9 -5 4 5
35 7 9 -4 31 31
2 7 9 -3 3 6
13 7 9 -2 28 28
43 7 9 -1 3 10
3 7 9 0 19 20
40 7 9 1 5 6
9 7 9 2 25 23
48 7 9 3 6 9
9 7 10 -3 4 2
39 7 10 -2 24 22
3 7 10 -1 4 5
25 8 0 -10 24 22
6 8 0 -8 31 31
31 8 0 -6 51 51
9 8 0 -4 55 56
30 8 0 -2 46 49
3 8 0 0 35 34
19 8 0 2 28 28
2 8 0 4 44 43
10 8 1 -10 8 15
3 8 1 -9 9 9
16 8 1 -8 8 10
20 8 1 -7 11 12
27 8 1 -6 10 6
22 8 1 -5 20 19
22 8 1 -4 8 3
20 8 1 -3 19 21
28 8 1 -2 3 3
13 8 1 -1 12 13
27 8 1 0 5 4
4 8 1 1 8 7
34 8 1 2 12 10
7 8 1 3 5 8
32 8 1 4 23 21
16 8 1 5 5 8
38 8 2 -9 6 5
15 8 2 -8 27 27
20 8 2 -7 5 3
14 8 2 -6 33 32
28 8 2 -5 6 7
13 8 2 -4 34 35
25 8 2 -3 3 2
16 8 2 -2 30 31
24 8 2 -1 9 3
Fobs
28
27
36
21
28
11
14
5
8
20
5
12
8
20
10
18
5
28
8
43
8
61
8
39
5
37
3
12
44
6
40
6
49
10
40
6
27
3
28
5
29
6
19
3
4
5
16
21
30
22
21
20
27
8
27
3
34
7
33
15
38
17
22
16
30
14
26
17
26
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h k 1 Fobs Fcal
8 2 0 41 41
8 2 1 5 5
8 2 2 36 33
8 2 3 13 11
8 2 4 36 34
8 2 5 17 15
8 3 -9 2 0 19
8 3 -8 7 13
8 3 -7 30 30
8 3 -6 3 2
8 3 -5 29 29
8 3 -4 6 0
8 3 -3 37 36
8 3 -2 5 6
8 3 -1 38 4 0
8 3 0 12 9
8 3 1 44 4 2
8 3 2 7 13
8 3 3 34 31
8 3 4 4 6
8 3 5 24 22
8 4 -8 8 11
8 4 -7 15 14
8 4 -6 8 7
8 4 -5 12 11
8 4 -4 11 11
8 4 -3 7 6
8 4 -2 11 10
8 4 -1 14 15
8 4 0 12 10
8 4 1 7 8
8 4 2 16 14
8 4 3 20 19
8 4 4 4 3
8 5 -8 5 5
8 5 -7 29 30
8 5 -6 4 5
8 5 -5 29 28
8 5 -4 5 4
8 5 -3 35 36
8 5 -2 5 8
8 5 -1 48 49
8 5 0 4 2
8 5 1 39 38
8 5 2 3 3
8 5 3 43 4 0
8 6 -6 11 11
8 6 -5 3 1
8 6 -4 10 8
8 6 -3 8 7
8 6 -2 6 11
8 6 -1 7 2
8 6 0 18 17
8 6 1 22 21
8 6 2 18 18
8 7 -5 30 29
8 7 -4 4 1
8 7 -3 31 31
8 7 -2 6 2
8 7 -1 26 22
8 7 0 3 1
9 0 -4 20 21
9 0 -2 12 15
9 1 -4 26 24
9 1 -3 6 4
9 1 -2 10 16
9 1 -1 3 4
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